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Glycosaminoglycans (GAGs) such as heparin, heparan sulfate (HS), chondroitin 18 
sulfate (CS) and dermatan sulfate (DS) are sulfated polysaccharides that exist on 19 
animal cell surfaces and in the extracellular matrix. GAGs are important in providing 20 
structural and hydrating support and interaction points for proteins of varied 21 
functions, for example growth factors and homeostasis regulatory proteins. 22 
Hepatocyte Growth Factor (HGF) is a protein growth factor that regulates cell 23 
growth, survival, proliferation, chemotaxis, cell morphology, tissue regeneration and 24 
angiogenesis. It is involved in embryogenesis, wound healing and many cancers. 25 
 26 
In this project, the interactions between the GAG binding N and NK -domains of 27 
HGF (HGF-N and HGF-NK) and different types of GAGs are characterised with 28 
biophysical techniques. GAG oligosaccharides were produced by enzymatic 29 
digestion and purified by preparative gel filtration and ion exchange 30 
chromatography. Different constructs of HGF were cloned from human cDNA, 31 
expressed with the Pichia pastoris expression system, purified to homogeneity and 32 
characterised by mass spectrometry and nuclear magnetic resonance (NMR).  33 
 34 
The dissociation constants between the different HGF protein constructs, different 35 
heparin oligosaccharide lengths and the drug Fondaparinux were shown by 36 
isothermal calorimetry (ITC) to vary between 0.35 and 9.26 µM. It was found that 37 
the entropy contribution was favourable for short oligosaccharides and disfavourable 38 
for long oligosaccharides and that the enthalpy contribution was less important for 39 
shorter oligosaccharides than for longer oligosaccharides. 40 
 41 
NMR titrations of CS, DS, heparin, Fondaparinux and sulfated maltose into 15N 42 
labelled protein samples showed that all ligands bind to the same HGF-N binding 43 
site, but different binding modes exists. The binding site consists of three regions, 44 
with the α2-helix and L2 loops playing key roles (residues 70-84). All GAGs also 45 
utilise the N-terminal residues 32-42, whereas long heparin oligosaccharides can also 46 
utilise a binding region formed mainly by the β2-strand (residues 59-64, 66, 95, 96). 47 
The GAG binding mode changes if HGF-N has an N-terminal truncation and the β2- 48 
strand residues become more important, emphasising the role of the N-terminal 49 
residues in the HGF-GAG interaction. Spin-labelled fully sulfated heparin-derived 50 
hexasaccharide was used to determine its binding direction on the HGF-N surface. 51 
Affinity chromatography confirmed the importance of the N-terminal residues and 52 
that HGF binds to all investigated GAGs. 53 
 54 
The oligomeric states of HGF-N and HGF-NK were investigated by AUC, gel 55 
filtration and ITC. The results suggest that the proteins oligomerise like beads on a 56 
string for long oligosaccharides. An HGF-N self-associating dimer with a slow 57 
on/off rate was characterised by affinity chromatography, gel filtration and NMR. 58 
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1 Introduction 310 
1.1 Background 311 
Hepatocyte Growth Factor (HGF) is a multifunctional growth factor that controls 312 
many physiological processes such as cell growth and morphology [1]. There is 313 
extensive evidence of its involvement in cancer and wound healing. HGF exerts its 314 
biological functions by binding the cell-surface receptor Met and a 315 
glycosaminoglycan (GAG) at the same time [2]. Because HGF is involved in many 316 
physiological processes and its dysregulation can cause disease, it is an important 317 
research target. 318 
 319 
GAGs are large linear and complex carbohydrates composed of a basic repeating 320 
disaccharide unit, which is extensively modified. They either exist as free 321 
carbohydrates or are covalently linked to proteins. Some types of GAGs bind water 322 
and work as a structural scaffold between cells, for example in cartilage and joints 323 
[3] and for a long time it was thought that the only function of GAGs was to provide 324 
structural support. However, during the last decades it has been realised that GAGs 325 
are also involved in complex signalling events such as the HGF signalling cascade. 326 
GAGs can bind to signalling proteins such as growth factors and modulate how they 327 
interact with their receptors. Protein – GAG interaction can therefore be targeted for 328 
drug development [4]. Heparin anticoagulant therapy is one treatment that targets a 329 
protein-GAG interaction that has been used for 7 decades. However, a new 330 
generation of innovative anti-cancer drugs are currently being developed by targeting 331 
the interaction between GAGs and growth factors [5-8].  332 
 333 
In order to target protein-GAG interactions for drug development and design 334 
effective drug molecules by structure-activity-relationships (SAR), an in-depth 335 
understanding of the interaction on a molecular level is needed. Many different 336 
aspect of HGF have been researched in detail, for example its cancer biology [9]. A 337 
number of biophysical studies of HGF are available, for example the affinity of the 338 
interaction has been determined by SPR [10-13], the structure of some domains of 339 
 
 2 
the protein has been determined by x-ray crystallography [14-16] and NMR [17] and 340 
the GAG binding site has been mapped.  341 
 342 
However, there are gaps in the understanding of this important protein-GAG 343 
interaction. For example, a comparison of the binding modes of different types of 344 
GAGs is lacking and the oligomerisation mode of some HGF protein constructs is 345 
still unclear. In addition, most of the current understanding of the HGF-GAG 346 
interaction is derived from a crystal structure in which the protein contains a cloning 347 
artefact. The effect of this cloning artefact and how it affects the GAG binding mode 348 
has previously not been investigated. Several solution based biophysical techniques 349 
are used in this thesis to further characterise the HGF-GAG interaction in order to aid 350 
future HGF basic research and drug development.  351 
 352 
1.2 Hepatocyte Growth Factor 353 
Growth factors are extracellular signalling proteins that bind cell surface receptors to 354 
stimulate cell growth, survival or proliferation [18]. Hepatocyte growth factor (HGF) 355 
is extraordinary among the growth factors in the way that it has been shown to 356 
regulate all these activities, plus chemotaxis, cell morphology, tissue regeneration 357 
and angiogenesis [1]. HGF has also been called hepatopoietin and scatter factor, 358 
although HGF is the current standard terminology. HGF was first cited in 1980 and 359 
since it was shown that HGF is the ligand for the receptor tyrosine kinase Met, it has 360 
been extensively studied for its role in cancer and tissue regeneration. 361 
 362 
1.2.1 The Structure of Hepatocyte Growth Factor 363 
HGF, ExPASy entry p14210, consists of one N-terminal PAN domain (abbreviated 364 
N), followed by four kringle domains (abbreviated K1-K4) and lastly a serine 365 
protease homology domain (abbreviated SPH). See Figure 1.1 for a schematic 366 
structure of HGF and Table 1.1 for an extract from ExPASy. The serine protease 367 
homology domain is not catalytically active; two of the inactivating changes 368 
affecting the catalytic triad are His534Gln and Ser673Tyr. Abbreviations are often 369 
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used for splice variants and fragments of HGF, for example NK2 consists of N, K1 370 
and K2. In this project, HGF-N denotes the N domain of HGF, HGF-NK, the N and 371 
the K1 domains, HGF-NK-C denotes the NK fragment that was cloned in this project 372 
and HGF-NK-G, the NK fragment that was originally cloned in Cambridge by the 373 
Gherardi research group. NK4 forms the α-chain, whereas the SPH domain forms the 374 
β-chain after proteolytic cleavage by a protease. Residues 1-31 make up the secretory 375 
signal that directs the protein for secretion via the endoplasmatic reticulum and Golgi 376 
apparatus. The secretory signal is cleaved off and not present in the native 377 
extracellular protein. NK1 has been detected in vivo as a splice variant of HGF [19]. 378 
In crystal structures, NK1 forms dimers [14-16], [20], but it is monomeric in solution 379 
[21]. 380 
 381 
Figure 1.1 Schematic structure of HGF. The first arrow is the signal peptide 382 






Table 1.1 Extract of HGF (P14210) from the ExPASy database. 386 
Function From – To Length Domain type 
SIGNAL 1  -  31 31 Signal peptide. 
CHAIN 32  -  494 463 Alpha chain. 
CHAIN 495  -  728 234 Beta chain. 
DOMAIN 37  - 123 87 PAN. 
DOMAIN 128  -  206 79 Kringle 1. 
DOMAIN 211  -  288 78 Kringle 2. 
DOMAIN 305  -  383 79 Kringle 3. 
DOMAIN 391  -  469 79 Kringle 4. 
DOMAIN 495  -  721 227 Peptidase S1. 
 387 
The structure of HGF has been extensively studied, there is one NMR structure of the 388 
N domain [17], several crystal structures of free NK1 and NK1 complexed with 389 
heparin [14-16] as well as crystal stuctures of free HGF-β and HGF-β complexed 390 
with the Met Sema domain [23], [24]. There is also a crystal structure of NK2 [25]. 391 
This crystal structure is shown in Figure 1.2, overlaid with the crystal structure of 392 
NK1 complexed with heparin. The secondary structure of the N domain is shown in 393 





Figure 1.2 Overlay of the 3HN4 NK2 PDB file and the 1GMO HGF-NK-G – 397 
heparin complex PDB file. Blue: 1GMO N-domain, Red: 3HN4 N-domain, orange: 398 
3HN4 K1-domain, green: 3HN4 K2-domain. 399 
 400 
 401 
Figure 1.3 The secondary structure of the N domain of HGF as determined in the 402 
2HGF PDB file. 403 
 404 
1.2.1 Molecular Physiology of Growth Factors 405 
Many growth factors bind receptor tyrosine kinases (RTKs) and cause the receptors 406 
to dimerise or oligomerise [26]. As illustrated in Figure 1.4, the intracellular tyrosine 407 
kinase domains of the receptors then cross-phosphorylate each other and the 408 
phosphorylations are recognised by adaptor proteins that trigger an intracellular 409 
signalling cascade. The role of proteoglycans and GAGs in this model is to attract the 410 








Figure 1.4 Typical activation event of an RTK. 0) Presentation of GF to RTK by 414 
PG/GAG. 1) Dimerisation of RTK by GF and GAG. 2) RTK cross-phosphorylation. 415 
3) Binding of adaptor proteins and initiation of signalling cascade. Abbreviations: 416 
RTK: Receptor Tyrosine Kinase, PG: Proteoglycan, GAG: Glycosaminoglycan, GF: 417 
Growth Factor, P: Phosphorylation, A: Adaptor Protein. 418 
 419 
Different growth factors employ different types of oligomerisation strategies. For 420 
example, PDGF is a protein homo-dimer and can thus bind two receptors [27]. 421 
FGF1, its receptor FGFR2c and heparin oligosaccharides form a 2:2:1 complex with 422 
the heparin acting like glue, making the FGF1 bind in a trans manner [28-30]. On the 423 
other hand, it has been shown by NMR that a biologically active hexasaccharide 424 
makes FGF1 dimerise in a cis or trans manner and it is proposed that FGF trans 425 
dimerisation is not a prerequisite for receptor activation [31]. There are several 426 
isoforms of EGF receptors and the composition of the heterodimeric receptors partly 427 
regulates the activation of the signalling complex [32-34]. For HGF, the 428 
stoichiometry of the active signalling complex still remains unclear [23-25], [2]. 429 
 430 
1.2.2 The Hepatocyte Growth Factor – Met Signalling Complex 431 
It has been postulated that HGF has one high affinity Met binding site in the α-chain 432 
and one lower affinity site in the β-chain, making HGF bivalent for Met and thus 433 
being able to dimerise the Met receptor [24], [23], [35]. This suggest that the active 434 
signalling complex has a 2 Met : 1 HGF stoichiometry, although the stoichiometry 435 
has not been completely clarified and a crystal structure of full-length HGF, Met and 436 
heparin is needed to ultimately answer the stoichiometry question. Analytical 437 
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ultracentrifugation and light-scattering experiments suggest that active Met and HGF 438 
form 1:1 complexes that can be stabilized with heparin to form a 1:1:1 complex [36]. 439 
No 2:1 complexes were detected in these experiments, but the absence of this 440 
stoichiometry could be due to the fact that at the 1:1 molar ratio of ligand and 441 
receptor used in these experiments, only high-affinity HGF α-chain:Met interactions 442 
are taking place, and low-affinity HGF β-chain:Met interactions are not taking place 443 
and therefore, 2:1 complexes cannot form. 444 
 445 
One could also imagine a 2:2 complex of Met:HGF where HGF binds in a dimeric 446 
fashion [2]. This model is partly supported by the fact that HGF-NK crystallises as a 447 
dimer, on the other hand it is monomeric on solution. The 2:1 and 2:2 complexes are 448 
illustrated in Figure 1.5 449 
 450 
  451 
Figure 1.5 Two different dimerisation models for the HGF-Met complex. A 2:1 452 
model on the left and a 2:2 model on the right. 453 
 454 
It has been shown that the presence of a HS like GAG potentiates the activity of 455 
HGF although it is not necessary [2], [37-39], [10]. DS and CS like GAGs have also 456 
been shown to potentiate HGF activity [40], [37], [41]. On the other hand, NK1 only 457 
binds Met in the presence of heparin. It is mainly the N domain that interacts with 458 
GAGs although some GAG binding is also seen for K1 and K2 [42].  459 
 460 
Full-length HGF can bind Met with similar affinities regardless if it is activated or 461 
not, although only activated HGF can activate Met [43]. Both the N and SPH - 462 
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domains have been shown to interact with Met [42], with the N domain binding 463 
tighter than the SPH domain [23], although the SPH domain has been shown to be 464 
vital for Met signalling [24]. By mutating residues in the SPH domain activation 465 
pocket, which are necessary for HGF activation, it is possible to convert the β-chain 466 
of HGF into a Met antagonist [44].  467 
 468 
Interestingly, HGF-NK1 is a Met agonist, crystallises as a head-to-tail dimer, but by 469 
mutating residues in the HGF-NK1 dimer interface, it is possible to convert it into a 470 
Met antagonist [45]. This is likely due to the fact that wild-type HGF-NK1 is able to 471 
dimerise the Met receptor as shown in Figure 1.5. HGF-NK2 crystallises in a 472 
globular monomeric fashion due to interactions between the N and K2 domains and 473 
works as a Met antagonist, likely through binding to Met and inhibiting Met 474 
dimerisation [25]. Mutations that were to open up the HGF-NK2 closed 475 
conformation by disrupting the N/K2 interface convert HGF-NK2 from a Met 476 
antagonist to an agonist. Remarkably, this mutated HGF-NK2 agonist can be 477 
converted back to an antagonist by a mutation that disrupts the NK1/NK1 dimer 478 
interface.  479 
 480 
What role a HS-like GAG would have in the active signalling complex is still 481 
unclear. It is however likely that a PG linked GAG contributes to presenting HGF to 482 
the Met receptor. It is possible that a GAG is also present in the active signalling 483 
complex, as suggested by the finding that HGF-NK1 needs heparin to bind Met and 484 
that Met has been shown to bind heparin [39], [37]. It has been suggested that the 485 
primary role of heparin in HGF-NK1 binding to Met is to neutralize the positive 486 
charged residues on the N-domain surface. Removal or charge reversal of heparin 487 
binding residues within the N-domain makes HGF-NK1 bind to Met independently 488 
of heparin [25]. Decorin, a secreted matrix proteoglycan belonging to the small 489 
leucine-rich proteoglycan family has been shown to bind directly to Met with a KD of 490 
1.5 nM [46]. Decorin bound to Met is displaced by HGF as it binds to Met with 491 
higher affinity. It has also been suggested that HGF binds Met as a monomer, but 492 
that heparin/HS is needed as a co-receptor to induce a conformational change [37]. 493 
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Although HS and heparin have higher affinity for HGF than dermatan sulfate, they 494 
have been shown to be equally potent co-activators of Met [37]. 495 
 496 
Some cell-based assays have shown that GAGs are required to activate Met, others 497 
have shown that HGF alone is also active. Clearly, results seem to vary with cell type 498 
and experimental setup, but there is general agreement that GAGs are important as 499 
co-activators [2].  500 
 501 
1.2.3 Activation of Hepatocyte Growth Factor by Hepatocyte 502 
Growth Factor Activator 503 
For HGF to be able to activate Met, it first has to be activated by proteolytic cleavage 504 
between residues Arg494 and Val495 [47]. The activation site can be knocked out by 505 
a R494E point mutation. Some of the activating proteases can also process a 506 
secondary site between Arg424 and His425 in the K4 domain. After the proteolytic 507 
cleavage, the α and β -chains are attached by a disulfide bond. It has been shown that 508 
many proteases such as coagulation factor XIa, XIIa, kallikrein, urokinase, and 509 
tissue-type plasminogen activator can perform the cleavage [47], but HGFA [48] and 510 
matriptase [49], [50] have been identified as the most potent and physiologically 511 
relevant activators. Both HGFA [51] and matriptase [50] are serine proteases that 512 
have been implicated in cancer. Matriptase is a transmembrane protein that also 513 
degrades extracellular matrix proteins such as gelatin, fibronectin and laminin [52]. 514 
Matriptase is thought to be a less efficient HGF activator than HGFA, but as it is 515 
often overexpressed in cancer, it is still thought to be physiologically relevant. 516 
 517 
The proteolytic cleavage leads to rearrangements in the activation domain of β-HGF 518 
and the reorientation of the β-chain relative to the α-chain. The activation domain 519 
consists of three surface-exposed loops and the newly formed N-terminus. It is 520 
thought that insertion of the new N-terminus into the activation pocket is related to 521 
the activation mechanism of other trypsin-like serine proteases [44]. This 522 
rearrangement results in the formation of what is the active site in other trypsin-like 523 
serine proteases, but for HGF it interestingly forms the Met binding site. It has been 524 
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shown that single-chain pro-HGF adopts a compact conformation, whereas activated 525 
HGF is elongated [53]. 526 
 527 
1.2.4 The Structure and Molecular Physiology of Hepatocyte 528 
Growth Factor Activator 529 
HGFA is secreted mainly by the liver and has been shown to be an important 530 
regulator of wound healing [22]. The crystal structure of HGFA has been solved, 531 
both in its free form and complexed with a Hepatocyte Growth Factor Inhibitor 532 
peptide [54]. In its free state, HGFA adopts an active site conformation that differs 533 
from many other trypsin-like proteases and the catalytic triad cannot function. 534 
Complexed with a HAI-1B peptide, HGFA undergoes a major conformational 535 
change and the resulting state closely mirrors the active site of other serine proteases, 536 
but the complex is inactive [54], [55]. 537 
 538 
HGFA is secreted as a 96 kDa zymogen with a domain structure similar to 539 
coagulation factor XII, consisting of six domains: an N-terminal fibronectin type II 540 
domain; an epidermal growth factor like domain; a fibronectin type I domain; 541 
another epidermal growth factor like domain; a kringle domain; and a trypsin 542 
homology serine protease domain, all together forming the pro-peptide that is 543 
removed by plasma kallikrein cleavage at the Arg372-Val373 bond, see Table 1.2 544 
and Figure 1.6. The most C-terminal domain is the trypsin homology serine protease 545 
domain that can be activated by cleavage of the Arg407-Ile408 bond by thrombin or 546 
kallikrein 5 in the presence of negatively charged molecules such as dextran sulfate 547 
and chondroitin sulfate. Alternatively, HGFA can be activated by kallikrein 4 that 548 
does not need negatively charged molecules to be present. Consequently, the active 549 
short form of HGFA is a 34 kDa protein containing a C-terminal 35-residue peptide 550 
linked by a disulfide to the protease domain [56], [57]. Thrombin can also activate 551 
the long 96 kDa form of HGFA, before it has been cleaved by plasma kallikrein (see 552 
Figure 1.7 for the different activation pathways of HGFA). Kallikrein 5 is a more 553 




Table 1.2 Extract of HGFA, Q04756 from the ExPASy database. 556 
Function From - To Length Domain type 
Signal peptide 1 – 35 35 Secretion signal 
Propeptide 36 – 372 337 Removed in mature form 
Chain 373 – 407 35 HGFA short chain 
Chain 408 – 655 248 HGFA long chain 
Domain 103 – 150 48 Fibronectin type-II 
Domain 160 – 198 39 EGF-like 1 
Domain 200 – 240 41 Fibronectin type-I 
Domain 241 – 279 39 EGF-like 2 
Domain 286 – 367 82 Kringle 
Domain 408 – 646 239 Peptidase S1 
Active site 447 1 Catalytic triad 
Active site 497 1 Catalytic triad 
Active site 598 1 Catalytic triad 
 557 
 558 
Figure 1.6 Overall structure of HGFA and the proteolytic cleavage sites. Cleavage 559 





Figure 1.7 The activation pathway of HGFA. Taken from [52]. 563 
 564 
Kunitz-type serine protease inhibitors called hepatocyte growth factor inhibitors 565 
(HAIs) regulate HGFA activity. Despite the name, HAIs can also inhibit other 566 
proteases such as matriptase, plasma kallikrein and kallikrein 4 and 5 [59]. The HAIs 567 
are expressed as transmembrane proteins. The primary HAI-1 translation product is a 568 
66 kDa protein, but the ectodomain can be shedded through proteolytic cleavage by 569 
metalloproteases at different cleavage sites [60]. This release of the inhibitors could 570 
decide the function of HAI-1 and HAI-2 [61]. It is the 50 amino acids long Kunitz 571 
domain of the HAIs that bind to HGFA and cause inhibition [54].  572 
 573 
The fact that HGFA is activated by thrombin, which is activated by tissue injury and 574 
the blood coagulation cascade, strongly links the HGFA/HGF/Met signalling 575 
pathway to tissue injury [22], [62]. HGFA is found in its active form in serum, but in 576 
its inactive form in plasma. Interestingly, it has been shown that unactivated HGFA 577 
has weak affinity for heparin but acquires stronger heparin affinity after activation 578 
[62]. This feature likely ensures immobilisation of the active enzyme at the site of 579 
injury. The HGFA short chain contains several basic residues and has a high pI, it is 580 
therefore likely that the heparin binding properties reside in this part of the protein 581 
and that the proteolytic cleavage mobilises the short chain, making it able to interact 582 
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with GAGs. It is noteworthy that HGFA, HGF and Met all exhibit some degree of 583 
heparin affinity and this points to the central role of GAGs in the activation and 584 
regulation of the HGFA/HGF/Met signalling pathway as shown in Figure 1.8.  585 
 586 
Figure 1.8 The central role of GAGs in the HGF signalling cascade. 587 
 588 
1.2.5 The Hepatocyte Growth Factor - Glycosaminoglycan 589 
Interaction 590 
The GAG binding site of HGF was first identified by mutational studies [11], 591 
confirmed by NMR [17], [21] and studied further by crystallising HGF-NK-G with a 592 
heparin-derived 14-mer oligosaccharide [14]. The heparin-binding site consists of a 593 
patch of positively charged arginines and lysines that are thought to form ionic 594 
intermolecular bonds with the negatively charged sulfate groups on the GAG, but 595 
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hydrogen bonds are also important. The most important protein residues in the 596 
interaction are the very N-terminal basic residues that cannot be seen in the structures 597 
[63], the residues of the β2-strand (Lys58, Lys60, Thr61, Lys62 and Lys63), the 598 
residues of the α2-helix (Arg73, Arg76 and Asn77) and the residues of the L2-loop 599 
(Lys78, Gly79 and Leu80) [14], [21]. Arg73 plays a central role in the interaction. 600 
 601 
Although only one arginine - sulfate interaction is annotated as an ionic interaction in 602 
the published HGF-NK-G - heparin structure [14] (Table 1.3), most of the 603 
arginine/lysine - sulfate intermolecular bonds are likely to be of an ionic positive - 604 
negative charge character rather than a hydrogen bond donor - acceptor character. 605 
Indeed, most of the arginine/lysine - sulfate interactions in the thrombin- 606 
antithrombin-heparin complex are classified as ionic bonds or salt bridges [64]. A 607 
possible explanation to the differences in nomenclature is that many of the HGF - 608 
heparin hydrogen bond donor - acceptor distances are 2.5-3.3 nm long and on this 609 
scale, both hydrogen and ionic bonding can take place [65]. Both the distance and the 610 
angle of the bond donor and acceptor are important in determining the strength of a 611 
hydrogen bond and the optimal distance and angle depends on the specific system. 612 
Some interactions between the protein backbone amides and heparin sulfates occur in 613 
the HGF-NK-G - heparin co-crystal and these intermolecular bonds are of a 614 
hydrogen bond character as the amides are polar but not charged. Figure 1.9 shows a 615 






Figure 1.9 HGF-NK-G – heparin interactions. Taken from [14]. 620 
 621 
The intermolecular bonds between HGF-NK-G and heparin seen in the crystal 622 





Table 1.3 Intermolecular interactions between HGF-NK-G and heparin as reported 625 
in the crystal structure [14]. 626 
GAG interaction point Type of bond 
GlcN 5 6-O sulfate  
Lys63 (backbone nitrogen) Hydrogen bond 
GlcN 5 N sulfate  
Thr61 (side chain oxygen) Hydrogen bond 
Thr61 (side chain oxygen + 
backbone nitrogen) 
Hydrogen bond 
Lys60 (side chain nitrogen) Hydrogen bond 
IdoA 6 COOH Oxygen 1  
Lys60 (side chain nitrogen) Hydrogen bond 
Arg73 (side chain nitrogen) Hydrogen bond 
IdoA 6 COOH Oxygen 2  
Arg73 (side chain nitrogen) Hydrogen bond 
IdoA 6 sugar ring O  
Lys62 (side chain nitrogen) Hydrogen bond 
IdoA 8 2-O sulfate  
Arg73 (side chain nitrogen) Hydrogen bond 
GlcN 7 carbon 6  
Arg73 (side chain carbon)  Hydrophobic 
GlcN 7 6-O sulfate  
Arg73 (side chain nitrogen) Ionic interaction 
Gly79 (backbone nitrogen) Polar 
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It has been suggested that 6-O-sulfates in GlcN units are the most important GAG 627 
interaction points for HGF, with IdoA 2-O-sulfates and N-sulfates playing minor 628 
roles [66]. As can be seen in Figure 1.9 and Table 1.3, there is only one 629 
intermolecular bond between the IdoA2S and HGF. The GlcN sulfates and in 630 
particular the 6-O-sulfates are involved in several intermolecular bonds, suggesting 631 
an important contribution and supporting the hypothesis that GlcN 6-O-sulfates are 632 
important interaction points. It has also been suggested that HGF has a general 633 
preference for IdoA containing GAGs [67]. This is likely due to the flexibility of 634 
IdoA allowing for better alignment of the protein-GAG intermolecular bonds and a 635 
similar preference is seen for many other GAG binding proteins. 636 
 637 
A recent study using specifically desulfated heparin tetrasaccharides showed that 638 
species containing only two sulfates (N, 2O or 6O –sulfates) bind to HGF with 639 
equivalent affinities, as did a disulfated DS tetrasaccharide and it was suggested that 640 
“Affinity is dictated by the need for a minimum of an IdoA residue and two sulfates, 641 
which can be positioned in a variety of ways, located within a dp3/dp4 segment of 642 
either a HS/heparin or DS backbone” [68]. 643 
 644 
Although the HGF-GAG interaction clearly exhibits some specificity, it has been 645 
shown that no specific sulfates or oligosaccharide motif in a panel of DS and HS like 646 
GAGs is needed for HGF interaction and activity [67]. As often seen in protein - 647 
GAG interactions, different species of similar sulfate density have comparable 648 
properties and affinities and Met/HGF activation potencies increase with increasing 649 
sulfate densities [69]. This is exemplified by the fact that chemically sulfated maltose 650 
oligosaccharides have similar properties as heparin in cell based assays [38]. 651 
 652 
A tetrasaccharide has been found to be the shortest heparin fragment that binds to 653 
HGF-NK1 and activates Met, but with DS a hexasaccharide is required [70]. In the 654 
crystal structure, a tetrasaccharide is the minimal fragment that fully occupies the 655 
whole binding site. The KD of the interaction does not change with the length of the 656 
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GAG, but GAGs longer than 10 sugar units are more active in cell based assays [10]. 657 
Although it seems like HS and heparin have higher affinity for HGF than DS, they 658 
have been shown to be equally potent activators for Met [37]. 659 
 660 
The KD for the interaction between GAGs, HGF and its NKx splice variants have 661 
been determined mostly by biosensor analysis to be in a low nM range [10-13]. The 662 
GAG KDs for full-length HGF, HGF-N, HGF-NK1 and HGF-NK2 are all similar. 663 
Surprisingly few studies have employed alternative methods to assess the KD of the 664 
HGF-GAG interaction. One study used FITC labelled heparin and fluorescence 665 
spectroscopy to establish that the KD for the HGF-N - heparin interaction is 1-2 µM 666 
[21]. This significantly weaker KD might partly be explained by experimental 667 
differences. The fluorescence spectroscopy experiment was performed in solution 668 
and the heparin was not immobilised. The incorporation of a FITC label, different 669 
sources and length of GAGs and different buffers might further explain the 670 
differences in experimental KDs. The binding affinity between NK1 and a fully 671 
sulfated heparin-derived tetrasaccharide (DP4C) in PBS has been determined by ITC 672 
to be in the micromolar range (Bärbel Blaum, University of Edinburgh, unpublished 673 
results), adding to the uncertainty of the actual strength of the interaction. 674 
 675 
Measured NMR 15N spin relaxation parameters of HGF-N indicate that parts of the 676 
protein undergo conformational exchange on a µS to mS timescale [21]. This NMR 677 
study also showed several new crosspeaks from the N-terminal residues and Asn77- 678 
Leu80 loop appearing in 1H-15N HSQC spectra due to the protein becoming more 679 
rigid upon GAG binding. Chemical shift changes were also seen for residues lying 680 
outside the central binding site, indicative of a possible structural rearrangement 681 
upon ligand binding. Changes in protein conformation upon GAG binding have been 682 
reported for other heparin binding protein such as TSG-6 [71]. Changes in 15N spin 683 
relaxation parameters upon GAG binding have been reported for FGF [72]. The 684 
seven N-terminal residues are not observable by NMR spectroscopy due to 685 
conformational exchange [21]. This is also likely why the N-terminal residues cannot 686 
be seen in crystal structures. 687 
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1.2.6 HGF in Cancer and as an Anti-Cancer Target 688 
HGF was first detected as a protein in rat serum that could increase hepatocyte DNA 689 
synthesis and was subsequently cloned and expressed [73], [74]. It was later shown 690 
that HGF binds the tyrosine kinase receptor Met [75], which was also characterised 691 
in the 1980s as a proto-oncogene [76]. Since then, the chemistry and biology of HGF 692 
and its relation to cancer have been extensively studied [77].  693 
 694 
The HGFA-HGF-Met pathway regulates cell functions such as cell growth, 695 
apoptosis, motility and invasion, all hallmarks of cancer [78]. Dysregulation of this 696 
important pathway can occur at different levels: the cell can start over-expressing its 697 
own HGF, becoming self-sufficient in growth signals; the Met gene can be over 698 
expressed; or the Met receptor can become overactive by mutations [79], [78]. The 699 
HGFA-HGF-Met pathway has been implicated in many forms of cancer and it is one 700 
of the most frequently dysregulated pathways in human cancer (Table 1.4) [80]. The 701 
HGFA-HGF-Met pathway is an appealing drug development target as it is involved 702 
in so many cancers and regulates such a wide span of functions. 703 
 704 
It has been shown that Met mediated cancer cell transformation is dependent upon 705 
HGF activation of Met, making the HGF-Met interaction an attractive point for drug 706 
development [81], [82]. Many different ways to target the HGFA-HGF-Met 707 
signalling cascade are being explored: small molecule tyrosine kinase inhibitors [83], 708 
[84]; gene therapy [85]; monoclonal antibodies targeting both HGF and Met [80], 709 
[81], [86]; injecting HGF-NK1 [87]; and injecting Met [79]. Small molecule tyrosine 710 
kinase inhibitors and antibodies towards Met seem to be the most common 711 
approaches, often used in combination with other therapies [80]. The activation of 712 
HGF by HGFA and matriptase is also being targeted for drug development by HGF 713 




Table 1.4 The involvement of HGF and Met in different types of cancer and 715 
supporting data. Y: Yes, N: No/Not yet. Taken from [89]. 716 






















Carcinomas        Y 
 Bladder  Y  Y  Y  N  Y  Y  Y 
 Breast  Y  Y  Y  Y  Y  Y  Y 
 Cervical  Y  Y  Y  N  Y  N  Y 
 Cholangiocarcinoma  Y  Y  N  N  Y  Y  Y 
 Colorectal  Y  Y  Y  N  Y  Y  Y 
 Endometrial  Y  Y  N  N  Y  N  Y 
 Esophogeal  Y  Y  Y  N  Y  N  Y 
 Gastric  Y  Y  Y  Y  Y  Y  Y 
 Head and Neck  Y  Y  Y  Y  Y  Y  Y 
 Kidney  Y  Y  Y  Y  Y  Y  Y 
 Liver  Y  Y  Y  Y  Y  Y  Y 
 Lung  Y  Y  Y  Y  Y  Y  Y 
 Nasopharyngeal  Y  Y  Y  N  Y  N  N 
 Ovarian  Y  Y  Y  Y  Y  Y  N 
 Pancreas/Gall Bladder  Y  Y  N  N  Y  Y  Y 
 Prostate  Y  Y  Y  N  Y  Y  Y 
 Thyroid  Y  Y  Y  Y  Y  N  Y 
Musculoskeletal sarcomas  Y  Y    Y    
 Osteosarcoma  Y  Y  N  Y  Y  Y  Y 
 Rhabdomyosarcoma  Y  Y  Y  N  Y  Y  Y 
 Synovial Sarcoma  Y  Y  Y  N  Y  N  N 
Soft tissue sarcomas     Y   Y   
 Kaposi's Sarcoma  Y  Y  N  N  Y  Y  N 
 Leiomyosarcoma  Y  Y  Y  N  Y  Y  Y 
 MFH/Fibrosarcoma  Y  Y  N  N  Y  Y  Y 
Hematopoietic Malignancies         
 Acute Myelogenous Leukemia  Y  N  N  N  Y  N  N 
 Adult T Cell Leukemia  Y  Y  Y  N  Y  N  Y 
 Chronic Myeloid Leukemia  Y  N  N  N  N  N  N 
 Lymphomas  Y  Y  Y  Y  Y  Y  Y 
 Multiple Myeloma  Y  Y  Y  N  Y  Y  Y 
Other Neoplasms  Y        
 Glioblastomas/Astrocytomas  Y  Y  Y  Y  Y  Y  Y 
 Melanoma  Y  Y  Y  N  Y  Y  Y 
 Mesothelioma  Y  Y  Y  N  Y  N  Y 
 Wilms' Tumour  Y  Y  N  N  Y  Y  Y 
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HGF-NK1 has been described both as a Met antagonist [90] and a partial agonist 717 
[91]. For therapeutic applications, HGF-NK1 and HGF-NK4 are being developed as 718 
antagonists [87]. Interestingly, it has been shown that HGF-NK4 is able to inhibit 719 
angiogenesis independently of its HGF/Met antagonism. It has been suggested that 720 
HGF-NK4 achieves this by binding perlecan, competing with fibronectin and other 721 
perlecan binding growth factors necessary for angiogenesis [92]. It is likely that 722 
HGF-NK1 exhibits similar properties. 723 
 724 
A relatively novel class of drugs targets the interaction between GAGs and proteins 725 
involved in cancer, such as GAG binding growth factors and heparanase [93]. The 726 
wide importance of protein-GAG interactions in cancer makes them appealing 727 
targets for drug development [94].  What is also appealing is that one GAG mimetic 728 
could work on multiple targets, for example HGF, FGF, VEGF, PDGF and 729 
heparanase, potentially making it a very effective class of drugs that can be used in 730 
combination with other more targeted treatments. These GAG mimetic drugs 731 
structurally resemble GAGs and are often highly negatively charged. Importantly, 732 
they have no or very low anti-coagulant activity [95]. 733 
 734 
Unfortunately, the use of a promiscuous GAG mimetic has the potential to cause 735 
severe side effects as GAGs are involved in many important physiological processes. 736 
Another problem might be the bioavailability of per os tablets, as many GAG 737 
mimetics composed of sugars will be degraded in the gastrointestinal tract and during 738 
first-pass metabolism. A GAG mimetic might therefore have to be administered in a 739 
manner similar to heparin anticoagulant therapy: intravenously or subcutaneously.  740 
 741 
The GAG mimetics developed to date range from sulfated peptides [96], [97], 742 
chemically oversulfated oligosaccharides [38], [98-100], sulfated carrageenan sugars 743 
from algae [101-105], modified GAGs [4], [106], [107], specifically synthesised 744 
heparin like oligosaccharides [30] to small synthetic molecules [108]. Many of the 745 
GAG mimetics show promising in vivo and in vitro results, but relatively few are in 746 
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clinical trials. Heparin anticoagulant therapy has been shown to decrease cancer 747 
mortality in several clinical trials [109], [110], strongly supporting the idea to use 748 
GAG mimetics as anti cancer agents [95], [111]. 749 
 750 
The development of a HGF specific GAG sequence similar to the FGF specific GAG 751 
sequence [30] could potentially be aided by the NK1-heparin complex crystal 752 
structure [14]. However, it has to be kept in mind that GAG oligosaccharides longer 753 
than DP4 can work as co-activators for HGF [112], something that has to be avoided 754 
in drug design. However, it is questionable if the HGF-GAG interaction is specific 755 
enough and it is unlikely to be as specific as the ATIII binding pentasaccharide, 756 
which seems to be a particularly specific protein-GAG interaction. 757 
 758 
An example of a successful GAG mimetic in development is Muparfostat, originally 759 
called PI-88 or phosphomannopentaose, developed by Progen Pharma as a general 760 
GAG mimetic (Figure 1.10). The drug has heparanase inhibitory properties, binds 761 
FGF and VEGF with high affinities and its main mode of action is that it is anti- 762 
angiogenic [5-8]. Muparfostat showed promising results in phase II clinical trials and 763 
is now in phase III for advanced melanoma and post resection liver cancer. New 764 
chemical entity analogues of Muparfostat called the PG500 series have been 765 
synthesised to improve pharmacokinetics and decrease anti-coagulant activity by 766 
attaching different lipophilic groups to the reducing end [113]. Muparfostat shows 767 





Figure 1.10 The anti-cancer drug Muparfostat is composed of five sulfated mannose 771 
units. Taken from [7]. 772 
 773 
As explained in section 1.3.6, GAG-protein interactions are also important players in 774 
regulating inflammation, which is tightly linked to cancer progression and there are 775 
also considerable possibilities for targeting protein-GAG interactions for anti- 776 
inflammatory drug development. 777 
 778 
1.2.7 HGF Research 779 
As HGF was first purified, cloned and expressed in the early 1980s [73], [74], HGF 780 
research was initially relatively slow. When Met was discovered in 1984 [76] and 781 
shown to be the receptor for HGF [75] in 1991, research into HGF/Met and its 782 
physiological roles increased quickly. However, similar to GAG research, the pace of 783 
HGF research has dropped somewhat in the new millennium compared to PubMed 784 





Figure 1.11 The graph shows number of total PubMed publications on the left axis 788 
in green and number of HGF publications in red on the right axis sorted per year. A 789 
PubMed search was performed for each year with the search term “(((((HGF) OR 790 
HGF/SF) OR "Hepatocyte growth factor") OR "Scatter factor") OR Hepatopoeitin- 791 
A)”.  792 
 793 
1.3 Glycosaminoglycans 794 
The extracellular matrix consists largely of complex protein linked carbohydrates 795 
called glycosaminoglycans (GAGs) that bind water and work as a scaffold [3]. 796 
Although GAGs might not make up a high percentage of the extracellular matrix 797 
weightvise, they form a hydrated gel that occupies a very large volume relative to 798 
their mass [18]. These highly elongated and negatively charged GAGs interact with a 799 
number of proteins such as growth factors, enzymes, complement proteins and 800 
cytokines. In recent years it has become clear that GAGs are not just 801 
hydrating/scaffolding molecules, but also play a central role in homeostasis [109], 802 




1.3.1 Proteoglycans 805 
GAGs often occur linked to proteins, forming proteoglycans. There are many 806 
different types of proteoglycans [117] and they can be classified according to the 807 
kind of GAG they carry, for example HSPG being a heparan sulfate (HS) 808 
proteoglycan. Proteoglycans can also be classified depending on what protein class 809 
they belong to or their physiological location. The cell-surface classes of 810 
proteoglycans that are linked to the cell-membrane are the glypicans [118], [119] and 811 
syndecans [120]. These two classes of proteoglycans carry HS chains (although 812 
hybrid forms containing both HS and CS (chondroitin sulfate) have been found in 813 
some tissues) and are likely to be the most relevant for the HGF-GAG interaction 814 
[119]. Glypicans are linked to the cell membrane by a GPI anchor whereas 815 
syndecans are transmembrane proteins. Syndecans typically carry 3-5 GAG chains 816 
and glypicans typically carry 2-3 GAG chains. Interestingly, the glypican GAG 817 
chains are attached close to the transmembrane region of the protein sequence, 818 
placing the GAG chains closer to the cell membrane than the main extracellular parts 819 
of the protein. This probably allows for GAG-binding signalling molecules to bind 820 
their cell surface target receptor easier. Syndecans are also found free in the 821 
extracellular matrix as a protease site in the ectodomain allows for shedding of the 822 
whole proteoglycan [121]. Shedding of the ectodomain is likely important in 823 
signalling regulation [122]. Other classes of proteoglycans such as the perlecans that 824 
present in the extracellular matrix in basal membranes have also been shown to 825 
interact with HGF [123].  826 
 827 
1.3.2 Primary Structure of Glycosaminoglycans 828 
GAGs are divided into different groups depending on their repeating disaccharide 829 
structure and acetylation/sulfation pattern [124] (Figure 1.12 and Figure 1.13). Most 830 
GAGs are linked via a glucuronic acid monosaccharide, two galactose 831 
monosaccharides and one xylose monosaccharide to a serine or threonine amino acid 832 




Figure 1.12 Overview of the different GAG structures, showing their sugar 835 
constituents and sulfation patterns. The GAG chains are shown as being attached to a 836 
protein molecule, forming proteoglycans. The S and A regions on HS indicated N- 837 
sulfated (NS) and N-acetylated (NA) regions. Taken from [124].  838 
 839 
Figure 1.13 Main disaccharide units in the different types of GAGs, H: 840 
Hexoseamine, G: Glucuronic acid, I: Iduronic acid. Carbon backbone numbering is 841 
shown for heparin. Note that the disaccharides are somewhat interchangeable, for 842 
example heparin-like disaccharides can be present in HS. Modified from [125].  843 
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The different classes of GAGs are heparin, heparan sulfate, chondroitin sulfate, 844 
dermatan sulfate (DS), hyaluronic acid and keratan sulfate (the two latter have been 845 
left out in Figure 1.12 and Figure 1.13 as they are not relevant for this project). There 846 
are also GAG subclasses such as chondroitin A, C and E [116] and reports about 847 
CS/DS hybrid GAGs [126], so the classification is clearly flexible and not always 848 
straightforward.  849 
 850 
Heparan sulfate is mainly built up of glucuronic acid (GlcA) that can be 2-O-sulfated 851 
and is 1-4 linked to a glucosamine (GlcN) that can be N-acetylated (GlcNAc) or N- 852 
sulfated. If the GlcA is N-sulfated, it can undergo epimerisation to iduronic acid, 853 
followed by O-sulfation at C-2 and C-6 of the GlcNS, producing a heparin like 854 
disaccharide. The C-3 position of HS disaccharides can be O-sulfated, usually in 855 
conjunction with N, C-2, and C-6 –sulfations, but only 0.15% of the disaccharides in 856 
HS are tetrasulfated [127]. Heparin consists mainly of iduronic acid (IdoA) that is 2- 857 
O-sulfated and 1-4 linked to a glucosamine that is usually N-sulfated (GlcNS) on the 858 
C-2 position and O-sulfated on the C6 position. The rare 3-O-sulfate that exists in HS 859 
also exists in heparin. The difference between heparin and HS is that the latter is 860 
more heterogeneous, contains extensive monosulfated domains and that HS also 861 
contains unsulfated disaccharides.  862 
 863 
Chondroitin sulfate (CS) consists of glucuronic acid 1-3 linked to an N-acetylated 864 
galactosamine (GalNAc). If the GalNAc is sulfated on the four position the species is 865 
classified as CSA, if the GalNAc is 6-sulfated the species is classified as CSC and if 866 
the species is both 4 and 6 –sulfated it is classified as CSE. Dermatan sulfate (DS) 867 
consists mainly of iduronic acid 1-3 linked to an N-acetylated galactosamine, which 868 
can be sulfated on the four or six positions of the GalNAc.  869 
 870 
Heparin is probably one of the most well known GAGs as it is a common 871 
anticoagulant drug [109]. Chondroitin is also relatively well known for working as a 872 
lubricant in joints. This project focuses mainly on heparin, CS and DS. 873 
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1.3.3 Biosynthesis of Glycosaminoglycans 874 
The heterogeneity of HS and other GAGs arises during the biosynthesis in the Golgi 875 
apparatus and the action of post-synthesis GAG modifying enzymes such as 876 
sulfatases that can modify the GAG motifs in the Golgi apparatus and on the cell 877 
surface [128]. GAG chain biosynthesis initiates after a xylose has been transferred to 878 
a translated protein chain that is destined to become a proteoglycan (Figure 1.14). 879 
The xylose is attached to a Ser-Gly dipeptide with one or several neighbouring acidic 880 
amino acids. After the xylose has been conjugated, two galactose sugar units are 881 
attached to it by galactosyl transferase I and II. Next, a glucuronic acid is appended 882 
by glucuronosyltransferase I. The GlcA-Gal-Gal-Xyl-[Ser] tetrasaccharide is the 883 
common core protein linkage sequence for heparin, HS, CS and DS. The linkage 884 
galactoses can be both sulfated (CS) and phosphorylated (CS, HS, heparin). The 885 
enzymes involved in the biosynthesis of this linker are vital for GAG chain initiation 886 
and without them there would be no GAG chains at all. 887 
 888 
Interestingly, the GlcNAc/GalNAc transferases not only recognize the 889 
tetrasaccharide, but also the amino acid motifs to which the tetrasaccharide is 890 
attached and both the tetrasaccharide sequence and the amino acid motif determine 891 
whether the synthesised GAG type will be of CS/DS or heparin/HS type. 892 
 893 
After the linkage tetrasaccharide has been attached and an α-linked GlcNAc has 894 
earmarked it for HS synthesis, the chain is elongated by alternating additions of 895 
GlcA and GlcNAc units by enzymes from the EXT gene family working 896 
synergistically with each other [129], [130]. The sugar units are transferred from 897 





Figure 1.14 The sequential enzymatic steps in heparin/HS biosynthesis. NA: N- 901 
Acetylated, NS: N-Sulfated, 2S: 2-Sulfated. Taken from [121]. 902 
 903 
After the linkage tetrasaccharide has been assembled, the chain is committed to HS 904 
elongation by the addition of an α-linked GlcNAc residue by αGlcNAc transferase, 905 
whereas the addition of a β-linked GalNAc commits the chain to CS/DS elongation.  906 
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As the chain is being elongated and finished, sulfotransferases and epimerases start 907 
to modify the HS chain. Some of the modifications take place in sequential order and 908 
others can take place unsystematically (Figure 1.14): 909 
a) GlcNAc N-deacetylase/N-sulfotransferase (NDST) removes the N-acetyl 910 
group of GlcNAc units and replaces it with a sulfate group. The NDST 911 
enzymes catalyse both reactions and the sulfate group is supplied by a PAPS 912 
cofactor. PAPS is an universal sulfate donor in biochemical reactions, it is 913 
somewhat similar in structure to ATP in that it contains an adenosine, but it 914 
donates a sulfate instead of a phosphate. The different NDST enzymes are 915 
expressed at different levels in different tissues and have varied deacetylation 916 
and sulfation efficiencies, for example NDST3 is an efficient deacetylater 917 
whereas NDST4 exhibits good sulfotransferase activity. The enzymes are 918 
likely involved in the regulation of HS sequences, for example NDST1 and 919 
NDST2 are widely expressed, whereas NDST3 and NDST4 have only been 920 
identified in adult brain and fetal tissues. The varied efficiencies in 921 
deacetylations/sulfations could explain why 0.7–4 % of deacetylated 922 
glucosamines in different HS and heparin preparations lacks an N-sulfate 923 
[131]. The de-N-acetylated disaccharides are often concentrated in the protein 924 
linkage region, but in aortic HS they also occur more peripherally, in general 925 
the free amines are located within the NA domains, or in transition NA/NS 926 
domains. The de-N-acetylated disaccharides contain free amines have been 927 
shown to be important in some protein-GAG interactions [132], [133]. As 928 
further explained in section 1.3.4, the NS regions are interspaced between NA 929 
regions in HS. How the overall structure of these NA/NS domains is 930 
determined is unclear, but it is thought that the NDST enzymes play a crucial 931 
role in the regulation [134]. The replacement of the N-acetyl group by a 932 
sulfate is the first modification in the GAG biosynthesis and is required for 933 
several subsequent modifications. The NDST enzymes are inhibited by O- 934 
sulfates on the disaccharide unit, which is an important regulatory function it 935 
helps the biosynthesis take place in a specific order. 936 
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b) After the GlcNAc residues have been N-sulfated, the reducing end 937 
neighbouring GlcA can be epimerised to IdoA by C-5 epimerase. To date, 938 
only one C-5 epimerase has been identified. The same enzyme epimerises 939 
heparin and HS chains [135] and interestingly, the epimerisation reaction is 940 
irreversible in vivo, but not in vitro [136]. The enzyme does not react with 941 
any GlcA residues that are O-sulfated or that are next to an O-sulfated 942 
glucosamine residue. This suggests that epimerisation happens after the first 943 
N-deacetylation/N-sulfation but before any O-sulfation reactions. Glucuronic 944 
acid epimerisation is regulated by: 1) the extent of N-sulfation, 2) the level of 945 
C-5 epimerase expression, 3) the extent of O-sulfation. IdoA is a very 946 
common residue in protein binding GAG motifs because it can adopt more 947 
conformations than GlcA as further discussed below.  948 
c) 2-O-sulfotransferase is thought to act at the same time as the NDST and C-5 949 
epimerase enzymes. Using PAPS as a cofactor, 2-O-sulfotransferase transfers 950 
a sulfate to the 2-O position of both IdoA and GlcA, but acts more efficiently 951 
on IdoA and thus more IdoA units are sulfated compared to GlcA. As 952 
expected, 2-O sulfation is more common in NS domains, but it is also present 953 
in NA domains, for example human cerebral cortex has a relatively high 2-O- 954 
sulfated GlcA content [137]. As 2-O-sulfotransferase performs its actions at 955 
the same time as NDST and C-5 epimerase and the resulting 2-O-sulfate 956 
group inhibits the two latter enzymes, 2-O-sulfation is a regulatory step. To 957 
date, only one 2-O-sulfotransferase has been found. 958 
d) The three members in the 6-O-sulfotransferase class of enzymes (6-OST-1, 6- 959 
OST-2 and 6-OST-3) exhibit different substrate specificities, but they all 960 
catalyse the same reaction: addition of a 6-O-sulfate to glucosamine residues 961 
[138]. 6-O-sulfates seem to be more common in NS domains. 6-OST-2 exists 962 
in two different splice forms with different tissue expression patterns [139]. 963 
6-OST-1 is expressed in liver, 6-OST-2 is expressed mainly in brain and 964 
spleen and 6-OST-3 is expressed ubiquitously. It is thought that 6-O-sulfation 965 
typically happens in the later stages of heparin/HS synthesis, although some 966 
flexibility probably exists. 967 
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e) Both 3-O-sulfation and 6-O-sulfation can be the final step in heparin/HS 968 
biosynthesis [140], although 3-O-sulfation is often thought to be the last step 969 
that only modifies a few residues per chain [141]. It is the most uncommon 970 
sulfation in heparin and heparan sulfate and is important in several protein 971 
binding motifs, for example for herpes simplex virus glycoprotein D, FGF-7 972 
and antithrombin III. Six different 3-O-sulfotransferases with different 973 
substrate specificities and tissue expression patterns have been identified to 974 
date.  As can be seen in Figure 1.15 and Table 1.5, the several isoforms of 3- 975 





Figure 1.15 HS/heparin disaccharide specificity for the different 3-O- 981 





Table 1.5 The table summarises the different 3-O-sulfotransferase disaccharide 985 




3OST-3A and -3B IdoA2S-GlcNH2±6S 
3OST-4 ? 
3OST-5 HexA±2S-GlcNH2±S6S 
3OST-6 IdoA2S-GlcNH2±6S (same as 3OST) 
 987 
After the GAG chains have been synthesised and the proteoglycans presented on the 988 
cell surface, post-synthesis modification can take place by the removal of sulfates by 989 
sulfatases [148]. QSulf1 and QSulf2 are sulfatases that remove 6-O sulfates from HS 990 
both in the Golgi apparatus as the GAGs are being synthesised and post-synthesis, 991 
extracellularly [149]. The enzymes are important in cell signalling, for example it has 992 
been shown that they promote Wnt signalling, but inhibit FGF signalling [150]. 993 
These sulfatases are special in the way that by removing sulfates they translate the 994 
GAG sequence information into a biological event, setting them apart from other 995 
sulfatases that are often involved in metabolism [151]. Both QSulf1 and QSulf2 have 996 
the same substrate disaccharide specificity for heparan sulfate NS domain 997 
disaccharides, namely UA±2S-GlcNS6S (a disaccharide consisting of an uronic acid 998 
that is optionally 2-O-sulfated, followed by a galactosamine that is N-sulfated and 6- 999 
sulfated) [152]. The two enzymes are not covalently attached to the cell surface as 1000 
they can be washed off with high salt buffer. 1001 
 1002 
As follows from the above discussion, there is a great deal of flexibility in GAG 1003 
biosynthesis machinery. Although some reactions take place sequentially, many 1004 
reactions take place in a random order and some enzymes work at relatively random 1005 
 
 34 
sites, but through the careful orchestration of isoenzyme expression in different 1006 
tissues, specific motifs can be synthesised as needed. Most of the GAG biosynthesis 1007 
takes place in the Golgi apparatus, where it has been shown that many of the 1008 
involved enzymes assemble in a big complex, called the GAGosome [141].  1009 
 1010 
Much of what is known about the physiological roles of GAGs, particularly in 1011 
development, has been learned from knocking out particular enzymes in model 1012 
organisms such as mice [153]. Although some enzymes are vital, there is often a 1013 
surprising flexibility and redundancy in the GAG synthesis machinery and similar 1014 
GAG motifs can be synthesised even when isoenzymes have been knocked out. This 1015 
is likely because other isoenzymes can step in for the knocked out enzyme. In some 1016 
enzyme knockout models, modified GAGs are produced that still can fulfil their 1017 
physiological roles. This compensatory effect of one GAG motif for another 1018 
emphasises that although GAG binding proteins usually prefer a specific motif, the 1019 
interactions are promiscuous and the proteins can bind alternative GAG motifs with a 1020 
lower affinity and still function. 1021 
 1022 
Some of the GAG biosynthesis enzymes are involved in diseases, for example EXT1 1023 
is a tumour suppressor that has been implicated in cancers and hereditary multiple 1024 
exostoses, a bone disease [154]. 1025 
 1026 
1.3.4 The Heterogeneity of Glycosaminoglycans 1027 
Referring back to Figure 1.12, it can be seen that heparan sulfate contains interspaced 1028 
highly and lowly sulfated regions [121]. The lowly sulfated regions are called NA 1029 
domains as they are N-acetylated and the highly sulfated regions are called NS 1030 
regions as they are N-sulfated. To further add to the complexity, HS also contains 1031 
NA/NS domains, which is a mix of NA and NS disaccharides. The length of a NS- 1032 
domain is roughly 2-9 disaccharides, being interspaced by 16-18 disaccharides of 1033 
NA and NA/NS domains [155], consequently the NA domains take up the largest 1034 
part of the HS chains with the shorter NA/NS domains bordering to the NS domains 1035 
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(Figure 1.16). However, the degree of HS sulfation and how tightly spaced the NS 1036 
domains are seems to vary between and within different organs [156], [155]. For 1037 
example, rat liver HS is much richer in NS domains and its chains are shorter than rat 1038 
skin fibroblast HS.  1039 
 1040 
 1041 
Figure 1.16 Domain structure of a heparan sulfate. The purple unit is the 1042 
tetrasaccharide protein-GAG linkage. 1043 
It is not only the overall NA/NS domain structure that varies between tissues, but 1044 
sugar units and sulfation patterns also differ between tissues on a very specific level 1045 
[157]. The HS disaccharide fingerprint has also been found to change with age [158] 1046 
and different diseases [159]. All these differences in HS sequences will be 1047 
recognised differently by signalling and regulatory proteins and are ways of 1048 
regulating signalling pathways in physiological processes, disease and during 1049 
embryogenesis [115]. The disaccharide composition, expression levels of GAG 1050 
modifying enzymes and sulfation patterns of HSPGs in different cancers have been 1051 
identified as possible bio-markers for diseases. For example an up-regulation of the 1052 
3-OST-1 sulfotransferase and an increase in 3-O-sulfation in hepatocellular cancer 1053 
was identified by RT-PCR and monoclonal antibodies recognising the 3-O-sulfate 1054 
epitope [160].  1055 
 1056 
It is clear that the heterogeneity of GAGs carries information in a manner similar to 1057 
DNA (although GAGs are not replicated or translated) and plays a central role in 1058 
homeostasis and regulation of signalling pathways. It is well known that CS and DS 1059 
are less heterogeneous than heparin and HS and physiological regulation has often 1060 
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been pinpointed to the latter two GAGs [124], [125], [161], [162], [66], [163]. 1061 
Although variance exists in DS and CS GAGs too and this heterogeneity is also 1062 
likely to be important for regulating biological activity, for example signalling 1063 
pathways [126], [164], [40], [165]. 1064 
 1065 
The highly sulfated NS regions of HS very much resemble the heparin structure and 1066 
it is thought that proteins preferably interact with these highly sulfated IdoA 1067 
containing regions in HS. Heparan sulfate is found on the cell surface and on matrix 1068 
proteoglycans and is thought to be the natural in vivo ligand for HGF and most other 1069 
heparin binding proteins such as the GAG binding growth factors FGF (Fibroblast 1070 
Growth Factor, a family of heparin binding growth factors involved in angiogenesis, 1071 
wound healing, and embryonic development) and VEGF (Vascular Endothelial 1072 
Growth Factor, a family of growth factors produced by cells that are exposed to low 1073 
oxygen levels that stimulates angiogenesis). However, heparin is often used in place 1074 
of heparan sulfate in experiments as heparin is readily available, has a more 1075 
homogeneous sulfation pattern and has a more or less identical structure to the HS 1076 
NS domains [166]. Heparin mimics the highly sulfated NS regions of HS, which are 1077 
usually the protein binding regions that are of most interest. This is also the argument 1078 
of using heparin instead of heparan sulfate in this thesis.  1079 
 1080 
The golden grail of protein-GAG interaction research is to understand how proteins 1081 
recognise a specific GAG motif. Although there has been some achievement in the 1082 
field, such as the identification of the ATIII binding pentasaccharide, the hunt for the 1083 
exact GAG epitope of a protein-GAG interaction is not trivial and complexity 1084 
quickly increases with increasing GAG length [167]. To date 23 different 1085 
disaccharide structures have been identified in heparin and HS and considering that a 1086 
typical binding motif might be a hexasaccharide to a decasaccharide there are 233 to 1087 




There are several tools available to identify the binding motifs, for example affinity 1090 
chromatography, microarrays, SPR and ITC. There are also several tools available to 1091 
identify the disaccharide composition of GAGs, for example disaccharide analysis, 1092 
mass spectrometry and NMR. Disaccharide analysis is a powerful technique that can 1093 
elucidate both disaccharide contents and sequence [168], [169]. NMR also has the 1094 
power to elucidate the complete sequence, but demands relatively large quantities of 1095 
material that sometimes can be hard to achieve. One might think that with these 1096 
powerful tools, it should be straightforward to identify binding motifs, but the 1097 
problem is often complicated by promiscuous binding and by the fact that some 1098 
proteins have similar affinities for several motifs. Furthermore, like in the ATIII 1099 
case, the binding motif can contain an uncommon 3-O-sulfate that is only present in 1100 
small quantities. 1101 
 1102 
Heparin and other GAGs obtained from different sources and batches differ in sugar 1103 
units, sulfation levels, patterns, sequences and chain lengths [170], [171], [156]. If 1104 
the GAGs are not further processed and purified or thoroughly characterised, 1105 
experimental results may well lead to different results in a series of analogous 1106 





Figure 1.17 Twenty three identified disaccharide structures in heparin and HS. 1110 
GlcA-containing disaccharides are shown on the left and IdoA-containing 1111 
disaccharides are shown on the right. X= H or SO3-. Taken from [128]. 1112 
 1113 
1.3.5 Secondary structure of Glycosaminoglycans 1114 
Figure 1.18 shows the NMR structure of heparin and as can be seen, heparin adopts a 1115 




Figure 1.18 NMR structure of heparin [173]. The 1hpn PDB file with the IdoA 1118 
residues in a 1C4 conformation was rendered in UCSF Chimera 1.4. 1119 
 1120 
Different GAGs can adopt different helical shapes [167], where the most important 1121 
parameters that determine the helical structure are the glycosidic linkage torsion 1122 
angles and the ring conformation of the sugar units. The glucosamine and 1123 
galactosamine residues adopt a 4C1 conformation, which is also the preferred 1124 
conformation of glucuronic acid (Figure 1.19). Iduronic acid is the most flexible 1125 
GAG component; as the energy difference between the 1C4 and 2S0 conformations is 1126 
very low, it can adopt both conformations. The energy difference between the 1127 
conformations is too high for the other sugar residues. As iduronic acid is more 1128 
flexible than glucuronic acid, this also makes the NS domains in HS relatively 1129 
flexible and the NA domains relatively rigid. The preferred conformation of IdoA 1130 
depends on its 2-O substitution and on the substitution pattern of the neighbouring 1131 
GlcN. 1132 
 1133 
Figure 1.19 The most common conformations of the GlcA and IdoA residues. Taken 1134 




1.3.6 Physiological Roles of Glycosaminoglycans 1137 
GAGs have many physiological roles, one of the classic examples being regulation 1138 
of blood clotting. In this case, antithrombin-III (AT-III), a serine protease inhibitor, 1139 
specifically recognizes a HS pentasaccharide fragment containing a 3-O sulfate. 1140 
When AT-III has recognized and bound the pentasaccharide, its serine protease 1141 
inhibiting activity drastically increases and by inhibiting proteases in the blood- 1142 
clotting cascade, homeostasis is maintained [174]. This interaction is one of the most 1143 
common examples of a highly specific protein-GAG interaction. 1144 
 1145 
Interestingly, patients on LMWH (Low Molecular Weight Heparin) anticoagulant 1146 
therapy have reduced incidence of cancer [110]. This is likely due to inhibition of 1147 
heparin binding growth factors such as HGF, FGF and VEGF, but could also be due 1148 
to heparin inhibiting heparanase and selectins that are vital for cancer cell metastasis 1149 
[95], [175]. Inhibition of heparanase and selectin mediated extravasation has also 1150 
been suggested to be the physiological role of heparin as an anti-inflammatory agent 1151 
released from mast cells [176]. As can be seen in Figure 1.20, selectins on immune 1152 
cells interact with proteoglycans on the endothelium and allow immune and cancer 1153 
cells in blood vessels to attach to the walls and extravasate to the inflammation site, 1154 
or in the case of cancer cells, metastase. This points to the importance of protein- 1155 
GAG interactions not only in cancer, but also in inflammation, two important 1156 
pathological processes that are being targeted for drug development by GAG- 1157 
mimetics [4]. 1158 
 1159 
Figure 1.20 points out many of the important protein-GAG interactions that are 1160 
targetable for cancer and inflammatory drug development. The start of an 1161 
inflammatory response can for example be that tissue damage activates macrophages 1162 
to release chemokines and other cytokines. Essentially all chemokines are able to 1163 
interact with GAGs as they are diffusing through the extracellular matrix [177]. The 1164 
cytokines and chemokines carry signals to the endothelial cells to display 1165 
proteoglycans such as syndecans and selectins, enabling circulating cells to bind to 1166 
the endothelium. Once the immune cells have bound to the endothelial cells and 1167 
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started to extravasate, heparanase and proteases are released by the immune cells to 1168 
degrade the basal membrane and extracellular matrix so that the cells can migrate 1169 
[178]. As the extracellular matrix is degraded, immobilised growth factors that have 1170 
been bound to the previously intact proteoglycans are freed. These released growth 1171 
factors (VEGF, FGF and HGF for example) can increase angiogenesis, supporting 1172 
inflammation or cancer growth. For example, it has been shown that FGF2 is stored 1173 
in a dormant form bound to syndecans that is cleaved by heparanase as a mitogenic 1174 
complex [4]. The release of heparanase itself is also important for angiogenesis, as 1175 
the basal membrane extracellular matrix needs to be degraded and remodelled for 1176 
angiogenesis [179]. 1177 
 1178 
Figure 1.20 The importance of protein-GAG interactions in the migration of immune 1179 
cells from blood vessels. Taken from [178]. 1180 
 1181 
Heparanase has been shown to be overexpressed in many types of cancers and in 1182 
tumours it confers an accelerated growth and invasive phenotype [180]. One of the 1183 
main roles of heparanase in cancer is likely to free immobilised HS-binding growth 1184 
factors through its enzymatic activity [4], [181]. The mobilised growth factors can 1185 
promote angiogenesis, cell proliferation and survival. The oligosaccharides that are 1186 
produced when heparanase digests HS can work as co-receptors for the released 1187 
growth factors. Through degrading and remodelling the extracellular matrix, 1188 
heparanase contributes to tissue remodelling and cancer cell invasion. Independently 1189 
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of its enzymatic activity, it has been shown that heparanase stimulates Akt-dependent 1190 
cell invasion and migration [182]. Interestingly, overexpression of heparanase has 1191 
also been shown to increase tissue factor activity, which in a second step can increase 1192 
the levels of HGFA (Hepatocyte Growth Factor Activator) and in a third step 1193 
increase the levels of active HGF, contributing to further cancer progression (Figure 1194 
1.8) [181]. It is possible that LMWH therapy inhibits heparanase or competes with its 1195 
natural target heparan sulfate. This would decrease the effects that heparanase has on 1196 
cancer development and progression [179].  1197 
 1198 
Heparin is only found in mast cell rich tissues such as the trachea and intestinal 1199 
mucosa. It is synthesised as a proteoglycan called serglycin, but is cleaved from its 1200 
core protein before it is stored in granules of immune cells such as mast cells and 1201 
basophiles. The heparin is secreted as a pure glycosaminoglycan chain after IgE 1202 
stimuli [183]. Serglycin typically has 10-15 GAG chains attached, which can also be 1203 
HS, CS and DS, depending on tissue and cell type [184]. The role of heparin in vivo 1204 
is still somewhat unclear, but it has been shown that it is vital for the storage and 1205 
release of proteases that regulate inflammatory responses from mast cell granula. It 1206 
has therefore, in conjunction with other evidence been suggested that heparin has an 1207 
anti-inflammatory effect as discussed above [185]. It has been shown that inhaled 1208 
heparin prevents exercise-induced asthma [186]. The action of heparin in this case is 1209 
likely a secondary effect related to a decrease of smooth muscle constriction 1210 
mediators such as histamine from mast cells. GAG-protein interactions are important 1211 
in many steps of the inflammatory process and it is not surprising that exogenous 1212 
heparin can modify the process. On a molecular level, heparin is likely to bind to 1213 
selectins and inhibit the interaction with their natural sialyl Lewisx ligand [176], 1214 
[187]. Selectins are displayed on the blood vessel endothelium at the location of 1215 
inflammation. If heparin binds to the selectins, immune cells will not be able to 1216 
extravasate to the inflammation site and the inflammatory response will be 1217 
suppressed (Figure 1.20). A big effort is currently going into identifying GAG 1218 




1.3.7 Protein-Glycosaminoglycan Interactions 1221 
The ionic interactions of sulfates and carboxyls with positively charged lysines and 1222 
arginines are usually the most important protein-GAG interaction points and thus the 1223 
sulfation positions/pattern of the GAG is the most important binding motif 1224 
determinant.  1225 
 1226 
Most of the free energy contribution, ΔG, of the interaction between positively 1227 
charged residues on proteins and sulfates on GAGs comes from the entropically 1228 
favourable displacement of Na+ or equivalent counter ions bound to the GAG [188- 1229 
190]. This is called the polyelectrolyte effect. The counter ions have high 1230 
translational entropy and when they are dispersed into the solvent after 1231 
complexation, the entropy gain can balance the loss of conformational entropy of the 1232 
GAG.  1233 
 1234 
Interestingly, arginines and lysines form intermolecular bonds with sulfates in 1235 
different manners [191], [192] and it has been shown that an arginine peptide binds 1236 
2.5 times tighter to heparin than the equivalent lysine peptide [193]. “Stronger 1237 
hydrogen bonding and a more exothermic electrostatic interaction” likely explained 1238 
the greater affinity of arginine for GAG sulfates and it is argued that “this can be 1239 
rationalized by soft acid, soft base concepts” [193]. 1240 
 1241 
The type of sugar units the GAG is built up of and their conformation will determine 1242 
the orientation of the sulfate, carboxyl and hydroxyl groups [174]. These groups are 1243 
the main interaction points between the GAG and the protein. The interconversion 1244 
between the IdoA 1C4 and 2S0 conformations only gives rise to small changes in the 1245 
glycosidic linkage torsions and thus preserves the helical shape of the GAG. On the 1246 
other hand, the orientation of the sulfate groups in the IdoA residues changes more 1247 
drastically between the 1C4 and 2S0 conformations (Figure 1.21). The helical shape 1248 




Figure 1.21 This is an overlay of heparin structures, showing the difference of 1251 
having the IdoA residues in 1C4 (purple) and 2S0 conformations (green). Glucosamine 1252 
residues are shown in grey with the C-2-N-sulfates in blue and the C-6-O-sulfates in 1253 
red. The figure was created by rendering the 1HPN pdb file [173] in UCSF Chimera 1254 
1.4. 1255 
 1256 
Both the glycosidic torsion angles and sugar conformations often change upon 1257 
protein binding, creating a distortion in the secondary structure to maximise ionic 1258 
and van der Waals interactions with the protein [125]. For example, in the FGF-GAG 1259 
interaction, an iduronic acid residue surrounded by two glucosamines adopts 1260 
conformations so that the oligosaccharide is kinked to optimise the number of non- 1261 
covalent bonds to the protein [194]. The IdoA residue is vital in this case as it allows 1262 
the binding motif to adapt to the protein binding site. The high flexibility of GAGs 1263 
and their ability to adapt to protein binding sites might explain why some protein- 1264 
GAG interactions are relatively promiscuous. 1265 
 1266 
It has been shown that heparin interacts specifically with Cu2+ [195], Ca2+ [196] and 1267 
many other cations in structurally distinct ways [197]. Interestingly, Ca2+ was found 1268 
to bind specifically between IdoA and GlcN residues where it induced a change in 1269 
the equilibrium of IdoA conformers towards 1C4, whereas Na+, K+ and Mg2+ binding 1270 
modes were less specific. Further, a heparin oligosaccharide that was unable to 1271 
support FGF signalling alone strongly supported signalling in the presence of Cu2+ 1272 
[197]. The results emphasise that different cations can promote certain GAG 1273 
conformations and that this is likely to affect protein – GAG interactions, something 1274 
that has to be considered when designing experiments. 1275 
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However, it should also be emphasised that hydrogen bonding, van der Waals 1276 
interactions and hydrophobic interactions can also be important for some 1277 
interactions. Fondaparinux and Idraparinux are 3-O sulfate containing HS mimetic 1278 
anti-coagulant drugs that bind tightly to ATIII (Figure 1.22). It has been shown that 1279 
the GAG mimetic Idraparinux binds with hundredfold higher affinity to antithrombin 1280 
than Fondaparinux and that 70% of the affinity of the interaction is made up of non- 1281 
ionic interactions [198]. This is in strong contrast to the normal antithrombin – 1282 
heparin interaction, where almost all of the binding affinity can be addressed to ionic 1283 
interactions [188]. It has been shown that by extending the Fondaparinux 1284 
oligosaccharide, more ionic interactions can be made, making the ionic contribution 1285 
even greater [189]. By performing experiments at different temperatures, in buffers 1286 
with different heats of ionisation and salt concentrations, it is possible to quantify the 1287 
ionic bond, hydrogen bond and hydrophobic interaction contributions. It is also 1288 
possible to quantify the number of hydrogen and ionic bonds that are formed in the 1289 
binding event, how many sodium ions that are displaced and the net uptake or release 1290 
of hydrogens from the buffer. 1291 
  1292 
 1293 




1.3.8 Enzymatic Depolymerisation of Glycosaminoglycans 1296 
GAG chains are typically 50-100 monosaccharide units long and commercial heparin 1297 
varies in size from 5-40 kDa, although size and other parameters vary between 1298 
batches [200], [126], [201], [69]. Long GAGs often precipitate heparin binding 1299 
proteins, it can therefore be necessary to digest them into shorter fragments to be able 1300 
to study the interaction. Further, the heterogeneity can be reduced and studied to 1301 
decipher the disaccharide sequence code [202]. There are several different ways to 1302 
depolymerise GAGs, the most gentle being enzymatic digestion, but chemical 1303 
depolymerisation is also commonly employed to produce GAG fragments [203].  1304 
 1305 
GAG degrading enzymes exist in both eukaryotes and prokaryotes, although many of 1306 
the enzymes used in research and for production of pharmaceutical products come 1307 
from the gram-negative soil bacterium Flavobacterium heparinum, also called 1308 
Pedobacter heparinus [204]. Bacteria can use GAGs not only as a carbon source, but 1309 
also as a sulphur source [205]. 1310 
 1311 
Three different heparinases (I-III) with different specificities have been cloned, 1312 
overexpressed and purified from Pedobacter heparinus [206]. They all digest heparin 1313 
and HS by cleaving the glycosidic linkage between a glucosamine and an uronic acid 1314 
through a β-elimination reaction, producing a double bond on the non-reducing end 1315 
of the oligosaccharide [207] (Figure 1.23).  1316 
 1317 
 1318 




Conveniently, the non-reducing end double bond is conjugated with the carboxylic 1321 
acid group and therefore absorbs UV light at 232nm, which can be used for 1322 
quantitation [208]. The catalytic mechanism of heparinase is calcium dependent and 1323 
calcium has to be included in the digestion buffer [209]. Heparinase I cleaves heparin 1324 
and HS between GlcNSO3 and IdoA-2SO3, heparinase II is more promiscuous and 1325 
cleaves between glucosamine and both kinds of uronic acid residues and heparinase 1326 
III which is selective for lowly sulfated regions of HS cleaves between GlcNSO3 or 1327 
GlcNAc and glucuronic acid residues (Figure 1.24) [210]. There are also 1328 
chondroitinases to digest CS and DS (Figure 1.24) [211-213]. Chondroitinases are 1329 




Figure 1.24 Specificities of the different chondroitinases are shown on the left. From 1334 
the top, the GAGs are CSA, DS and CSC. Chondroitinase B refers to the old name 1335 
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for dermatan sulfate, chondroitin sulfate B. The different heparin disaccharides that 1336 
heparinases digest are shown on the right. Taken from [214] and modified from 1337 
[215]. 1338 
 1339 
The enzyme digest can be stopped before it goes to completion and the produced 1340 
oligosaccharide sizes can be separated by gel filtration. After gel filtration, strong 1341 
anion exchange chromatography (SAX) can be employed to isolate fully sulfated 1342 
species from those that lack sulfates. The use of SAX chromatography is only 1343 
practically realistic for shorter heparin/HS oligosaccharides. Individual heparin/HS 1344 
tetrasaccharides can be readily purified and some individual hexasaccharide species 1345 
can be separated, but for octa to deca –saccharides, only fully sulfated species can be 1346 
purified. If homogeneous, fully sulfated oligosaccharides are purified, most of the 1347 
material will be lost due to the heterogeneity. 1348 
 1349 
The GAG lyases are also important in GAG sequencing techniques and disaccharide 1350 
analysis [168], [169]. Disaccharide analysis plays a central role in unlocking the 1351 
structural basis of protein-GAG interactions and identifying the binding motif. The 1352 
technique relies on digesting the GAG oligosaccharide of interest into its 1353 
disaccharide components and comparing the disaccharides’ elution times on capillary 1354 
electrophoresis, SAX or reverse phase HPLC to known standards. By comparing the 1355 
sample disaccharides to the standard disaccharides, the disaccharide composition will 1356 
be clarified, but not necessarily the sequence in which the disaccharides are linked. 1357 
To elucidate the sequence, incomplete digests or NMR techniques have to be 1358 
employed. Thus, the technique is particularly powerful when coupled to other 1359 
analytical techniques such as NMR and mass spectrometric techniques [216]. 1360 
 1361 
1.3.9 Glycosaminoglycan Research 1362 
More and more is learnt about the importance of GAGs in many physiological 1363 
functions. Figure 1.25 shows how the number of GAG related publications has 1364 
grown linearly during the last 28 years. PubMed publications have been growing 1365 
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faster compared to the glycosaminoglycan related publications in the last 20 years 1366 
and show signs of a more exponential like growth curve, showing that other research 1367 
topics have attracted more interest. 1368 
 1369 
 1370 
Figure 1.25 The graph shows number of total PubMed publications per year on the 1371 
left axis and number of glycosaminoglycan publications per year on the right axis 1372 






2 Aims 1376 
Hepatocyte Growth Factor is a multifunctional growth factor that controls many 1377 
physiological processes, for example, cell proliferation, growth and morphology. 1378 
HGF exerts its biological functions by binding Met, a tyrosine kinase receptor that 1379 
activates intracellular signalling cascades. There is extensive evidence of HGF’s 1380 
involvement in disease, especially in cancer and in benign physiological processes 1381 
such as wound healing. It has been suggested that glycosaminoglycans such as 1382 
heparan sulfate (HS) and dermatan sulfate (DS), help or are required in the formation 1383 
of a ternary active GAG-HGF-Met signalling complex. The HGF-GAG interaction is 1384 
therefore a target for drug development, in particular for anti-cancer therapy. One 1385 
potential approach is to use GAG-mimetics that bind HGF, but do not activate Met. 1386 
Such drugs are currently being developed by pharmaceutical companies. In order to 1387 
successfully target protein-GAG interactions for drug development, an in-depth 1388 
understanding of these interactions is required. The overall aim of this thesis was 1389 
therefore to contribute to the molecular-level understanding of the HGF-GAG 1390 
interaction. 1391 
  1392 
In order to achieve the aim of clarifying which protein residues that are involved in 1393 
the interaction and how these interact with different GAGs, recombinant proteins and 1394 
enzymatically depolymerised GAGs had to be produced. The goal was to study the 1395 
interaction from both a protein and GAG perspective, establishing which structural 1396 
features of the GAGs and HGF that are important for this interaction.  1397 
 1398 
Although HGF-NK-G has been crystallised in the presence of heparin DP14, all 1399 
aspects of the HGF-heparin interaction are still not understood. For example, the 1400 
protein construct used in the crystal structure contains an N-terminal cloning artefact, 1401 
which introduces negatively charged residues near the GAG binding site. It was 1402 
therefore judged important to use a more native protein to study the interaction and 1403 
determine if this cloning artefact affects the binding mode of the GAG. Heparin and 1404 
DS are the only GAGs that have previously been used in molecular-level studies of 1405 
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HGF-GAG interactions. Therefore, another important aim of this thesis was to 1406 
elucidate any differences in binding mode of an extended set of GAGs under 1407 
identical conditions using solution-based techniques. 1408 
 1409 
Ionic intermolecular bonding is typically the most important force in protein-GAG 1410 
interactions and therefore, many proteins have a preference to bind to NS region over 1411 
NA regions in heparin/HS. It has been suggested that this is also the case for HGF. 1412 
However, limited data is available to answer the question whether a specific motif or 1413 
sulfation patter in a heparin/HS oligosaccharide binds tighter than others. A goal of 1414 
this thesis was therefore to investigate which heparin sequence in a mixture of 1415 
heparin oligosaccharides that binds tightest to HGF-N. 1416 
  1417 
The KDs for the interaction between GAGs, HGF and its NKx splice variants have 1418 
been determined mostly by biosensor/SPR analysis. Several experimental designs 1419 
with different immobilisation techniques have previously been employed in these 1420 
studies. The biosensor/SPR results suggest that the KD of the interaction is in a low 1421 
nM range. Some protein-GAG interactions are of high affinity with KDs in a low nM 1422 
range, for example the ATIII-pentasaccharide and bFGF-heparin interactions, 1423 
whereas most other protein-GAG and protein-carbohydrate interactions have KDs in 1424 
the µM range. Solution based methods and preliminary ITC studies of the HGF – 1425 
heparin interaction have suggested that the interaction in a low µM range. A key aim 1426 
of this thesis was therefore to investigate the affinity of the interaction further with 1427 
solution based techniques, in particular NMR and ITC to contribute to the 1428 
understanding of the affinity of the interaction and whether the KD of the interaction 1429 
is in a low µM range or low nM range. 1430 
 1431 
It has been proposed that HGF and in particular the NK1 protein construct 1432 
oligomerises upon GAG binding and that the oligomerisation process can be 1433 
involved in the action mechanism of HGF. The oligomerisation process has 1434 
previously not been studied in great detail and one aim of this thesis was to extend 1435 
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the oligomerisation studies to different types and lengths of GAGs and to investigate 1436 
the oligomerisation mode of HGF. This includes the identification of the shortest 1437 
GAG oligosaccharide that is sufficient to induce oligomerisation and how 1438 
oligosaccharide length and type affects oligomerisation mode. 1439 
 1440 
It has been demonstrated in the past that linear carbohydrates, as asymmetric 1441 
molecules, can bind to proteins in different orientations (reducing-to-non-reducing 1442 
end or non-reducing-to-reducing end).  One of the aims of this thesis was therefore to 1443 
clarify if GAGs bind to HGF in a preferred direction. To achieve this aim, a spin- 1444 
labelled heparin oligosaccharide was prepared and titrated into 15N labelled HGF. 1445 
Monitoring of proton relaxation times of backbone NH resonances allowed this 1446 







3 Materials and Methods 1452 
3.1 Analytical Techniques 1453 
3.1.1 Quantification of Proteins and GAGs 1454 
Protein extinction coefficients were calculated by using ProtParam 1455 
(http://expasy.org/tools/protparam.html) and the protein concentrations were 1456 
determined by A280. The extinction coefficients for the protein constructs used in this 1457 
thesis are given in Table 3.1. 1458 
 1459 
Table 3.1 Molar extinction coefficients for the different protein constructs. 1460 
Construct Molar extinction coefficient 
HGF-N 8730 M-1 cm-1 
HGF-K 17335 M-1 cm-1 
HGF-NK-C 26065 M-1 cm-1 
HGF-NK-G 27555 M-1 cm-1 
 1461 
All enzymatically digested GAG oligosaccharides were quantified by A232, using a 1462 
molar extinction coefficient of 5200 M-1 cm-1 [208]. 1463 
 1464 
3.1.2 SDS-PAGE 1465 
Protein samples were mixed with Invitrogen NuPage 4X loading buffer (NP0007), 1466 
10X reducing agent (NP0004) and heated to 75 ºC for 10 minutes. The final samples 1467 
were run on a 4-12 % NuPage Bis-Tris gel (NP0321BOX) with MES (NP0002) or 1468 
MOPS (NP0001) running buffer at 250 volt for 40 minutes and then stained with 1469 




3.1.3 Akta FPLC System 1472 
The Akta FPLC system (GE Healthcare) consisted of a UPC900 UV unit monitoring 1473 
the 280 nm trace, a P920 pump unit and a Frac-900 fraction collector, all controlled 1474 
via the UNICORN 3.21 software. 1475 
 1476 
3.1.4 BioCAD FPLC System 1477 
The FPLC instrument was a BioCAD 700E system with a Waters fraction collector 1478 
capable of collecting 120 fractions. 1479 
 1480 
3.1.5 Waters HPLC System 1481 
The Waters HPLC system consisted of a 486 tuneable UV detector, a 600 control 1482 
unit and a 616 pump unit controlled via the Millennium 3.05.01 software and a 120 1483 
fractions Waters fraction collector that was programmed manually. 1484 
 1485 
3.1.6 NMR Spectrometers 1486 
The AVA600 spectrometer was a Bruker Avance 14.1 T spectrometer (600 MHz 1487 
proton Larmor frequency) equipped with a 5-mm triple resonance TXI probe. 1488 
 1489 
The BIO600 spectrometer was a Bruker Avance 14.1 T spectrometer (600 MHz 1490 
proton Larmor frequency) equipped with a 5-mm triple resonance TXI cryoprobe. 1491 
 1492 
The AVA800 spectrometer was a Bruker Avance 18.8 T spectrometer (800 MHz 1493 
proton Larmor frequency) equipped with a 5-mm triple resonance TCI cryoprobe. 1494 
 1495 
3.1.7 Processing of NMR Data 1496 
NMR data was acquired using Bruker TOPSPIN 1.2 patch 8. Spectra were processed 1497 
using the process program from the AZARA 2.7 suite and then imported into 1498 
CcpNmr Analysis 1.0 R15 [217] for assignment and data analysis. The assignment of 1499 
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15N-1H HSQC crosspeaks of HGF-N was achieved by comparison of the spectra with 1500 
a previously published assignment [17].  1501 
 1502 
3.1.8 MALDI-TOF Mass Spectrometry of Proteins 1503 
Spectra were collected on an Applied Biosystems DE-STR MALDI-TOF with a 1504 
nitrogen laser. Sinapinic acid was used as matrix for protein samples and prepared by 1505 
sonicating and vortexing 10 mg sinapinic acid from Sigma-Aldrich (85429-1G) in 1 1506 
ml 50 % acetonitrile/ddH2O mixture with 0.03 % TFA. 0.5 µl protein sample was 1507 
mixed with 0.5 µl matrix directly on the target plate. The lowest laser intensity that 1508 
gave a clean peak was used. When needed, the instrument was calibrated with the 1509 
external standards cytochrome c, horse myoglobin and hen egg white lysozyme. 1510 
 1511 
3.1.9 MALDI-TOF Mass Spectrometry of GAGs 1512 
To collect MALDI-TOF spectra of GAGs, 25 mg/ml 3-Hydroxypicolinic acid from 1513 
Sigma-Aldrich (56197-250MG) was dissolved in 50% Acetonitrile/ddH2O. No acid 1514 
was added to the matrix solution. A RGRGRGRGRGRGRGRGRGRGRG ((RG)11) 1515 
peptide was synthesised by Peptide Protein Research Ltd 1516 
(http://www.peptidesynthetics.co.uk/). A small volume of fresh matrix with 5-50 µM 1517 
peptide (typically 10 µM) was prepared fresh before each experiment. It was found 1518 
that the (RG)11:GAG ratio was very important to give high quality spectra and 1519 
typically one to ten times excess of (RG)11 peptide was used. Occasionally, this was a 1520 
problem when only a small sample volume with an unknown GAG concentration 1521 
was available. To get the right (RG)11:GAG ratio, ten matrix-(RG)11 solution spots 1522 
were pipetted onto the target plate, the sample was mixed with the first spot and nine 1523 
1:1 dilutions were made on the remaining spots. High quality spectra could be 1524 
collected when the matrix crystallised as long rods, if the matrix crystallised as dots, 1525 
spectra could usually not be collected at all. The method of using peptide-GAG 1526 
complexes for MALDI-TOF analysis of GAGs has been described before [218-221]. 1527 
 1528 
Spectra were collected on the same instrument as for protein MALDI-TOF in 1529 
positive reflectron mode with 65% grid voltage, 25 000 accelerating voltage, 225 ns 1530 
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extraction delay time and 0.05% guide wire. Higher laser intensity had to be used 1531 
compared to proteins and peptides. For proteins, a laser intensity of approximately 1532 
1700 was used, but for GAGs a laser intensity in the range of 2100 gave good 1533 
spectra. 1534 
 1535 
3.2 Protein Production 1536 
3.2.1 Cloning and Transformation of HGF-N, HGF-K and HGF-NK- 1537 
C into P. pastoris 1538 
Image Consortium cDNA clone 40146317, corresponding to Entrez nucleotide 1539 
bc130286.1 was obtained from Geneservice (Cambridge, UK) in a PCR4-TOPO 1540 
vector. A Stratagene Quickchange kit was used to make the silent mutation t615a to 1541 
remove a XHOI restriction site as XHOI was going to be used to insert the gene 1542 
fragment into the pPICZalphaB expression vector.  1543 
Primer set for mutagenesis was: 1544 
5' (Forward) Primer: 5'-CTACTGTCGAAATCCACGAGGGGAAGAAGGG-3' 1545 
3' (Reverse) Primer: 5'-CCCTTCTTCCCCTCGTGGATTTCGACAGTAG-3' 1546 
 1547 
The Stratagene Quickchange mutagenesis was performed as described by the 1548 
manufacturer and the DPNI digested PCR product was transformed into chemically 1549 
competent TOP10 E. coli cells. 20 µl and 200 µl aliquots of the transformation 1550 
reaction were plated and incubated over night on 100 µg/ml LB-ampicillin plates. 1551 
The day after, 10 colonies were inoculated in 5 ml LB broth containing 100 µg/ml 1552 
ampicillin. Next, plasmid DNA from the 10 colonies was prepared by using the 1553 
Qiagen QIAprep Spin Miniprep Kit following the manufacturer’s protocol, which 1554 
typically yielded 50 µl 250 µg/ml DNA. To screen for clones containing the gene 1555 
insert, 10 µl DNA was incubated with 0.5 µl (10 units) XHOI restriction enzyme 1556 
from New England Biolabs (R0146S) and run on 1% agarose gel stained with SYBR 1557 
Safe from Invitrogen (S33102). The DNA for two clones that ran higher than uncut 1558 
control DNA was sequenced using M13 primers and BigDye Terminator v3.1 from 1559 
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Applied Biosystems. The sequence verified the T615A mutation and the clone was 1560 
inoculated in a 5 ml LB-ampicillin Falcon tube overnight. The following morning, 1561 
850 µl of the culture was mixed with 150 µl autoclaved glycerol and snap-frozen in 1562 
liquid nitrogen to produce a glycerol stock stored at -80 °C. 1563 
 1564 
Next, the different HGF fragments were amplified by PCR and later cloned into the 1565 
pPICZalphaB expression vector. Forward primers contained 4 random bases 1566 
followed by an XHOI restriction site, then the KEX2 cleavage site glutamic acid, 1567 
arginine and lysine residues followed by the protein sequence. Reverse primers 1568 
contained the last codons of the cloned sequence, a TAA stop codon followed by an 1569 
XBAI restriction site and four random residues. The four random bases improve 1570 
restriction enzyme activity. The KEX2 arginine and lysine had to be rebuilt with 1571 
PCR when using the pPICZAlphaB XHOI restriction site (Figure 3.1). Refer to Table 1572 
3.2 for a complete list of the different primers and protein constructs. 1573 
 1574 
The forward primers for HGF-N and HGF-NK-C (Table 4.1) were chosen so that the 1575 
first residue of the expressed protein was 31G. The first residue of native HGF is 1576 
32Q, but 31G was chosen as the first residue because that would produce the same 1577 
protein as used for the determination of the NMR structure by Zhou et al [21], 1578 
making it uncomplicated to copy the assignment of 15N-1H crosspeaks. 1579 
 1580 
The  α-factor signal sequence was used to direct the expressed protein for secretion. 1581 
The Kex2 enzyme in P. pastoris cleaves the α-factor signal sequence as the 1582 
expressed protein is secreted between Arg and Glu in the sequence Glu-Lys-Arg * 1583 
Glu-Ala-Glu-Ala, where * is the cleavage site. The Glu-Ala repeats are not necessary 1584 
for Kex2 cleavage, but often makes the cleavage more efficient. The Glu-Ala repeats 1585 
are further cleaved by the Ste13 gene product. For some expressed proteins, Ste13 1586 
cleavage of Glu-Ala repeats is not efficient and Glu-Ala repeats are left on the N- 1587 
terminus. For this reason, the protein constructs in this thesis were cloned without the 1588 




Figure 3.1 The pPICZAlphaB multiple cloning site. The blue arrow indicates where 1591 
the protein sequence was inserted in this project. The red arrow indicates where the 1592 
protein sequence would have been inserted if the Glu-Ala-Glu-Ala cloning artefact 1593 
would have been included in the protein. The artefact is removed post-translation by 1594 
the Ste13 enzyme, but cleavage is sometimes inefficient, leaving one or two Glu-Ala 1595 























































































































































































































































































































































































































































A 50 µl PCR reaction containing 5 ng template HGF DNA, 1 nM (1 µl 100 µM) of 1600 
each primer, 1 µl 10 µM Bio-Rad dNTP mix and 1 µl Herculase DNA Polymerase 1601 
(Stratagene) was set up with the cycling conditions in Table 3.3. 1602 
 1603 
Table 3.3 PCR cycling conditions for amplifying DNA to be cloned into expression 1604 
vector. 1605 
Temperature Time 
95 °C 1:30 
95 °C  30 
60 °C  30 
72 °C  45 
Goto 2 Rep  35 
72 °C  8:00 
4 °C Hold 
 1606 
Amplification was confirmed by running an aliquot of the DNA on an agarose gel. 1607 
The template vector was cut with SPEI and AlwNI to make sure that it wouldn't 1608 
contaminate the cloning reaction and giving false positives. Ideally the template and 1609 
target vector should have carried different antibiotic resistances as some false 1610 
positives were still detected. A 2 µl aliquot of the digested PCR reaction was used to 1611 
clone the PCR product into a TOPO vector using a Zero Blunt TOPO PCR Cloning 1612 
Kit from Invitrogen, following the protocol. After that, 3 µl of the TOPO cloning 1613 
reaction was transformed into TOP10 cells. To screen for positive TOPO cloning 1614 
reactions, 8 colonies of each construct were diluted in 200 µl ddH2O and 9 µl of this 1615 
cell suspension was used as DNA template in a PCR reaction with 1 µl gene specific 1616 
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primer and 10 µl PCR Master Mix from Promega with the cycling conditions in 1617 
Table 3.4. 1618 
 1619 
Table 3.4 PCR cycling conditions for screening E. coli clones containing the correct 1620 
inserts. 1621 
Temperature Time 
95 °C 8:00 (to lyse cells) 
95 °C  30 
58 °C  30 
72 °C  60 
Goto 2 Rep 35 
72 °C  8:00 
4 °C Hold 
 1622 
The PCR reactions were loaded onto an agarose gel to confirm that the inserted DNA 1623 
was of the correct length. Five clones of each construct were grown overnight, 1624 
minipreped and sequenced. One positive clone of each construct was used to make a 1625 
glycerol stock. 1626 
 1627 
Next, each TOPO construct was prepared for cloning into the Pichia expression 1628 
vector pPICZAlphaB from Invitrogen by digesting 21.5 µl DNA (~250 ng/ml) with 1629 
XHOI and XBAI. The reaction was stopped by heating to 65 °C for 20 min. 1630 
 1631 
An E. coli clone carrying empty pPICZAlphaB vector was grown over night in 250 1632 
ml of LB broth with 50 µg/ml Zeocin. The culture was used to maxiprep DNA with a 1633 
Sigma-Aldrich GenElute HP Kit. The prepared DNA was digested with XHOI and 1634 
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XBAI. After that, 50 µl pPICZAlphaB and gene insert DNA was gel extracted with a 1635 
Qiagen Qiaquick Gel Extraction Kit. To further purify the gel extracted DNA, it was 1636 
phenol:chloroform extracted with Phenol:Chloroform:Isoamyl Alcohol 25:24:1, 10 1637 
mM Tris, pH 8.0 from Sigma-Aldrich. To concentrate and purify the DNA further, it 1638 
was ethanol precipitated in 100% EtOH with 0.1 volume 3 M Sodium Acetate pH 5.2 1639 
and washed with 70% EtOH.  1640 
 1641 
The pPICZAlphaB vector and the cDNA genes were mixed at a 1:4 ratio and ligated 1642 
using a Quick Ligation Kit from NEB, following the protocol. The ligated DNA was 1643 
transformed into E. coli TOP10 cells and screened for correct insertion by PCR, 1644 
amplifying the inserted cDNA with PCR MasterMix and primers that bound 5’ and 1645 
3’ of the gene insert in pPICZAlphaB (Table 3.5). Positive clones were submitted for 1646 
sequencing and glycerol stocks were made of positive clones. 1647 
 1648 
Table 3.5 pPICZAlpha sequencing primers. 1649 
5’ pPICZAlpha sequencing primer GGGGATTTCGATGTTGCTGTT 
3’ pPICZAlpha sequencing primer CCGGTCTTCTCGTAAGTGCC 
 1650 
To transform the finalised HGF-N, HGF-K and HGF-NK-C pPICZAlphaB 1651 
expression vectors into P. pastoris, the three vectors were maxipreped and 100 µg 1652 
DNA was linearised with SACI from NEB (R0156S) in a volume up to 500 µl. A 1 1653 
µl aliquot of the digested DNA was analysed on a 0.5% agarose gel to confirm that 1654 
the DNA was properly linearised. The DNA was then phenol:chloroform extracted 3 1655 
times, ethanol precipitated and dissolved in 22 µl ddH2O. A 2 µl aliquot of the 1656 





Electrocompetent KM71H P. pastoris cells were prepared according to the manual 1660 
[222], with the exception that the first two centrifugation steps were performed at 1661 
1000 g instead of 1500 g to give the cells a softer treatment and make the pellet 1662 
easier to resuspend. Usually 20, 40 and 80 µl starter culture in late exponential phase 1663 
were used to inoculate 100-500 ml YPD the night before. Three different inoculation 1664 
volumes were used to make sure that the cells could be prepared at the right OD at 1665 
the right time. For transformation, 10 µl DNA (roughly 10 µg) was mixed with 80 µl 1666 
cell suspension, incubated on ice for circa 3 minutes and electroporated with a 1667 
BioRad Gene Pulser II according to the manufacturers recommendations (0.2 cm 1668 
cuvette, 1.5 kV voltage, 7.5 kV/cm field strength, 25 µF capacitor, 400Ω resistor, 8 1669 
msec time constant). The cells were resuspended in 1 ml 1 M sorbitol and incubated 1670 
for two hours at 30 ºC. To select transformants and screen for multi-copy mutants at 1671 
the same time, 250 µl of the cell suspension was plated on 100 - 300 µg/ml YPDSZ 1672 
plates. 1673 
 1674 
Molecular cloning of all constructs into the pPICZAlphaB expression vector was 1675 
successful. It is a tedious procedure and recent advances in codon optimisation and 1676 
DNA synthesis make full codon optimised gene synthesis a more attractive approach 1677 
[223]. PCR screening was employed to identify successful cloning of the protein 1678 
sequences into the expression vector for all three protein constructs (Figure 3.2). 1679 
Primers that bind 5’ and 3’ of the gene insert in the pPICZAlphaB vector were used 1680 
to amplify DNA. High running bands confirm the presence of inserted DNA, low 1681 






Figure 3.2 Colony PCR screening for clones with correctly ligated gene inserts into 1686 
pPICZAlphaB. Each lane is one clone. The first two lanes are control PCR reactions. 1687 
An empty lane separates the HGF-N and HGF-K constructs. Low running bands 1688 
have migrated through the gel relatively quickly, which indicates a smaller size and 1689 
therefore, they do not contain the inserted DNA. High running bands have migrated 1690 
slowly through the gel slowly due to their relatively large size, which indicates that 1691 
they contain the inserted DNA.  1692 
 1693 
DNA sequencing was used to confirm that all protein sequences were correctly 1694 
cloned into the  pPICZAlphaB vectors (Figure 3.3).  1695 
 1696 
 1697 
Figure 3.3 Sequencing chromatogram showing HGF-N correctly cloned into 1698 
pPICZAlphaB. The DNA sequence can be read on the top, and the translated 1699 
sequence is in grey. The KEX2 cleavage site is indicated with a blue arrow. The first 1700 







pPICZAlphaB vectors with protein inserts were linearised with SACI before being 1703 
transformed into P. pastoris. An agarose gel was run to confirm that the digest had 1704 
worked and that the vector was completely linearised (Figure 3.4). Supercoiled 1705 
vector DNA migrates much faster than linear digested vector DNA through an 1706 
agarose gel and will therefore have a lower apparent kilobase. This principle was 1707 
used to compare digested and undigested DNA to judge if the vector was 1708 
successfully linearised. 1709 
 1710 
 1711 
Figure 3.4 A 0.7 % agarose DNA gel of HGF-N cloned into pPICZAlphaB for 1712 
transformation. The first lane is a kilobase ladder and the numbers indicate the 1713 
number of kilobases in the ladder. The second lane (A) is undigested control vector 1714 
and the last lane (B) is linearised vector, digested with SACI. 1715 
 1716 
3.2.2 Selection of Clones, Expression and Purification of HGF-N, 1717 
HGF-K and HGF-NK-C 1718 
To identify potential multi-copy insert clones that express protein, several clones of 1719 
each construct were screened for protein expression on a small scale. After 1720 
transformation, the Pichia cells were incubated for 4 days at 30 ºC and 10 of the 1721 
largest colonies on the highest Zeocin concentration plates were inoculated in 10 ml 1722 
BMG Falcon tubes and incubated at 30 ºC, 250 rpm for 2 days. The tubes were then 1723 
centrifuged for 5 minutes at 1000 g and resuspended in 1-2 ml BMM. The cultures 1724 
 
 66 
were fed 1 % Methanol every 24 hours for 4 days. To harvest the cultures, tubes 1725 
were centrifuged at 4000 g for 20 min and 750 µl of the supernatant was 1726 
concentrated 10-15 times in a Sartorius Vivaspin 500 5000 MWCO concentrator 1727 
(FIL8550). Next, 15µl of the concentrated supernatant was analysed by SDS-PAGE. 1728 
The clones that showed the strongest protein band of the right size after SDS-PAGE 1729 
analysis were inoculated in 5 ml YPD broth to make glycerol stocks. 1730 
 1731 
After identifying the best expressing clone for each protein construct, the proteins 1732 
were expressed in a fermenter to yield larger protein quantities. A 10 ml BMG starter 1733 
culture was incubated for one day and used to inoculate a 200 ml BMG shaker that 1734 
was incubated for one more day. The shaker culture was centrifuged for 5 minutes at 1735 
1500 g and the pellet was resuspended in 30 ml sterile PBS and used to inoculate a 1736 
fermenter with fermentation minimal medium (Table 3.6 and Table 3.7).  1737 
 1738 
Table 3.6 Unlabelled fermentation minimal medium. 1739 
Phosphoric acid, 85 % 27 ml/l 
CaSO4 0.95 g/l 
K2SO4 18.2 g/l 
MgSO4 x 7H2O 15 g/l 
KOH 4.2 g/l 
Glycerol 25 ml/l 
dH2O Up to 1 litre 
After autoclaving, 4.35 ml PTM1 salts and 0.5 ml AntiFoam 204 (Sigma-Aldrich) 





Table 3.7 15N-labeled fermentation minimal medium. 1742 
CaSO4 0.75 g 
MgSO4 x 7H2O 12 g 
K2SO4 8 g 
1M KPO4 pH 6.0 60 ml 
Glycerol 20 ml 
dH2O Up to 600 ml 
After autoclaving, 4.35 ml PTM1 salts and 0.5 ml AntiFoam 204 (Sigma-Aldrich) 
per litre medium were added. 
A New Brunswick Bioflow3000 system equipped with a pH probe and a dissolved 1743 
oxygen probe from Mettler Toledo was used for fermentation. A Windows PC 1744 
running the BioCommand application controlled, monitored and recorded the 1745 
fermentation. For unlabelled fermentations, a 10-litre vessel was used, for 15N- 1746 
labelled fermentations a 2-litre vessel was used. The dissolved oxygen set point was 1747 
40 %, minimum agitation 200 rpm, maximum agitation 1000 rpm and temperature 1748 
was maintained at 30 °C for growth. A control loop was setup so that dissolved 1749 
oxygen was controlled firstly by agitation increasing from 200 to 1000 rpm followed 1750 
by enriching the airflow with increasing concentrations of O2. The pH was 1751 
maintained at pH 5 by addition of 0.88 M NH4OH for unlabelled fermentations and 2 1752 
M KOH for 15N-fermentations. For unlabelled fermentations an initial volume of 2.5 1753 
lit was used and 250 ml 50% glycerol with 1.5 ml PTM1 salts was added three or 1754 
four times when the cells had consumed all the glycerol. For 15N labelled 1755 
fermentations, the initial medium volume was 600 ml, 5 g (15NH4)2SO4 in 50 ml 1756 
dH2O and 40 ml 50% glycerol with 0.5 ml PTM1 salts was added when the medium 1757 
was inoculated. 1758 
 1759 
Before induction of protein expression, the cells were allowed to consume all 1760 
glycerol and the temperature was set to 15 °C. The first methanol feed was 0.5% and 1761 
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the cells slowly consumed the feed as they started to produce AOX enzyme. 1762 
Subsequent methanol feeds were 1.5% and the cells consumed the methanol much 1763 
quicker as the AOX enzyme was already present. It typically took 3-6 hours for the 1764 
cells to consume each methanol feed, as indicated by an increase in dissolved oxygen 1765 
and a decrease in agitation. The methanol contained 4.4 ml PTM1 salts/L methanol.  1766 
 1767 
After 4 days of methanol feeding, the culture was harvested by centrifugation at 1768 
5,000 rpm for 15 minutes. The supernatant was centrifuged again at 10 000 g for 30 1769 
min and filtered through a 0.45 µm PES filter. The filtrate was diluted 1 to 4 with 1770 
dH2O and 5 mM EDTA, 0.5 mM PMSF and 0.02% w/v sodium azide were added to 1771 
inhibit proteolysis and bacterial growth.  1772 
 1773 
High Zeocin resistant clones were successfully screened for protein expression for all 1774 
protein constructs. After expression had been confirmed by miniscale SDS-PAGE 1775 
analysis, the clones were fermented in a bench-top fermenter to yield larger 1776 
quantities of protein. 1777 
 1778 
In the fermenter, agitation rises more and more after inoculation, as the cells grow 1779 
and consume oxygen (Figure 3.5). After the cells had consumed all the initial 1780 
glycerol, additional glycerol was fed in twice as can be seen by a rise in agitation at 1781 
30 and 50 hours. The green line in Figure 3.5 shows how the cells produced acid as 1782 
they grew on glycerol, but not on methanol: initially ammonia had to be added to 1783 
keep the pH at the set point. The temperature was relatively stable; a decrease can be 1784 
seen as the temperature (cyan line) is set to 15 °C to reduce proteolysis before 1785 
methanol induction. The temperature increased somewhat as the cell metabolism 1786 
increased every time the culture was fed methanol. The agitation also increased every 1787 
time the culture is fed, except in the end when the culture was fed so often that there 1788 
was always methanol present for the cells to feed on. The DO remained relatively 1789 





Figure 3.5 Data chart from expressing HGF-NK-C in the fermenter. Red line: 1793 
agitation, blue line: dissolved oxygen, green line: feed of ammonia, cyan line: 1794 
temperature, black line: feeding of methanol. 1795 
 1796 
As the Pichia cells were fed methanol, the expressed protein was secreted into the 1797 
medium. After fermentation, the protein was captured on a heparin or SP -Sepharose 1798 
resin and eluted, collecting fractions and monitoring the A280 trace. 1799 
 1800 
To capture, purify and concentrate HGF-N and HGF-NK-C, the filtrate was pumped 1801 
over night with a peristaltic pump through a 20 cm long Pharmacia XK26 column 1802 
packed with 12.5 ml Heparin-Sepharose Fast Flow resin from GE Healthcare. HGF- 1803 
K was captured in the same way on Fast Flow SP-Sepharose resin. For HGF-N and 1804 
HGF-NK-C, the pH of the filtrate was adjusted to pH 6 and for HGF-K to pH 4.2 to 1805 
allow selective binding to the resin. 1806 
 1807 
HGF-N and HGF-NK-C were first purified by heparin affinity chromatography and 1808 
then by strong cation exchange chromatography. For HGF-N and HGF-NK-C, buffer 1809 
A was 20 mM KPO4 pH 7.5 with 0.02% (v/v) sodium azide, buffer B was the same, 1810 
but contained 2 M NaCl.  1811 
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The loaded XK26 heparin-Sepharose column was washed with buffer A and then 1812 
eluted with a 5 CV gradient to buffer B on the BioCAD FPLC system at a flow rate 1813 
of 5 ml/min, monitoring the absorbance at 280 nm, collecting 3 ml fractions. Peak 1814 
fractions were pooled and subjected to strong cation exchange chromatography using 1815 
a MonoS 4.6/100PE column (GE Healthcare) connected to the Akta FPLC system 1816 
with the following gradient: 0-15 % B in 1CV, 15-60 % B in 30 CV, wash with 100 1817 
% B and equilibrate. 1818 
 1819 
HGF-K was first purified by SP-Sepharose chromatography in the same manner as 1820 
HGF-N and HGF-NK-C, but the pH of the buffers was adjusted to pH 6.5. SP- 1821 
Sepharose fractions were pooled and purified by gel filtration. For gel filtration, a 1822 
XK16/60 Superdex HiLoad from GE healthcare was connected to the Akta FPLC 1823 
system described above, with 1 ml/min PBS flow rate, collecting 2 ml fractions. 1824 
 1825 
Protein purity was assessed by SDS-PAGE and MALDI-TOF mass spectrometry, 1826 
correct amino acid sequence was confirmed by FTICR-MS and correct folding was 1827 
confirmed by 1H-15N HSQC NMR. 1828 
 1829 
3.2.3 FTICRMS Characterisation of HGF-N and its Modified 1830 
Versions 1831 
200 µl, 20-50 µM samples were dialysed against 2 litres of 50 mM NH4OAc buffer 1832 
with 1000 MWCO tube-o-dialyzers from WebScientific (BE786-610) at 4 °C for ~24 1833 
hours. Samples were then reduced with an 8X molar excess of TCEP, acidified and 1834 
50 % methanol added. The samples were directly infused with a nESI interface for 1835 
mass determination and ECD in a Bruker Daltonics 12 T FTICR instrument. The 1836 




3.3 Preparation and Purification of GAG Derived 1839 
Oligosaccharides 1840 
Many different conditions for GAG digestion and purification were attempted; the 1841 
conditions presented here are the preferred ones. Typically, 100-1000 mg of bovine 1842 
lung sodium salt heparin from Calbiochem (375093), bovine intestinal mucosa 1843 
heparin sodium salt from Sigma-Aldrich (9041-08-1), porcine intestinal mucosa DS 1844 
from Celsus laboratories a gift from Malcolm Lyon - University of Manchester, 1845 
porcine intestinal mucosa DS from Grampian Enzymes, bovine trachea CSA from 1846 
Sigma-Aldrich (C9819) or shark cartilage CSC from Fluka (27043) was dissolved in 1847 
50 ml 50 mM Tris pH 7.2-8.0, 1-5 mM CaCl2, 50 mM NaCl pH 7.5.  1848 
 1849 
Depending on how quickly and how far the digest was to be completed, 0.025-0.1 1850 
international units of enzyme per 100 mg of GAG was added to the digest and 1851 
incubated at 25-30 °C. The pH of the digest was maintained and more enzyme was 1852 
added to maintain or speed up the digestion. CSA and CSC were digested with 1853 
chondroitinase AC, DS was digested with chondroitinase B and heparin was digested 1854 
with heparinase I, all enzymes were from Grampian Enzymes. Less enzyme was 1855 
added to the CSC digests as chondroitinase AC seemed to have a higher turnover rate 1856 
for that CSC compared to CSA. If digestion was poor, addition of 0.1-1 mg/ml BSA 1857 
drastically improved enzyme activity, suggesting that some GAG batches were 1858 
contaminated with proteases. The DS from Malcolm Lyon was found to be heavily 1859 
contaminated by proteases and adding BSA was vital to achieve good digestion. 1860 
 1861 
The digest was monitored by injecting 5-20 µl aliquots on a Superdex Peptide 10/300 1862 
column, with a flow rate of 0.5 ml/min in 100-200 mM ammonium bicarbonate or 1863 
PBS, monitoring the 232 nm UV-trace. The incubation time varied from 4-72 hours. 1864 
When sufficient digestion was achieved, the reaction was either heat inactivated at 90 1865 




The freeze-dried material was dissolved in 2 ml ddH2O, filtered through a 0.45 µm 1868 
filter and injected on two serially connected 2.6x90 cm columns packed with BioGel 1869 
P10 fine resin from BioRad (1504144). The flow rate was 0.4 ml/min in PBS or 150 1870 
mM NaCl and 5-8 ml fractions were collected as the 232 nm UV-trace was 1871 
monitored on the BioCAD FPLC system. Ammonium bicarbonate was avoided as 1872 
running buffer, although it has the advantage of being volatile, it miscolours the 1873 
GAGs and makes them precipitate when concentrated. 1874 
 1875 
To purify different specific species of heparin-derived tetrasaccharide and 1876 
hexasaccharide, an analytical or semi-preparative AS-17 lonpac strong anion 1877 
exchange column from Dionex was connected to the Waters HPLC system and a 1878 
gradient from 100% buffer A to 100% buffer B was applied over 60 min at a 1 1879 
(analytical) or 4 (semi-preparative) ml/min flow rate, monitoring 232 nm UV- 1880 
absorbance. Buffer A was dH2O titrated with HCl to pH 3, buffer B was the same, 1881 
but with 1 M NaC1. Samples were desalted by injecting up to 5 ml sample on a 1882 
1.6x30 cm GE Healthcare Sephadex G-25 superfine column with dH2O as running 1883 
buffer on the BioCAD FPLC system. If a small quantity of GAG needed desalting, 1884 
the Superdex Peptide column was used instead. For preparation of large quantities of 1885 
hexasaccharide for TEMPO-conjugation, the semi-preparative SAX column was 1886 
connected to the BioCAD FPLC system and an automated method was setup to make 1887 
12 consecutive runs with the instrument autoinjector. 1888 
 1889 
Chemically sulfated maltose and maltohexaose were kind gifts from Dr Craig 1890 
Freeman, Division of Immunology and Genetics, John Curtin School of Medical 1891 
Research, Australian National University, Canberra, Australia.  1892 
 1893 




3.4 Biotinylation of GAG Oligosaccharides by Reductive 1896 
Amination 1897 
Bovine lung heparin (Calbiochem 375093), dermatan sulfate (Celsus Laboratories) 1898 
and chondroitin sulfate C (Fluka 27043) were digested with heparinase I, 1899 
Chondroitinase B or Chondroitinase AC (Grampian Enzymes), respectively, and the 1900 
decahexasaccharide was purified by gel filtration as described in section 3.3. 1901 
Typically, 1x10-6 moles of decahexasaccharide was dissolved in 10% H2O, 20% 1902 
HOAc and 70% DMSO in a total volume of 200 µL. Thereafter, 5x10-6 moles of 1903 
biotinamidohexanoic acid hydrazide (Sigma-Aldrich B3770) in DMSO and 1x10-4 1904 
moles of NaCNBH3 in 50% DMSO / 50% H2O were added to the reaction. The 1905 
reaction mixture was incubated over night at 65 °C, preferably shaking, desalted on a 1906 
1.6x30 cm Sephadex G25 superfine column and lyophilised. 1907 
 1908 
3.5 Affinity Chromatography 1909 
3.5.1 In-House Preparation of a Crude Heparin Affinity Column 1910 
Linked via Free Amines 1911 
10 mg bovine lung heparin (Calbiochem 375093) dissolved in PBS and 2 mg EZ- 1912 
Link NHS-PEG4-Biotin (Pierce 21329) dissolved in PBS were mixed vigorously in 1913 
an Eppendorf tube and incubated at room temperature for one hour. The sample was 1914 
desalted on a 1.6x30 cm Sephadex G25 superfine column before loaded onto a GE 1915 
healthcare HiTrap 1 ml streptavidin column. 1916 
 1917 
3.5.2 In-House Preparation of DP16 GAG Affinity Columns  1918 
Biotin conjugated GAGs were prepared as described in section 3.4, dissolved in PBS 1919 
and the 232nm UV absorbance was measured. Next, the GAGs were loaded onto a 1920 
GE Healthcare 1 ml HiTrap Streptavidin column and the 232 nm UV absorbance of 1921 
the flow through was measured again. The UV absorbance measurements were used 1922 





The hyaluronan affinity column was manufactured by loading 5 mg of biotinylated 1926 
hyaluronan from Sigma-Aldrich (B1557) onto at GE Healthcare HiTrap streptavidin 1927 
column.  1928 
 1929 
3.5.3 GAG Affinity Chromatography 1930 
Proteins were loaded onto the columns and eluted with a 50 CV gradient on the Akta 1931 
system. Buffer A was 20 mM KPO4 pH 7.5, 0.02% NaN3. Buffer B was the same but 1932 
contained 2 M NaCl. 1933 
 1934 
For the hyaluronan affinity column, HGF-N was loaded in 20mM HEPES pH 7.5 and 1935 
eluted with a 20 CV 0-1 M NaCl gradient on the BioCAD FPLC system. 1936 
 1937 
3.5.4 Preparation of a HGF-N Affinity Column 1938 
Different conditions were explored, but in the final optimised reaction, 3 mg HGF-N 1939 
in PBS was incubated with a tenfold excess of heparin DP10 and a twofold excess of 1940 
NHS-PEG4-Biotin from Thermo Scientific (21329) at room temperature for 30 1941 
minutes. To purify active HGF-N that was not biotinylated on the GAG binding site 1942 
and has normal heparin affinity, the biotinylated protein was injected on a GE 1943 
Healthcare HiTrap heparin column and eluted with a NaCl gradient. The high affinity 1944 
biotinylated HGF-N fractions were buffer exchanged into PBS and loaded onto a GE 1945 
Healthcare HiTrap streptavidin column. A280 was measured before and after loading 1946 
the biotinylated protein onto the column and it was determined that 1.8x10-7 mole 1947 
HGF-N was bound to the finalised HGF-N affinity column. 1948 
 1949 
3.5.5 HGF-N affinity chromatography 1950 
To perform HGF-N affinity chromatography on a mixture of heparin-derived DP6 1951 
species, 2-4x10-7 mole of hexasaccharide was loaded onto the column in PBS and 1952 
eluted with a NaCl gradient from 100 mM NaCl to 1 M NaCl buffered with KPO4 1953 
pH 7.2 in 80 minutes with a flow rate of 1 ml/min. The 232 nm UV trace was 1954 
monitored and fractions collected on the Waters HPLC system. 1955 
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3.5.6 High Resolution Heparin Affinity Chromatography of 1956 
truncated HGF-N 1957 
Protein samples were loaded on a 1 ml heparin HiTrap column from GE healthcare 1958 
connected to the Akta FPLC system. The gradient was as follows: 0-35 % B in 4 CV, 1959 
35-75 % B in 30 CV, wash with 100 % B and equilibrate. 1960 
 1961 
3.6 Characterisation of Dimeric HGF-N 1962 
To investigate what caused the protein to elute as two peaks and what was different 1963 
between the two forms, high affinity protein was purified by standard heparin 1964 
chromatography and diluted 1/5 with buffer A. Half of the high affinity protein was 1965 
incubated at 37° C for 2.5 hours and the remaining half was incubated at 4° C for 2.5 1966 
hours. After the incubation, both samples were analysed by heparin affinity 1967 
chromatography again.  1968 
 1969 
To characterise the oligomeric state of the high and low affinity forms of HGF-N, gel 1970 
filtration was carried out at 4° C on the Akta system, using a XK16/60 Superdex 1971 
HiLoad column in PBS, collecting 2 ml fractions. HGF-NK-G was used as a 20.5 1972 
kDa standard, representing the size of dimeric HGF-N. The position of the 1973 
conductivity peaks of the high salt buffer, in which both protein samples were 1974 
dissolved, confirmed that samples were injected in the same manner. It was found 1975 
that the high affinity form was likely a dimer. The dimeric protein was isolated from 1976 
the gel filtration column, incubated at 37° C for 2.5 hours, spin concentrated and 1977 
injected onto the gel filtration column again. This time the protein eluted as a 1978 
monomeric species. 1979 
 1980 
For NMR characterisation, heparin chromatography was carried out on 15N labelled 1981 
protein to isolate the high affinity dimeric form of HGF-N. The high affinity 1982 
fractions were kept on ice or at 4 °C as they were spin concentrated and buffer 1983 
exchanged into NMR buffer. The final NMR sample was put into the AVA800 1984 
spectrometer and the dissociation of the dimeric high affinity form of HGF-N into its 1985 
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normal affinity monomeric form was studied by collecting 6 consecutive 5-15 minute 1986 
SOFAST 1H-15N HSQCs followed by 57 minute long 1H-15N HSQC experiments. 1987 
 1988 
3.7 Gel filtration Studies of HGF-N and HGF-NK-G Complexed 1989 
With Different GAGs 1990 
Gel filtration was performed to investigate the oligomeric state of HGF-N and HGF- 1991 
NK-G in the presence of GAGs. Before the proteins were analysed by gel filtration, 1992 
they were dialysed into PBS buffer and mixed with an equimolar amount of GAG 1993 
dissolved in dH2O. The 400-800 µL protein + GAG sample was incubated for 5 1994 
minutes at room temperature before being analysed by gel filtration. A XK16/60 1995 
Superdex HiLoad column from GE Healthcare was equilibrated with PBS at room 1996 
temperature and used for all the experiments. The column was attached to the Akta 1997 
FPLC system with a 1 ml/min PBS flow rate, monitoring the A280 trace and 1998 
collecting 2 ml fractions. After all experiments were finished, the collected protein 1999 
fractions were repurified by heparin chromatography to remove the GAGs and the 2000 
protein was reused for other experiments. 2001 
 2002 
3.8 Analytical Ultracentrifugation 2003 
Analytical Ultracentrifugation experiments were carried out with the help of 2004 
Alexandra Solovyova, University of Newcastle. 2005 
 2006 
The sedimentation velocity experiments were performed on a Beckman Coulter 2007 
ProteomeLab XL-I analytical ultracentrifuge using both UV absorbance at 280 nm 2008 
and interference optics. All AUC runs were carried out at 48,000 rpm and at 30 °C. 2009 
The sample volume was 400 µl and the sample concentrations ranged between 0.25 2010 
and 0.95 mg/ml. The protein GAG ratios were 1:1. The heparin DP16 used in the 2011 
AUC runs was purified as described, but reapplied to the BioGel P10 column once 2012 
again and only the middle of the peak was used to produce a more homogeneous 2013 
GAG sample. 2014 
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The partial specific volumes ( ) for the proteins were calculated from the protein 2015 
amino acid sequence, using the program SEDNTERP [224] and extrapolated to the 2016 
experimental temperature following the method of Durchschlag [225] in (3.1). 2017 
 2018 
  (3.1) 2019 
The partial specific volume value of Fondaparinux and heparin DP16 was assumed 2020 
to be 0.5 ml/g [226], [227]. The partial specific volumes of the protein-GAG 2021 
complexes were calculated using (3.2). 2022 
 2023 
 (3.2) 2024 
The distribution of sedimenting material was modelled as a distribution of Lamm 2025 
equation solutions [228] where the measured boundary a(r,t) was modelled as an 2026 
integral over differential concentration distributions c(s) using (3.3). 2027 
 2028 
  (3.3) 2029 
where ϕ is the noise component, r is the distance from the centre of rotation 2030 
diffusion, D is the diffusion coefficient and t is time. The expression χ(s, D, r, t) 2031 
denotes the solution of the Lamm equation [229] for a single species by finite 2032 
element methods [230].  2033 
 2034 
The integral for (3.3) was implemented in the program SEDFIT 11 Beta 2035 
(http://www.analyticalultracentrifugation.com) and solved numerically by 2036 
discretisation into a grid of 200 sedimentation coefficients for both absorbance and 2037 
interference data. The best-fit concentrations for each plausible species were 2038 
calculated as linear least square fits. The sedimentation velocity profiles were fitted 2039 
using a maximum entropy regularisation parameter of p = 0.95. The weight average 2040 
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sedimentation coefficient was calculated by integrating the differential sedimentation 2041 
coefficient distribution using (3.4) [231]. 2042 
 2043 
  (3.4) 2044 
Sedimentation coefficients were extrapolated to zero concentration and converted to 2045 
20°C H2O standard conditions. The diffusion coefficient (D) corresponding to each 2046 
sedimentation coefficient value was estimated from a weight-average frictional ratio 2047 
(f/f0)w [231] as in (3.5). 2048 
 2049 
  (3.5) 2050 
The integration of the mass distribution c(M) with a similar approach to (3.4) gave 2051 
the weight average molecular mass of the solute.  2052 
 2053 
 A two-dimensional size-and-shape distribution model (c(s,f/f0)) was applied in order 2054 
to precisely determine the value of molecular mass from sedimentation velocity data 2055 
[232]. In this model a differential distribution of sedimentation coefficients and 2056 
frictional ratios (f/f0) was defined using (3.6). 2057 
 2058 
  (3.6) 2059 
where all symbols are the same as in (3.3).  2060 
 2061 
In this model, the sedimentation coefficient and friction ratio, i.e. mass, for 2062 
sedimenting species were fitted as independent variables. The numerical solutions of 2063 
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(2.6) were obtained in a discrete grid of 100 sedimentation coefficients and 20 values 2064 
of f/f0. 2065 
 2066 
The HYDROPRO 7 [233] software was used to calculate the protein sedimentation 2067 
coefficient based on their atomic coordinates using the 2HGF and 1GMN PDB files. 2068 
 2069 
3.9 Isothermal Calorimetry 2070 
ITC data was collected on a Microcal Auto VP-ITC at 30 °C, the autosampler was 2071 
maintained at 4 °C. The cell volume was 1.4 ml and the syringe volume was 280 µL. 2072 
The ligand was titrated by 44 x 6.4 or 88 x 3.2 µL injections lasting 12.8 seconds 2073 
with a 180 second delay between injections. Protein and GAG concentrations were 2074 
carefully determined by A280 and A232, respectively, in a glass cuvette on SpectraMax 2075 
M5 multimode plate reader from Molecular Devices. The protein concentrations 2076 
varied between 75 and 95 µM in PBS and the GAG concentrations were 630-1100 2077 
µM in PBS. The following control titration experiments were performed and 2078 
subtracted: buffer into protein, ligand into buffer and buffer into buffer. The data was 2079 
analysed in the Microcal version of Originlab 7E. 2080 
 2081 
3.10 NMR Monitored Thermal Denaturation 2082 
The AVA600 spectrometer and the multi_zgvt command were used to collect a 2083 
series of 15N-1H HSQC spectra and 1D 1H spectra using Double-Pulse-Field- 2084 
Gradient-Spin-Echo for water suppression. Spectra were collected at 30 °C, 50 °C, 2085 
60 °C, 70 °C, 75 °C, 80 °C, 85 °C and 90 °C with a temperature equilibrium period 2086 
of 800 s between each experiment. A 105 µM 15N labelled sample of HGF-N was 2087 
used to collect spectra in the presence of ten times excess heparin DP10 and a 56 µM 2088 




3.11 NMR Titrations 2091 
Spectra were acquired on the AVA800 or BIO600 Spectrometer at 30 °C. The 2092 
samples were dialysed using a 1000 MWCO tube-o-dialyzer (WebScientific 786- 2093 
143) at 4°C for approximately 12 hours against 100 mM NaCl, 20 mM potassium 2094 
phosphate, pH 6.8. The starting sample volume was 600 µl and protein 2095 
concentrations were 50 - 100 µM containing 5-10 % D2O and 0.001-0.002 % w/v 2096 
sodium azide. The pH was monitored during the titration, but normally no addition of 2097 
acid or base was needed.  2098 
 2099 
GAG oligosaccharides used in titrations were desalted, quantified by A232, freeze- 2100 
dried and re-dissolved in H2O, producing very concentrated stock solutions that were 2101 
then diluted so that no more than 1 µL was added to the sample at each titration 2102 
point. 2103 
 2104 
To estimate the KDs of the interactions, CcpNmr Analysis was used to fit titration 2105 
data according to (3.7). 2106 
  (3.7) 2107 
Where ,  2108 
 and  2109 
 2110 
 2111 
The KD was then determined in Open Office Calc 2.3 by solving the equation 2112 
 for residues with large CCSDs fitting well to the equation 2113 




The combined chemical shift perturbation was expressed as in (3.8). 2116 
  (3.8) 2117 
where ΔδH and ΔδN are the chemical shift changes in the proton and nitrogen 2118 
dimension, respectively, between the unbound and bound state in ppm. 2119 
 2120 
3.12 Reductive Amination to Conjugate 4-Amino TEMPO to Fully 2121 
Sulfated Heparin Hexasaccharide 2122 
Fully sulfated heparin hexasaccharide was purified by standard SAX 2123 
chromatography and desalted on a Sephadex G25 superfine column. Typically, five 2124 
hundred nanomole mole hexasaccharide was lyophilised and dissolved in 10% dH2O, 2125 
70% DMSO and 20% acetic acid, 1 M 4-amino TEMPO in DMSO was added to 2126 
thirtyfold molar excess and 5 M NaCNBH3 in 50% DMSO/dH2O was added to three 2127 
hundredfold excess. The reaction was incubated at 65 °C over night, preferably with 2128 
shaking. As a last step, the reaction was desalted on a Sephadex G25 superfine resin 2129 
and purified by SAX chromatography. 2130 
 2131 
3.13 Titration of TEMPO Conjugated Heparin Hexasaccharide into 2132 
15N-Labelled HGF-N Monitored by NMR 2133 
A 75 µM 15N labelled sample of HGF-N was prepared in 550 µl of the standard 2134 
NMR buffer and all experiments were carried out on the AVA800 spectrometer. 2135 
NMR data was collected at the following TEMPO-heparin DP6:protein ratios: 0:1, 2136 
0.5:1, 1:1 and 1.8:1. A 1D 1H spectrum was collected at each titration point, using 2137 
Double-Pulse-Field-Gradient-Spin-Echo for water suppression [234]. A 1H-15N 2138 
HSQC spectrum was collected to determine the chemical shift perturbation for each 2139 
titration point. To determine the T1 relaxation times of NH protons at each titration 2140 
point, a pulse sequence that combines inversion recovery with a 1H-15N HSQC was 2141 
used [235]. T1 values were measured at each titration point using the following 2142 
 
 82 
relaxation delay times: 40, 100, 250, 600, 800 and 1200 ms. The t1 and t2 acquisition 2143 
times were 92 and 316 ms respectively. The spectral width was 30 ppm in the 2144 
nitrogen dimension and 14 ppm in the proton dimension. For each t1 increment, 16 2145 
scans were collected and the total experiment time needed to acquire one relaxation 2146 
point at a given protein:GAG ratio was approximately 12 hours. 2147 
 2148 
To determine T1 values, spectra were processed in Azara and imported into CcpNmr 2149 
Analysis 2.1.2. Peaks were assigned, peaklists copied to all delay times and the 2150 
experiment series for each titration point were fitted to the equation  with 2151 
jiggling error method. The contribution of the spin label to the relaxation of NH 2152 
protons was determined by subtracting the relaxation rate  of the uncomplexed 2153 
HGF-N from the relaxation rate measured using the 1:1 TEMPO-heparin DP6: HGF- 2154 
N complex. HSQC shift perturbations were quantified using Analysis and equation 2155 
(3.8). The relaxation and chemical shift perturbation data were plotted in Open 2156 
Office Calc 3.1.1. Finally, crosspeaks with a shift dist ≥0.09 ppm and with a delta R1 2157 
≥ 0.00035 ms for the 1:1 TEMPO-heparin DP6:HGF-N titration point were mapped 2158 




4 Results and Discussion 
4.1 Design and Comparison of Different HGF Protein Constructs 
Several different protein constructs are used in this thesis and references are made to 
protein constructs used by other research groups. These protein constructs are 
summarised in Table 4.1. 
 
As explained in section 1.2.1 and Figure 1.1, HGF consists of the following six 
domains from the N- to the C-terminus: N, K1, K2, K3, K4 and finally the SPH 
domain. In this project, HGF-N denotes the N domain of HGF, HGF-NK, the N and 
the K1 domains, HGF-NK-C denotes the NK fragment that was cloned in this project 
and HGF-NK-G, the NK fragment that was originally cloned in Cambridge by the 
Gherardi research group.  
 
HGF-N is the same protein construct that was expressed in E. coli and used for 
determining the NMR structure of the HGF N domain by Zhou et al [21]. This 
protein construct was chosen to allow for easy transfer of the published assignment 
of 1H-15N crosspeaks. The N-domain contains the GAG binding site of HGF and the 
main purpose of this protein construct was to use it for NMR titrations of GAG 
oligosaccharides.  
 
HGF-K was expressed with an intention to investigate if the K domain contributes to 
GAG binding, but this protein construct was never used in any experiments. 
 
HGF-NK-C was expressed to allow for comparison with the HGF-N and HGF-NK-G 
protein constructs. The latter protein construct has been extensively studied by the 
Gherardi research group in Cambridge, for example this protein construct was used 
to determine the HGF-NK-G – heparin co-crystal structure [14]. Initially, HGF-NK-




Table 4.1 Table summarising different HGF constructs, their N-termini, PDB files 
and protein constructs. The red Q indicates the first residue of the native protein. 
Bold letters represent residues which coordinates can be seen in the PDB files. 















































































































































































































4.2 Expression, Purification and Characterisation of Protein 
Constructs 
4.2.1 HGF-N 
The cloned version of HGF-N is 97 amino acids, has a molecular weight of 11376.2 
Da and a theoretical pI of 10.03. The first residue of the construct is 31G. The very 
first residues of the native protein (residues 1-32) belong to the signal peptide that is 
cleaved after translation and the first residue of the native HGF protein is 32Q. 
 
Pichia transformants expressing HGF-N were identified by miniscale protein 
expression in Falcon tubes and analysed by SDS-PAGE (Figure 4.1). The first three 
clones from the left (A-C) grew on 300 µg/ml YPDSZ plates, the remaining three 
(D-F) grew on 100 µg/ml YPDSZ plates. HGF-N can be clearly seen as a double 
band at about 15 kDa. It is also clear that the clones with higher Zeocin resistance 





Figure 4.1 SDS-PAGE analysis of a mini-scale expression of HGF-N. The 
supernatant of a 5 ml Falcon-tube cell-culture was loaded onto the gel. Lanes A-F are 
different clones. The lane furthest to the right is the protein ladder and the numbers 
indicate the kDa weight of the proteins in the ladder. The rectangles indicate HGF-N 
expression. The high background in lane B is likely due to that the pipette tip 
touched the supernatant when preparing the sample and intracellular proteins from 
lysed cells contaminated the SDS-PAGE gel lane. Clone C was chosen for large 
scale protein production. 
 
An unlabelled version of HGF-N was produced for general experiments as well as a 
15N-labelled version for NMR experiments. 15N labelled protein was expressed in a 
similar manner but on 1-litre scale. The protein was initially purified on a heparin-
Sepharose resin and eluted as a peak with a shoulder at 15-22 minutes (Figure 4.2). 
Unspecific binding of Pichia proteins was also visible in the chromatogram. A 5-litre 






Figure 4.2 Elution of 15N labelled HGF-N from heparin-Sepharose fast flow beads. 
The blue line is the A280 trace, the red line is the conductivity trace. 
 
To assess the purity of the heparin affinity-purified protein, fractions were analysed 
by SDS-PAGE (Figure 4.3). 
 
As evident from Figure 4.2 and Figure 4.3 the expression of HGF-N did not produce 
a homogeneous protein and further purification was necessary. SDS-PAGE analysis 
showed two bands of similar size. The lower molecular weight band eluted first and 
the higher molecular weight band eluted later from the heparin-Sepharose resin (data 
not shown), implying that the higher molecular weight bands had higher heparin 
affinity. Similar molecular weights of the bands suggested that gel filtration would 
not be successful, therefore MonoS strong cation exchange chromatography was 








Figure 4.3 SDS-PAGE analysis of fractions eluting between 16 and 21 minutes from 
the heparin-Sepharose affinity chromatogram in Figure 4.2. The lane furthest to the 
left is the protein ladder and the numbers indicate the kDa weight of the proteins in 
the ladder. The numbers at the bottom of the gel indicates elution time in Figure 4.2. 
The band at 30 kDa in lane 19 is likely a contaminant from the SDS-PAGE analysis. 
 
Figure 4.4 MonoS purification of HGF-N. The blue trace is a fraction from the first 
shoulder (17 minutes) from the heparin-Sepharose column in Figure 4.2, the red trace 
is from a late fraction of the major peak (21 minutes).  
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MALDI-TOF mass spectrometry confirmed that the red peak 4 in Figure 4.4 is a pure 
species with the correct MW of native HGF-N (Figure 4.5). Preliminary MALDI-
TOF results (data not shown) confirmed that peak 1 and 2 in Figure 4.4 contained 
truncated proteins and that the third peak had a posttranslational modification, 
possibly a phosphorylation. As the different MonoS peaks exhibited different heparin 
affinities, it was relevant to investigate in detail what the differences between the 
peaks were.  
 
 
Figure 4.5 MALDI-TOF spectrum of MonoS purified HGF-N. No internal standards 
were used to calibrate the spectrum. The experimental mass was determined to 
11378.2 Da, the theoretical mass of 11372.2 Da. As no internal standards were used 
in the MALDI spectrum, the experimental mass is within acceptance criteria and a 
more accurate mass was determined by FTICR-MS. 
 
To confirm and further clarify the MALDI-TOF results, one and two-dimensional 
FTICR mass spectrometry was employed (Figure 4.6 and Figure 4.7). Data was 









Figure 4.6 FTICRMS spectra of HGF-N. The 15+-charge state was used for accurate 
mass determination.  
 
Accurate mass determination and isotope simulation of the non-native proteins 
purified by MonoS chromatography clearly indicated that the proteins had N-
terminal truncations and that one version was phosphorylated. To further confirm the 
results, electron capture dissociation spectra were collected (Figure 4.7). Sequence 





Figure 4.7 Electron capture dissociation FTICR mass spectrum of native HGF-N.  
 
The FTICR mass spectrometry analysis results are summarised in Table 4.2. 
 
Table 4.2 Summary of FTICR MS mass determination and isotope simulation data. 








NMR HSCQC Name 
Peak 1 Blue 10593.5 0.3 - GQRKRR 
Lacks 32Q, binding 
site shift differences 
HGF-N-Δ6 
Peak 2 Blue 10749.6 1.6 - GQRKR 
Lacks 32Q, binding 
site shift differences 
HGF-N-Δ5 
Peak 3 Blue 11456.0 1.5 + PO4 
Binding site shift 
differences 
HGF-N-PO4 
Peak 4 Red 11375.1 0.7 - Reference HGF-N 
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1H-15N HSQC NMR spectra were collected for both the native and truncated HGF-N 
proteins. In general, the crosspeaks of the truncated HGF-N-Δ6 and HGF-N-Δ5 
proteins overlaid well with HGF-N, but amino acids close to the N-terminus and 
those of the heparin binding site α2-helix exhibited chemical shift changes. 
Crosspeaks for residues 32Q and 38T were missing, crosspeaks for residues 39-41 
were shifted and residues 70-75 were also shifted, as they are close in space to the N-
terminus (Figure 4.8).  
 
 
Figure 4.8 Partial 15N-1H HSQC spectrum of HGF-N-Δ6 in red overlaid with the 
15N-1H HSQC spectrum of HGF-N in green. The crosspeaks in the blue spectrum are 
somewhat elongated due to fewer increments in the nitrogen dimension. 
 
Phosphorylation by P. pastoris has not been observed in our laboratory before and is 
not widely mentioned in the literature. FTICR ECD mass spectrometric analysis 
showed that either T38 or T38 and S45 could be phosphorylated. Phosphorylation 
site prediction with NetPhos 2.0 and NetPhos Yeast 
(http://www.cbs.dtu.dk/services/NetPhos/) predicted both T38 and S45 as possible 
phosphorylation sites (Figure 4.9). To date no phosphorylation sites of HGF have 
been mapped (http://www.phosphosite.org, http://phospho.elm.eu.org, 2010-05-25). 
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The phosphorylations are interesting as they are a possible way to regulate the HGF-
GAG interaction and thus the whole signalling cascade as discussed in section 1.2.  
 
 
Figure 4.9 NetPhos Yeast (upper histogram) and NetPhos 2.0 (lower table) 
phosphorylation site prediction results. The two mapped phosphorylations (T38 and 
S45) are marked with red asterisks for NetPhos Yeast (upper histogram), for NetPhos 
2.0 (lower table) the score is given. The higher the score, the higher the likelihood of 
the specific residue being phosphorylated, 1 is the highest score. 
 
The 5 or 6 amino acid truncation of some of the HGF-N protein is due to faulty Kex2 
cleavage during secretion of the protein in P. pastoris. When the proteins were 
cloned into the PPICZAlpha vector, the α-factor signal sequence was used to direct 
the expressed protein for secretion. The Kex2 enzyme in P. pastoris cleaves the α-
factor signal sequence from the expressed protein as it is being secreted. The Kex2 
cleavage takes place between Arg and X in the sequence X - X - Lys/Arg - Arg ^ - X 
sequences, where ^ indicates the cleavage site. Kex2 has a complex and promiscuous 
preference for the X residues [236] and usually, the X amino acids following after 
the cleavage site are glutamic acid and alanine for proteins cloned into a 
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PPICZAlpha vector, but in this thesis work, the proteins were cloned without these 
residues.  
 
In conclusion, Kex2 cleaves at KR or RR sequences in the secretion signal sequence 
and HGF-N has this sequence in the N-terminal part of the protein. This confuses 
Kex2 and two cleavage sites are created. Kex2 does not recognize the RK sequence 
present in the N-terminus, only KR and RR as can be seen in (Figure 4.10). 
 
 
Figure 4.10 The first native kex2 cleavage site in the vector α-mating factor and the 
two new cleavage sites produced by the KRR sequence in the protein sequence.  
 
4.2.2 HGF-K 
The cloned version of HGF-K contains 83 amino acids, has a molecular weight of 
9427.6 Da and a theoretical pI of 8.29.  
 
The protein was first expressed in Falcon tubes (Figure 4.11) and then fermented in a 





Figure 4.11 SDS-PAGE gel of mini-scale supernatants of HGF-K. The lane furthest 
to the left is a positive control of a clone expressing HGF-N. The second lane from 
the left is a protein ladder and numbers indicate the kDa weight of the proteins in the 
ladder. Lanes A-J are different clones. A clear band at 13 kDa in lanes B, C and I 
suggests protein expression of HGF-K as indicated by the rectangles. Clone C was 
chosen for large scale protein production. 
 
Due to the lower pI and heparin binding of HGF-K compared to HGF-N and HGF-
NK-C, a SP-Sepharose resin was used instead of heparin-Sepharose and the 
supernatant was titrated to pH 4.2 before loading to achieve good binding to the 
resin. The lower pH caused higher binding of secreted Pichia proteins to the resin as 
evident from a large A280 peak before the main HGF-K peak during the elution of 





Figure 4.12 Chromatogram of the elution of 15N labelled HGF-K from a SP-
Sepharose resin. The UV-trace is shown in red and the conductivity is shown as mM 
NaCl in blue. The first peak corresponds to Pichia proteins and the second peak to 
HGF-K. 
 
Higher A280 values observed when eluting HGF-K compared to when eluting HGF-N 
from the SP-Sepharose resin (Figure 4.12 vs Figure 4.2) indicates higher expression 
of HGF-K, despite the fact that the HGF-K extinction coefficient is twice that of 
HGF-N. The first eluting peak contains secreted Pichia proteins, as evident from the 
gel in Figure 4.13. A longer wash step would have given better separation between 







Figure 4.13 SDS-PAGE gel of the major HGF-K peak fractions in Figure 4.12. Each 
lane represents one fraction. The first lane from the left is a protein ladder and 
numbers indicate the kDa mass of the proteins in the ladder. 
 
The beginning of the HGF-K peak at 22-27 min (Figure 4.12) contains a double band 
(Figure 4.13), which implied that either the later eluting protein had been truncated 
or that the earlier eluting protein had a post-translational modification. P. pastoris 
often glycosylates secreted proteins with mannose sugar units that can be highly 
branched. MALDI-TOF analysis suggested that the protein was not homogeneous 





Figure 4.14 MALDI-TOF spectrum of fraction 22 of the SP-Sepharose purified 
HGF-K in Figure 4.13. 
 
To purify the protein further, gel filtration was investigated, using fractions 24-28 
from Figure 4.12, the chromatogram can be seen in Figure 4.15. 
 
 






As can be seen in Figure 4.15, the gel filtration chromatogram only contains one 
main symmetrical peak. SDS-PAGE analysis (Figure 4.16) of the fractions showed 
the presence of higher molecular weight species in the early part of the peak. 
 
 
Figure 4.16 SDS-PAGE analysis of peak fractions in Figure 4.15. The protein ladder 
with its molecular weights is in the lane furthest to the right. The other lanes are 
chromatography fractions from Figure 4.15. A double band can be observed in lanes 
56-58 and a single band in lanes 59-63. 
 
Fraction 59 to 63 in Figure 4.16 were pooled and concentrated to collect a 15N-1H 





Figure 4.17 15N-1H HSQC spectrum of 15N labelled HGF-K. 
 
The HGF-K 15N-1H HSQC spectrum is characteristic of a folded protein with well 
dispersed, strong peaks. The low intensity peaks in the middle of the spectrum are 
likely due to the protein not being purified to homogeneity. 
 
No further work was done on HGF-K. If more experiments were to be performed, the 
possible modification would have to be characterised and the protein purified to 
homogeneity by alternative methods such as ion exchange or reverse phase 
chromatography. The reason to that work on HGF-K was discontinued was not due 
to the heterogeneity of the sample, but rather due to the direction of the project and 
what experiments were planned. 
 
4.2.3 HGF-NK-C 
HGF-NK-C refers to the version of HGF-NK cloned in this project, to distinguish it 
from HGF-NK-G cloned by the Gherardi research group in Cambridge. HGF-NK-C 




HGF-NK-C was expressed in the same manner as HGF-N, but no 15N-labelled 
protein was produced. Initial SDS-PAGE analysis of mini-scale supernatants showed 
no bands of the correct size (Figure 4.18).  
 
 
Figure 4.18 SDS-PAGE analysis of the Pichia-cell supernatants after mini-scale 
expression of HGF-NK-C. The first lane from the left is a protein ladder and 
numbers indicate the kDa weight of the protein. The letters for the remaining lanes 
are supernatants from different clones. The protein is expected to appear at 20-25 
kDa, but no corresponding bands can be observed. Some new low molecular weight 
species can be observed in lanes F, G, J and L, as indicated by rectangles. Clone J 
was chosen for large scale protein production. 
 
The SDS-PAGE analysis did however show some new low molecular weight bands 
for some of the clones, for example F, G, J and L in Figure 4.18, suggesting that the 
protein might be degraded. To investigate further, a larger shaker culture of clone J 
was set up to produce more protein for mass spectrometry analysis. The culture was 
harvested and loaded onto a 1 ml HiTrap heparin-Sepharose column and eluted with 





Figure 4.19 Elution of HGF-NK-C from a 1 ml HiTrap heparin-Sepharose column. 
 
The chromatogram shows two distinct peaks and the fractions were analysed by 
SDS-PAGE in Figure 4.20. 
 
 
Figure 4.20 SDS-PAGE analysis of fractions 14-28 in Figure 4.19. A protein ladder 
with its molecular weights is in the lane furthest to the left. The remaining lanes are 
numbered according to the fraction number from the chromatogram in Figure 4.19 
Two proteins of a similar size but of different heparin affinity can be observed. 
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The HGF-NK-C construct is expected to run at approximately 20 kDa, but bands can 
only be seen at 15 kDa for the early fractions and below 10 kDa for late fractions on 
the SDS-PAGE gel. It was important to clarify what these two peaks are in order to 
solve a possible truncation problem, may it be protein degradation or premature 
protein translation termination. FTICR mass spectrometry was employed on fractions 
19 and 23 in Figure 4.19.  
 
Fraction 19 had an experimental mass of 9818.68 Da and an ECD fingerprint 
matching the sequence: 
DYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENY
CRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSE 
Fraction 23 had an experimental mass of 9539.58 Da and an ECD fingerprint 
matching the sequence: 
IRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCR
NPRGEEGGPWCFTSNPEVRYEVCDIPQCSE 
The two sequences correspond closely to the K1 domain. It was concluded that it is 






Where the ^ indicates the cleavage sites, red is the N domain, blue is the K domain 
and green is in the linker between the two domains. 
 
The cleavage sites are in the linker region between the N and the K1 domain, which 
according to the ExPASy database consists of the residues in green DYIRNC, but the 
neighbouring residues are also relatively flexible and exposed in the crystal structure, 
leaving the linker prone to protease cleavage. There are different ways to minimise 
 
 104 
protein degradation in P. pastoris [222], [237-240] and three feasible possibilities 
were identified to avoid the degradation problem: 
1. Screen different medium conditions that minimise protein degradation. 
2. Mutate the degradation site. 
3. Use a protease deficient Pichia pastoris strain.  
 
As there is less work and cost in screening different media, that possibility was 
explored first. One aim with the HGF-NK-C construct was to perform NMR studies 
on 15N-labelled protein, therefore ideally no nitrogen source could be added to the 
medium. Seven different types of yeast media or conditions were investigated: 
1. BMM. As a reference medium. 
2. BMM supplemented with AEBSF. AEBSF is an irreversible serine protease 
inhibitor like PMSF, but it is more active. 
3. BMM supplemented with AEBSF and EDTA. EDTA would also inhibit the 
activity of metalloproteases. 
4. MM, contains no phosphate buffer and the pH goes acidic, which minimises 
proteolysis as many proteases work better at high pH. The yeast cells can 
cope well with the lowered pH. 
5. BMM with casein amino acids. The casein amino acids are short peptides and 
compete with the expressed protein for proteases. The proteases degrade the 
casein amino acids rather than the protein and the casein amino acids are then 
purified away during the protein purification steps. This approach would not 
allow 15N labelling. 
6. BMM with daily harvesting. Harvesting the culture on a daily basis would 
minimise the time that the expressed protein is exposed to proteases. 
7. BMMY, i.e. BMM supplemented with yeast extract and peptone or tryptone. 
The principle is the same as for casein amino acids supplementation, the 
proteases are saturated with peptone/tryptone to minimise degradation of the 
expressed protein. This approach would not allow 15N labelling. 
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The different media conditions were screened by expressing the protein in shakers, 
harvesting the cultures and loading the supernatants onto a 1 ml heparin-Sepharose 
column that was eluted with a NaCl gradient (Figure 4.21 - Figure 4.27). 
 
Expressing the protein in standard BMM medium gave a chromatogram with two 
low affinity peaks, similar to the results in Figure 4.19 (Figure 4.21). The heparin 
affinity is low as only the K1 domain remains intact and it has relatively low heparin 
affinity compared to the N domain. From experience it is known that HGF-N elutes 
at roughly 30-35 minutes with the used NaCl gradient, this implies that HGF-NK-C 
should elute at approximately the same time and that the N domain is missing. 
Possibly, the N domain is completely degraded. 
 
 
Figure 4.21 Elution of the culture grown in standard BMM from a 1 ml HiTrap 
heparin-Sepharose column. 
 
To allow the protein to be expressed under minimal medium conditions, compatible 
with isotope labelling, the effect of AEBSF and EDTA addition to the medium were 
explored. The addition of these molecules to the medium might be toxic to the yeast 
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cells as EDTA chelates necessary trace metals and AEBSF may inhibit proteases that 
are involved in vital cellular processes. Comparing the chromatograms after 
expressing the protein in AEBSF (Figure 4.22) and AEBSF + EDTA (Figure 4.23) 
with that of Figure 4.21, it can be seen that expression was poor, implying that these 
protease inhibitors were indeed toxic. The small amount of protein that was 
expressed was still degraded. 
 
 
Figure 4.22 Elution of the culture grown in BMM supplemented with AEBSF from a 





Figure 4.23 Elution of the culture grown in BMM supplemented with AEBSF and 
EDTA from a 1 ml HiTrap heparin-Sepharose column. 
 
 





P. pastoris secretes different types of proteases that are sensitive to pH differences. 
By lowering the pH of the medium to 3-5, neutral and basic proteases will be less 
active and P. pastoris cells cope well with pH conditions in this range [241], [242]. 
With this in mind, minimal unbuffered medium (MM) was investigated, but lowering 
the pH did not lower proteolysis (Figure 4.24). 
 
The Invitrogen Pichia manual [222] recommends adding casein amino acids to the 
medium to avoid proteolysis and stabilise the expressed proteins. The approach is 
often applied in biochemical research, for example BSA is often added to protein 
samples as a stabilising agent. Supplementing the medium with casein amino acids 
helped to minimise proteolysis and a native HGF-NK-C peak eluting at 30-35 
minutes appeared in the chromatogram (Figure 4.25). As casein amino acids contain 
carbon and nitrogen, this approach would not allow isotope labelling of the protein 
and does not completely eliminate the proteolysis. The peaks in the chromatogram 




Figure 4.25 Elution of the culture grown in BMM supplemented with casein amino 
acids from a 1 ml HiTrap heparin-Sepharose column. 
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To minimise the time the expressed protein was in contact with the Pichia proteases, 
standard BMM medium was used, but the culture was harvested on a daily basis. The 
advantage of this approach is that it allows for isotopic labelling. The approach 
worked and approximately 40% of the protein was full-length native HGF-NK-C 
eluting at 30-35 minutes (Figure 4.26). The disadvantage of this approach is that it is 
stressful for the cells and labour intensive. 
 
 
Figure 4.26 Elution of the culture grown in BMM, but harvested on a daily basis 
from a 1 ml HiTrap heparin-Sepharose column. 
 
The most successful approach was to induce expression in BMMY medium, which is 
similar to supplementing BMM medium with casein amino acids, the proteases work 
on the peptone or tryptone instead of the expressed protein. The chromatogram in 
Figure 4.27 shows a major HGF-NK-C peak eluting at 30-35 minutes. There is also a 
shoulder at 27 minutes. MALDI-TOF and FT-ICR mass spectroscopy analysis 
showed that the peak eluting at 30-35 minutes contained the full, undegraded HGF-
NK-C sequence and that the shoulder at 27 minutes contained the same 
heterogeneous N-terminuses as HGF-N (data not shown). This approach does not 





Figure 4.27 Elution of the culture grown in BMMY from a 1 ml HiTrap heparin-
Sepharose column. 
 
A fermentation of HGF-NK-C was carried out to produce larger quantities of the 
protein in fermentation minimal medium. The cells were grown just like for the other 
protein constructs, but before induction, yeast extract and peptone were added to the 
culture to mimic BMMY medium, which was most effective in reducing HGF-NK-C 
proteolysis in shaker flasks. The protein was captured on a heparin-Sepharose resin 
that had to be discarded afterwards due to peptone and yeast extract contamination. 
From the chromatogram in Figure 4.28, it can be seen that more than 50% of the 
protein is not native, likely having N-terminal truncations or other degradations and 
modifications. The reason why more degradation was seen under fermentation 
expression conditions compared to shaker flask protein expression conditions may be 





Figure 4.28 Elution of fermented HGF-NK-C supernatant from a heparin-Sepharose 
resin. 
To further purify the protein, MonoS chromatography was carried out in a similar 
manner to HGF-N. The chromatograms in Figure 4.29 show similar features to HGF-
N, with the later heparin purified fractions being purer than the earlier fractions. 
 
 
Figure 4.29 MonoS chromatography of HGF-NK-C expressed in a fermenter. The 
blue trace represents fractions 23-27, the green trace represents fractions 28-30 and 
the red trace represents fraction 31 from Figure 4.28, respectively. 
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In conclusion, HGF-NK-C had the same N-terminal truncation problems as HGF-N, 
which could not be avoided. Further, a protease site between the N and K domain 
was mapped and degradation at this site could be minimised to a certain extent by 
adding peptone or tryptone to the medium. Expression of HGF-NK-C was still 
relatively poor compared to HGF-N. 
 
4.3 Characterisation of Dimeric HGF-N 
During the purification of HGF-N, it was noticed that a new peak sometimes 
occurred during heparin affinity and gel filtration chromatography. Interestingly, the 
new peak displayed higher heparin affinity than HGF-N, but had a native molecular 
weight as determined by mass spectrometry. Initial 15N-1H HSQC spectra of the high 
affinity form showed some differences and more high affinity protein was purified to 
characterise the high affinity form in detail. During this purification, it was found 
that the high affinity form converts into the normal affinity version once isolated, but 
not the other way around. To confirm this observation the following experiment was 
performed: 
1) High affinity protein was purified by heparin affinity chromatography (blue 
curve in Figure 4.30). 
2) 50% of the high affinity protein was incubated at 37° C for 2.5 hours and 
50% of the high affinity protein was incubated at 4° C for 2.5 hours. 
3) Both samples were analysed by heparin affinity chromatography (Figure 
4.30). 
 
The aim of the experiments in this section is to characterise the high affinity form of 
HGF-N to find out what causes the extraordinary heparin affinity and how the 
protein can convert between a high and low affinity form. The results are important 





It was observed that the aliquot of the high affinity protein incubated at 4° C 
maintained the higher affinity (black curve in Figure 4.30) while the high affinity 
protein incubated at 37° C converted back into the normal affinity form (red curve in 
Figure 4.30). The small elution volume shift for the incubated normal affinity form is 
probably due to less protein loading onto the column. 
 
The conclusion from this experiment is that the protein can exist in a high affinity 
and a normal affinity form. The high affinity form is relatively stable at 4° C, but 
converts back to the normal affinity form if incubated at 37° C. It was hypothesised 
that the protein existed in two different conformations that interconvert slowly as has 
been described for some proteins [243] and in the case of HGF-N, these two different 
forms have different heparin affinities. 
 
 
Figure 4.30 Heparin affinity chromatography of HGF-N. The blue trace is a HGF-N 
sample containing both high and normal heparin affinity HGF-N. The red trace is 
high affinity HGF-N that has been incubated at 37° C and the black trace is high 
affinity HGF-N that has been incubated at 4° C. The dashed curves are conductivity. 
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Several attempts were made to convert the low affinity form into the high affinity 
form. The protein was incubated on a heparin column over night at room temperature 
and at 4° C, it was freeze-thawed several times in high and low salt buffers, 
incubated with heparin DP16 at room temperature and at 4° C. Heparin affinity 
chromatography was also carried out in the presence of Ca2+ or EDTA, but none of 
the attempts to convert normal heparin affinity HGF-N into the high heparin affinity 
form were successful. It is possible that dimerisation happens during protein 
production and purification, or that when monomeric HGF-N is left in a liquid 
buffer, it slowly starts to dimerise until equilibrium is reached. 
 
To further characterise the high and low affinity forms, gel filtration of both forms 
was carried out (Figure 4.31). The high and low affinity protein forms from the 
heparin affinity chromatography were kept cold at all times as they were spin 
concentrated and then injected on a gel filtration column in PBS kept at 4 °C. 
 
Figure 4.31 Gel filtration of different forms of HGF-N in PBS. The green curve is 
the normal affinity form isolated from heparin chromatography. The red curve is the 
high affinity form isolated from heparin chromatography. The blue curve is the 
fractions from the red curve after 2.5 hours at 37 °C. The dark blue curve is HGF-




The high affinity form eluted at the same time as HGF-NK-G, indicating that the 
high affinity form is dimeric since the molecular weight of HGF-NK-G is 
approximately twice that of HGF-N. Incubating the dimeric form at 37° C for 2.5 
hours converts it into a monomeric form. It can be concluded that the high affinity 
form of HGF-N is a dimer. 
 
To further characterise the HGF-N dimer, it was studied by NMR: 15N labelled 
dimeric HGF-N was purified by heparin affinity chromatography and buffer 
exchanged into NMR buffer at 4 °C. As the sample was put in the NMR instrument, 
the temperature was maintained at 30° C and the dissociation of the dimer could be 
monitored by 1H-15N HSQC spectra (Figure 4.32). Initially, SOFAST 1H-15N HSQC 
spectra were collected to be able to see any fast changes, but the protein 
concentration was too low and spectral quality relatively poor. However, the 
dissociation process was slow enough at 30° C to be monitored by acquiring standard 
1H-15N HSQC spectra. 
 
Figure 4.32 shows an overlay of the initial spectrum (approximately one hour 
acquisition time) and the fifth spectrum acquired after 5 hours at 30° C. The latter 
spectrum contains peaks from both monomeric and dimeric forms of HGF-N. The 
overlay of the spectra indicates a slow exchange process where the crosspeaks can't 
be traced by gradual chemical shift differences, they just change in intensity. The off-
rate of the dimer must be very slow as the dissociation can be monitored by NMR, 





Figure 4.32 Overlaid 1H-15N HSQC spectra of HGF-N prepared at 4 °C. The red and 
black spectrum is the first and fifth of a series of 57 min spectra, respectively. 
 
Studying the HSQC spectra, some of the new slow exchange cross peaks can be 
assigned with reasonable confidence, but for some new crosspeaks the spectrum is 
too crowded and the chemical shift differences too big, giving an unsecure and 
incomplete identification of affected residues. However, two consistent patches can 
be assigned with relatively high confidence, namely residues 63 to 68 and 86 to 90, 
belonging to the α2-helix/β2-strand and β3-strand, respectively. These two patches 
are relatively close to each other in the protein structure, but residues 86 to 90 are not 






Figure 4.33 The 1BHT pdb file was rendered in UCSF Chimera 1.4 to show residues 
63 to 68 and 86 to 90 in red. These are the two patches that displayed large chemical 
shift differences in the dimeric vs monomeric state and that could be assigned with 
relatively high confidence. The patch consisting of residues 63-68 is surface exposed, 
but the patch consisting of residues 86-90 is not and therefore has to be affected by 
secondary effects in the dimeric state. 
 
The lack of a complete assignment of the affected residues prevented identification 
of a possible dimer interface. It was noted that the intensity of the signals increased 
with time and the signals became narrower (Figure 4.34). This implies that the 
protein tumbles faster, which supports the hypothesis that the protein goes from a 
dimeric state to a monomeric state. The intensity increase could also be due to 
chemical exchange, but this is unlikely. The black vertical line in Figure 4.34 is over 
a crosspeak, which decreases in intensity with time. This peak is one of the dimer 







Figure 4.34 Upper: Overlaid 1H-15N HSQC spectra. The black spectrum is the first 
HSQC, the red is the third and the green is the sixth. Lower: 1H projection of the 
HSQC spectra. The blue spectrum is from the first HSQC, the red is from the third 
and the green is from the sixth. 
 
An alternative approach to mapping the HGF-N dimer interface could be to use 
chemical crosslinking, trypsin digestion and mass spectrometry [244]. The problem 
when using this approach to map a homodimer interaction is that intra and inter -
protein crosslinks need to be distinguished. One way of doing that is to mix 14N and 
15N labelled protein and only take into consideration crosslinked peptides that 





The NK1 crystal structures 1GMO, 1GMN and 1BHT PDB files were inspected for 
HGF-N protein-protein interactions. In the HGF-NK-G crystal structure without 
heparin (1BHT), a N-domain protein-protein interaction interface could be identified 
and UCSF Chimera 1.4 was used to search for possible hydrogen bonds in the 
interface (Figure 4.35). The dimer interface consists of two charged patches, 
36RNTIH40 and 122KDYIRN127, that interacts with the same residues on the 
opposite protein molecule. These two patches do not match with the patches mapped 
in Figure 4.33. In crystal structures, unspecific protein-protein interactions are very 
common and HGF-NK1 crystallises as a head to tail dimer, where the N and K1 
domains of the two protomers interact with each other. 
 
 
Figure 4.35 Columbic surface colouring of one protomer of the 1BHT PDB file and 
ribbon structure of the other protomer. Rendered in UCSF Chimera 1.4. 
 
4.4 Purification of GAG derived oligosaccharides 
HGF-N precipitates in the presence of crude heparin [21]. In order to avoid 
precipitation and study the HGF-N - GAG interaction in solution, oligosaccharides 
have to be produced. Preparing oligosaccharides by enzymatic digests also have 
other benefits discussed in section 1.3.8. To be able to compare the binding between 




oligosaccharides size-fractionated. In some instances, fully sulfated species from a 
specific size-fraction were purified from the mixture of different sulfation patterns. 
 
A wide range of oligosaccharide lengths were sought and the digest was stopped 
before the GAG polysaccharides were completely digested into disaccharides. To 
stop the digest at the right point, aliquots of the digest were analysed on a GE 
Healthcare Superdex Peptide column at different time points. As can be seen in 
Figure 4.36, when the digest has just started, most of oligosaccharides are undigested 
as evident from a large broad peak eluting between 12 to 20 minutes. The 
disaccharide fraction can be seen eluting at 30 minutes, the tetrasaccharide at 26 
minutes and the hexasaccharide at 24 minutes. Some low molecular weight 
contaminants can also be seen eluting at 35 minutes. 
 
 
Figure 4.36 Superdex Peptide gel filtration chromatogram of a heparinase I digest of 
heparin one hour after starting the digest. 
 
Comparing the 1-hour digest (Figure 4.36) with overnight digestion (Figure 4.37), it 
is evident that the overall absorbance has increased 10 fold. This is due to that the 
enzymatic cleavage produces a conjugated double bond at the non-reducing end 
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monosaccharide that absorbs at 232 nM and more of these conjugated double bonds 
have been formed. It is also clear that most of the longer oligosaccharides have been 
digested into shorter fragments as the broad peak eluting at 15 minutes is now gone. 
 
 
Figure 4.37 Superdex Peptide gel filtration chromatogram of a heparinase I digest of 
heparin after the digest has been incubated over night. 
 
After the digest was stopped, the oligosaccharides were freeze-dried, redissolved in a 
small volume of H2O and applied onto a preparative gel filtration column. Using a 
relatively long 180 cm BioRad P10 column, DP12 can be purified to homogeneity 
and DP18 can be prepared with good purity (Figure 4.38). There are small shoulders 
between the DP2 and DP4 fraction and the DP4 and DP6 fractions. These are likely 
some uncommon tri and pentasaccharides. Their appearance is hard to explain, but 
the presence of these oligosaccharides in CS and DS digests is well established and 






Figure 4.38 Preparative gel filtration of DS digested by chondroitinase B. 
 
Gel filtration can separate species by size, but the sulfation pattern and carbohydrate 
backbone structure will still vary within each size fraction, especially for heparin and 
HS. These species with different sulfation patterns can be separated by strong anion 
exchange chromatography. Figure 4.39 shows a SAX chromatogram of a heparin 
DP4 fraction, separating the different species depending on the number of sulfations 
and backbone sugar units.  
 
The structures of the three major tetrasaccharides separated by SAX in Figure 4.39 
have been determined by NMR [247], [248]. Structures A, B and C (Figure 4.40) 
correspond to peaks A, B and C in the chromatogram of Figure 4.39. Tetrasaccharide 
A has one unsulfated GlcA sugar unit instead of sulfated IdoA, tetrasaccharide B 











Figure 4.40 Structures of heparin-derived tetrasaccharides separated by SAX in 
Figure 4.39.  
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The homogeneity and purity of the enzymatically derived GAGs was assessed by 
SAX chromatography as show above, MALDI-TOF spectrometry (Figure 4.56) and 
by 1H NMR (Figure 4.41). The latter technique is particularly suitable to assess the 
overall purity of samples and to identify any non-carbohydrate contaminants as all 
hydrogen containing molecules can be seen, whereas MALDI-TOF and HPLC are 
more selective techniques and impurities can go undetected. The enzymatically 
derived oligosaccharides were generally very pure according to MALDI-TOF and 
HPLC analysis. Some small molecule contaminants could often be seen in 1H 
spectra, resonating between 2.4 and 3 ppm (Figure 4.41). 
 
 
Figure 4.41 1H NMR spectrum of enzymatically derived heparin DP10. 
 
The complexity of the different species in a specific size fraction increases quickly 
with oligosaccharide length. The DP4 in Figure 4.39 contains three major peaks, the 
DP6 in Figure 4.42 contains eight major peaks and the DP10 in Figure 4.43 contains 
a forest of undistinguishable peaks. To make the highly charged DP10 species elute 
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CS and DS are much more homogeneous GAGs than heparin and HS. They are also 
less sulfated. This results in less variation of oligosaccharides produced by enzymatic 
digestion as can be seen in the SAX chromatograms of the decasaccharide fractions 
shown in Figure 4.44. 
 
 
Figure 4.44 SAX chromatogram of CSC (upper) and DS (lower) decasaccharides 




4.5 Affinity Chromatography 
4.5.1 In-house Prepared DP16 GAG Affinity Columns  
There are many ways to compare GAG/heparin affinity between proteins and one of 
the most basic and straightforward ways is affinity chromatography. Heparin affinity 
chromatography has been used to study the HGF-GAG interaction in many previous 
studies, but no study has used the method to objectively compare the affinity 
between several different GAGs and HGF protein constructs. The aim of these 
experiments was therefore to produce GAG affinity columns with oligosaccharides 
of similar length so that the HGF-N and HGF-NK-G affinity for different GAGs 
could be quantitatively compared. The results are important in that it is the first time 
that a wide range of GAG affinity columns are used to compare the HGF affinity for 
different GAGs. Further, the results clarify the difference in GAG affinity for the 
different protein constructs HGF-N, HGF-NK-C and HGF-NK-G. 
  
Heparin affinity chromatography typically relies on heparin chains immobilised to 
Sepharose or a similar type of bead. The studied protein binds to the heparin chain 
and is eluted with an increasing concentration of NaCl. The concentration required 
for elution is generally proportional to the KD of the interaction. High affinity 
interactions with KD values in the range of 0.1 µM to 1 nM typically require at least 
1 M NaCl to elute the bound protein from the column [3]. Proteins with low heparin 
affinity (KDs in the range of 100 µM to 10 µM) either do not bind at physiological 
salt concentrations or require less than 0.5 M NaCl to elute. The method makes the 
assumption that protein - heparin interactions are entirely ionic, which is not 
completely true as evident from the Fondaparinux/Idraparinux example in section 
1.3.7. 
  
Crude heparin and different GAG DP16 oligosaccharides were biotinylated on the 
reducing end and loaded onto streptavidin columns to prepare GAG affinity columns. 
This allowed easy affinity comparison between different GAGs and protein 
constructs. Table 4.3 summarises the different columns that were used. 
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Table 4.3 The different GAG affinity columns and their corresponding colour in the 
chromatograms. 
Standard heparin column from GE Healthcare Dark blue 
Heparin-biotin-streptavidin linked via free amines Pink (only HGF-N) 
Heparin DP16-biotin-streptavidin Red 
Chondroitin sulfate C DP16-biotin-streptavidin Green 
Chondroitin sulfate A DP16-biotin-streptavidin Grey 
Dermatan sulfate DP16-biotin-streptavidin Orange 
 
 
The decahexasaccharide fraction was chosen for all GAGs for affinity 
chromatography, AUC and ITC experiments to make comparison between the 
different experiments easier. As heparin, chondroitin and dermatan -sulfate chains 
vary widely in length, using only one defined length makes comparison between the 
different GAGs easier and more objective. Furthermore, DP16 is the longest heparin 
oligosaccharide that can be prepared with reasonable purity in our laboratory (Figure 
4.38). A relatively long GAG chain was preferred over shorter oligosaccharides to 
mimic in vivo conditions. Using a long oligosaccharide also ensures that the whole 
GAG binding site of the protein will be spanned and that highly sulfated GAG motifs 
will be preserved.  
 
There are many ways to immobilise GAGs for affinity chromatography, SPR and 
similar experiments [249]. The most straightforward way to introduce only one 
linkage to the matrix is by reductive amination at the reducing end carbonyl. By 
using NHS-chemistry, utilising the odd free amine that appears in heparin chains, a 
limited number of linkages are created. The GAG can either be directly linked to the 
matrix or surface, or a biotin with a linker can be conjugated to the GAG, 
subsequently utilising the very tight biotin-streptavidin interaction to immobilise the 
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GAG to the matrix [250]. In these experiments, the biotin conjugation approach was 
selected as the reaction was relatively straightforward and the biotinylated GAGs 
could potentially be used for other experiments such as SPR if required. Reductive 
amination of GAGs have been used to attach biotin affinity labels and other types of 
labels such as reporter labels to allow many different types of experiments [168], 
[251-262]. Reductive amination is described in detail in section 4.11.1. A schematic 
explanation of the process and the structures of the biotin labels used in this 
experiment are shown in Figure 4.45. 
 
Figure 4.45 Structure of the biotin labels and targeted reactive groups of GAG 
oligosaccharides. Biotin-LC-Hydrazide was used for conjugating biotin to the 
reducing end and NHS-PEG4-Biotin was used for biotinylating heparin on free 
amines. 
 
The reducing end conjugation has the advantage of producing less steric hindrance 
compared to the free amine conjugation as it leaves most of the GAG chain free for 
protein interaction. The disadvantage of the reducing end conjugation is that it opens 
the reducing end sugar unit. This could be a problem for shorter oligosaccharides, but 
modifying one out of 16 monosaccharide units is unlikely to pose a problem. 
Another potential problem is that the conjugation reaction conditions are relatively 
harsh compared to the NHS-chemistry conditions. Although some researchers report 
successful biotinylation under mild reductive amination conditions [11], [263], [264], 
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sufficient biotinylation under such conditions was not achieved with a CSA DP4 
model system in this study. Possibly, the reaction could have been incubated longer 
and the pH adjusted to achieve better conjugation under milder conditions. 
 
To confirm that the reaction conditions described in section 3.4 did not alter the 
GAG structure, a heparin hexasaccharide was exposed to the same reaction 
conditions, but without the biotin label (biotinamidohexanoic acid hydrazide). The 
SAX chromatograms and MALDI-TOF spectra of the GAG were identical before 
and after the reaction, indicating that the reaction conditions did not alter the 
structure (data not shown). 
 
All proteins clearly bound to the prepared GAG affinity columns and eluted as sharp 
symmetrical peaks, except when heparin was biotinylated via free amines, as seen in 
Figure 4.46. HGF-N and HGF-NK-C elutes from the standard GE Healthcare heparin 
column at approximately 1 M NaCl, but from the prepared GAG columns at 
approximately 750 mM NaCl. All proteins bound tighter to the standard heparin 
column from GE Healthcare than to the prepared heparin DP16 column. This can be 
explained by: 
A) On the GE Healthcare column, the heparin chains are longer and can contain 
more complete high affinity sites from both a quantity and quality point of 
view.  
B) Differences in heparin batches and sources: it is well known that there is a 
difference in structural features between different heparin sources and batches 
[170], [171], [156]. 
C) The heparin is linked to the resin in a different manner. 
D) As the heparin on the prepared column is shorter, conjugated to a biotin 
molecule and linked to streptavidin there is a larger possibility that the 
streptavidin and resin generate steric hindrance. 
E) A difference in the abundance and quantity of immobilised heparin chains. 
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HGF-N and HGF-NK-C elute at the same time from the standard heparin column, 
which is expected as the main heparin binding site is thought to be in the N domain 
of HGF [11], [21], [14], [42], [265]. HGF-NK-C elutes somewhat later on the in-
house prepared columns compared to HGF-N, but at the same time on the standard 
GE healthcare column. This could be explained by more sterical hindrance on the in-
house prepared column or by experimental variation. 
 
In Figure 4.46 it can clearly be seen that HGF-N and HGF-NK-C has higher affinity 
for all GAGs compared to HGF-NK-G. This is likely due to the difference in the N-
terminal residues between the different constructs as discussed in section 4.5.2.  
 
In following the binding of individual proteins to different GAG columns in Figure 
4.46, there is a general trend that all protein constructs bind tightest to the standard 
GE Healthcare heparin column followed by the in-house prepared heparin column. 






















Figure 4.46 Chromatograms showing HGF-N (solid line), HGF-NK-C (dotted line) 
and HGF-NK-G (dashed line) on all the different GAG affinity columns. The elution 
volume is shown on the X-axis and the UV response on the Y-axis. The gradient 
going from buffer A to buffer B is shown as a solid blue line. A general trend is that 
all proteins bind with the highest affinity to heparin and with lower but similar 
affinities to CSA, CSC and DS. HGF-NK-G binds with lower affinity to all GAGs 
compared to HGF-NK-C and HGF-N.  
 
 133 
Turning our attention to the HGF-N chromatogram for the column where biotin was 
linked to free amines of heparin (pink trace in Figure 4.46), it is clear that the binding 
is impeded compared to conjugating the biotin to the reducing end even though crude 
heparin was used instead of DP16. This could possibly be explained by the fact that 
each heparin polymer can contain several free amines spaced along the whole length 
of the chain. Immobilisation could constrain the heparin chain, forcing it to lie in a 
more horizontal mode along the matrix, creating steric hindrance for protein binding 
with the biotin linker, streptavidin and the matrix. 
 
There are small, but noticeable differences in the binding of HGF-N to chondroitin A 
and C: the protein seems to bind tighter to the latter column. Whether this is due to 
experimental variation or if it reflects real differences in the binding is difficult to 
say. One could possibly argue that the 6-sulfate of chondroitin C is more amenable to 
interact with the protein since it is attached to a CH2 group and this additional 
flexibility could strengthen the binding. On the other hand, the affinities for both 
chondroitin A and C are the same for HGF-NK-C, suggesting that the difference for 
HGF-N might be a small experimental variation. 
 
There are very few, if any reports at all on that HGF binds to CS. Some studies 
suggest that HGF only binds to HS like GAGs [266], whereas other studies suggest 
that HGF binds to DS [12]. The main difference between CS and DS is that CS 
contains glucuronic acid backbone sugar units that are less flexible compared to the 
iduronic acids sugar units in DS. It has been argued that this allows DS to adopt a 
more favourable conformation for binding with higher affinity to HGF. However, in 
this study it was found that HGF binds with similar affinity to CS and DS.  It is 
noticeable that the dermatan peaks are somewhat wider than the chondroitin peaks in 
general, implying that used dermatan used in these experiments is somewhat more 




Additional small peaks can occasionally be observed after the main peak for the 
chondroitin and dermatan columns. These peaks likely correspond to the binding of 
dimeric HGF-N that binds with higher affinity than the monomer as described in 
section 4.3. Analogous dimeric peaks can also be seen for the heparin columns, 
although these are much smaller. In this case, the same batch of protein was used, but 
for the chondroitin and dermatan affinity chromatography, the protein had been left 
at room temperature for a longer time than for the heparin affinity chromatography. 
 
Elution of HGF-NK-C from the different GAG affinity columns is very similar to the 
behaviour of HGF-N. As the main GAG binding site is in the N-domain, the result is 
not surprising. HGF-NK-G follows the pattern of the two other protein constructs, 
the affinity for chondroitin A and C are similar and the affinity for dermatan sulfate 
is the lowest. For both types of heparin columns, there is a small shoulder at the 
beginning of the elution peak. This might be due to a heterogeneous protein sample 
or possibly due to a more complex binding event. HGF-NK-G elutes earlier than 
HGF-NK-C from both the in-house prepared and the standard GE Healthcare heparin 
affinity columns. As explained earlier, this is likely due to the different N-termini 
that these proteins have. A similar trend is observed for the binding to CSA, CSC and 
DS. 
 
All protein constructs bound to sulfated GAGs (Figure 4.46). To investigate the 
importance of the sulfates and to see if HGF-N binds to non-sulfated GAGs, a 
hyaluronan affinity column was prepared in the same way as for the other GAG 
affinity columns. As can be seen in Figure 4.47, HGF-N interacts with hyaluronan, 




Figure 4.47 HGF-N eluted from a hyaluronan affinity column. The UV-trace is 
shown in blue and the conductivity is shown as mM NaCl in black. The protein binds 
to the column, but elutes at physiological NaCl concentration and is therefore 
unlikely to be physiologically relevant. 
 
4.5.2 Affinity Chromatography of HGF-N with different N-Termini 
To clarify the role of the N-terminal residues, the HGF-N proteins with different N-
terminal kex2-cleavage sites described in section 4.2.1 were subjected to heparin 
affinity chromatography. The aim of the experiments was to understand how the N-
terminal 6 residues contribute to the HGF-GAG interaction. The results are important 
in that they shed more light on the importance of the N-terminal residues that cannot 
be studied by NMR and x-ray crystallography.  
 
Based on the fact that the N-terminus contains several basic residues, it was 
hypothesised that the more basic residues that are lacking from the N-terminus, the 
lower the heparin affinity and the earlier the proteins will elute from the heparin 
affinity column. This would also correspond to the order that the different proteins 
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elute from the MonoS cation exchange column during protein purification, as the 
heparin affinity is likely related to the pI of the protein.  
 
It has previously been shown that the N-terminus of HGF is important for heparin 
binding [63]. The results further emphasise the importance of the N-terminal residues 
in the HGF-GAG interaction and although the residues are unstructured, they do 
indeed contribute to binding as shown by heparin chromatography (Figure 4.48). 
 
 
Figure 4.48 Heparin affinity chromatography of HGF-N with different N-termini as 
characterised in section 4.2.1. Blue trace: HGF-N-Δ6, lacking the first six residues 
(GQRKRR). Grey: HGF-N-Δ5, lacking the first five residues (GQRKR). Orange: 
S45 or T38 phosphorylated. Red: HGF-N. Black: Dimeric HGF-N. 
 
The phosphorylation of S45 or T38 is expected to reduce GAG binding as it 
introduces a negatively charged, relatively big and bulky PO4 group in the binding 
site. As only a small portion of the protein expressed in P. pastoris is 
phosphorylated, it cannot be correlated to human in vivo conditions, but it shows that 
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protein phosphorylation can be a way to regulate GAG binding in vivo. It is well 
established that protein phosphorylation is an important posttranslational 
modification for cell signalling in both extracellular and intracellular proteins. For 
example, it has been shown that neuroglycan c, a brain-specific transmembrane 
chondroitin sulfate proteoglycan can be phosphorylated [267]. 
 
Various protein constructs have been used for the structure determination of both 
free HGF and HGF-GAG complexes [21], [14], [17], [15]. The N-terminal residues 
have varied in these structures due to cloning procedures as summarised in Table 4.1.  
 
Although it has been established that the N-terminal residues are important for the 
HGF-GAG interaction, these residues are disordered and it is therefore difficult to 
determine their structural role in the interaction. In the 2HGF NMR structure [17], 
the N-terminal residues are included, but inspection of the structure ensemble clearly 
shows that that the N-terminus is unstructured. In the 1GMO X-Ray structure [14], 
no electron density can be seen for the N-terminal residues and they are not included 
in the PDB file. The 1BHT X-ray structure determined by Ultsch et al [15] includes 
more N-terminal residues than the 1GMO PDB, but a 10 residue long N-terminal 
Flag epitope was included in this protein construct to facilitate purification, which 
likely disrupts the N-terminus.  
 
In the HGF-NK-G – heparin structure (1GMO), the protein was crystallised with a 
14mer heparin oligosaccharide, but only a maximum of 9 sugar units can be seen in 
the pdb file whereof four form the core binding site (Figure 4.49) [14], [2], [70]. The 
lack of sugar units at both ends of the heparin oligosaccharide is explained by poor 
electron density, as is evident from low B-factors in the pdb file [14]. 
Glycosaminoglycans are in general more flexible than proteins, but will to a certain 
extent be stabilised by protein binding. For the HGF-heparin interaction, it is likely 
that the GAG does binds across the N-terminus, but it cannot be visualised in the 
crystal structure due to low electron density.  
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It is also possible that steric hindrance and charge repulsion from the added N-
terminal residues in the HGF-NK-G/1GMO protein construct (Table 4.1) distorts the 
native N-terminal protein-GAG interaction. Comparing different structures of the N 
domain, it looks like that the N-terminal residues reach towards the GAG and likely 
interact with it, becoming more structured upon binding (Figure 4.49). This theory is 
supported by the heparin chromatography results, the occurrence of new peaks in 1H-
15N HSQC spectra when adding GAGs as discussed in section 4.10 and by the 
general importance of the N-terminal residues [63]. 
 
 
Figure 4.49 The PDB files 1BHT (Red), 1GMO (Blue) and 2HGF (Green) were 
overlaid and rendered in UCSF Chimera. Only the 1GMO PDB file contains heparin. 
 
4.5.3 HGF Affinity Chromatography 
Different GAG binding proteins often display a preference for a certain GAG 
sequence, although many different sequences often can be accommodated. It has 
previously been suggested that HGF binds preferentially to highly sulfated GAGs, 
just like many other GAG-binding proteins [69]. To investigate which heparin 
hexasaccharide sequence that binds tightest to HGF-N in a mixture of enzymatically 
digested heparin hexasaccharide, an HGF-N affinity column was produced by 
biotinylating the protein and immobilising it on a streptavidin column. The results 




hexasaccharide mixture and that HGF-N binds with the highest affinity to fully 
sulfated heparin hexasaccharide containing iduronic acid. Further, it is the first time 
that the current straightforward experimental setup is used to study the HGF-GAG 
interaction. 
 
A GE Healthcare HiTrap streptavidin column containing streptavidin immobilised on 
Sepharose beads was used for the experiment. A PEG4 linker was in place between 
the biotin group and the protein in order to minimise any sterical hindrance. A 
heparin DP6 mixture was loaded onto the column and eluted with a salt gradient, 
monitoring A232. The last eluting peak should be the tightest binding GAG. Figure 
4.50 summarises the overall concept of the experiment. 
 
 
Figure 4.50 Outline of the HGF-N affinity experiment. Biotinylated HGF-N was 
immobilised on a streptavidin column. A heparin DP6 mixture was loaded onto the 
column and eluted with a NaCl gradient. The last eluting peak was judged to be the 
oligosaccharide binding with highest affinity. 
 
There are several different reactive groups that can be employed to biotinylate 
proteins [268]. In this experimental setup, either the lysine/arginine and N-terminal 
amines or the aspartic/glutamic acid and C-terminal carboxyls could be targeted. As 
electrostatic sulfate - lysine/arginine interactions are among the most important 
points for protein-GAG interactions [269], aspartic/glutamic acid carboxyls are the 
preferred biotinylation target in order not to affect GAG binding at first glance. 
However, after carefully studying the structure of the HGF-N-GAG complex, it 
becomes clear that targeting the carboxyls would attach biotins in the binding site. 
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Targeting the amines with NHS chemistry is very efficient and straightforward. 
Keeping this in mind, it was decided to target the amines for biotinylation rather than 
the carboxyls, but to protect the binding site with heparin oligosaccharides to allow 
fewer biotins to attach there (Figure 4.51). 
 
 
Figure 4.51 Protecting the binding site against biotinylation. HGF-N is symbolised 
by a blue smiley face with the binding site in red.  
 
Although the binding site was protected by carrying out the biotinylation reaction in 
the presence of tenfold excess heparin DP8, it was expected that some biotin 
molecules would attach to the binding site and hinder the GAG interaction. To purify 
active HGF-N that bound heparin with normal affinity, the protein was heparin-
affinity purified after the biotinylation reaction. Different ratios of the biotinylation 
reagents and protective heparin were explored (Figure 4.52). It was found that a 
twofold excess of biotinylation reagent and a tenfold excess of protective heparin 





Figure 4.52 Heparin affinity purification of biotinylated HGF-N. The different 
chromatograms correspond to different reaction conditions as follows: Orange: 
tenfold excess of biotinylation reagent, fivefold excess of heparin DP8. Red: twofold 
excess of biotinylation reagent, fivefold excess of heparin DP8. Blue: twofold excess 
of biotinylation reagent, tenfold excess of heparin DP8. 
 
The fractions of heparin affinity purified biotinylated HGF-N were analysed by 
MALDI-TOF mass spectrometry to assess how many biotin molecules were 
attached. The mass spectra show how the early eluting, low heparin affinity fractions 
in Figure 4.52 tend to have more biotin molecules attached than the later eluting high 
heparin affinity fractions. Fraction 17 in Figure 4.52 has 1, 2, 3, or 4 biotins attached, 
fraction 20 has 0, 1, 2 or 3 biotins attached, fraction 23 has 0, 1 or 2 biotins attached 
and fraction 25 has 0 or 1 biotin attached (Figure 4.53). These results show that even 
one biotin is enough to impede heparin binding if the biotin molecule is attached to 







Figure 4.53 MALDI-TOF analysis of biotinylated HGF-N fractions from Figure 



















Based on the information obtained from the heparin affinity chromatography and the 
MALDI-TOF analysis, it was decided that fractions 21 to 26 in Figure 4.52 would be 
used for producing the final HGF-N affinity column.  
 
To perform HGF-N affinity chromatography, approximately a twofold excess of 
size-exclusion purified heparin DP6 over HGF-N was loaded onto the HGF-N-
affinity column and eluted with a salt gradient, monitoring A232 (Figure 4.54). As 
expected, the chromatography peaks are broad but distinguishable. Five different 
fractions were collected and analysed by SAX chromatography and MALDI-TOF 
mass spectroscopy. 
 
Figure 4.54 HGF-N affinity chromatography of heparin DP6. Fractions: 0) 0-13 
minutes, 1) 14-18 minutes, 2) 19-25 minutes, 3) 26-34 minutes, 4) 35-45 minutes. 
 
As expected, the affinity-purified heparin DP6 fractions elute late from the SAX 
column compared to the heparin DP6 mixture that the affinity-fractions were purified 
from (Figure 4.55). From experience, the SAX chromatograms indicate that the 
tightest binder (fraction 4) is fully sulfated heparin hexasaccharide containing 
iduronic acid residues and that the second tightest binder (fraction 3) lacks a sulfate 
or contains glucuronic acid motifs. 





Figure 4.55 SAX chromatography of fractions from Figure 4.54. For comparison, 
the SAX chromatogram of the heparin DP6 mixture that was loaded onto the HGF-N 






The SAX fractions were subsequently desalted and subjected to MALDI-TOF mass 
spectrometry to determine the degree of sulfation of the species. The MALDI-TOF 
spectra were calibrated with insulin and insulin b chain internal standards to improve 
accuracy. The standards contain several Na+ adducts, although that does not impede 
spectrum quality (Figure 4.56). Both the free (RG)11 and (RG)11 + GAG complex can 
be identified, but most of the (RG)11 peptide is complexed with the GAG. A small 
peak at 77 M/Z below the (RG)11 + GAG complex indicates loss of one sulfate 
during the ionisation process. The calculated theoretical mass for fully sulfated 
protonated heparin DP6 is 1730.9 Da. The experimental mass from the spectrum in 
Figure 4.56 is 4095.95  - 2367.27 = 1728.65 Da. 
  
 
Figure 4.56 MALDI-TOF spectrum of peak 4, fully sulfated heparin DP6, 
complexed with (RG)11 peptide. M/Z assignments: 2367.27: free (RG)11 peptide, 
3496.14: insulin b chain standard with Na+ adducts, 4019.22: (RG)11 + heparin DP6 
that has lost one sulfate during ionisation, 4095.95: (RG)11 + fully sulfated heparin 
DP6 and 5733.81: insulin standard with Na+ adducts. 
(RG)11 
(RG)11 + Hep DP6 
-SO3 
Insulin 
Insulin B Chain 
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The spectrum in Figure 4.56 has not been deisotoped. With the employed 
experimental setup, reasonable isotope resolution can usually be achieved, but not for 
all samples (Figure 4.57). 
 
 
Figure 4.57 Zoom in of a (RG)11 + heparin DP6 peak showing isotope resolution. 
 
For spectra with poor isotope resolution, deisotoping is difficult. Even with relatively 






Figure 4.58 Deisotoped and calibrated (RG)11 + heparin DP6 spectrum 
 
The results from the SAX and MALDI-TOF analysis are summarised in Table 4.4. 
 
Table 4.4 Summary of MALDI-TOF and SAX analysis of the different HGF-N 
affinity purified heparin DP6 oligosaccharides in Figure 4.54. 
Fraction Molecular Weight SAX 
0 Lack 2 or more sulfates Many species 
1 Lack 1 and 2 sulfates 3 Species 
2 Lack 1 and 2 sulfates 4 Species 
3 Lack 1 sulfate 2 Species 




It is likely that two of the species in fraction 2 are the same as in fraction 3 as they 
have the same MW and elute from the SAX column at the same retention time 
(Figure 4.55).  
 
As expected, the tightest binding heparin hexasaccharide is fully sulfated, consisting 
of IdoA2S - GlcNS6S disaccharides. The HGF-GAG interaction is mainly charge 
driven [14], as most other protein-GAG interactions [269]. Affinity experiments with 
Fondaparinux containing an extra 3-O sulfate described in section 4.8 showed that it 
bound very tightly and in general the more sulfates, the tighter protein-GAG 
interaction [269]. It was hypothesised that the tightest binding heparin DP6 
oligosaccharide could contain a 3-O sulfation. The reason why a 3-O sulfation was 
not found could be due to: 
1) The amount of 3-O sulfated heparin was too low to be detected on the HGF-
N affinity column. 
2) The used batch of heparin did not contain any 3-O sulfations or only in very 
low quantities. 
3) A 3-O sulfation is not in the tightest binding GAG motif. 
4) The 3-O sulfate motif was in the fully sulfated peak 4 fraction, but after SAX 
chromatography, it was not detected by MALDI-TOF due to very low 
absorbance (Figure 4.55). 
 
A limitation of the current experimental setup might be the relatively low sensitivity 
of the employed UV-detection. The extinction coefficient of enzymatically digested 
GAGs at 232 nm is 5200 M-1 cm-1, which is relatively low compared to many other 
fluorescent detection methods [168]. Attaching a fluorescent reporter would enhance 
sensitivity, but at the same time modify the GAG and thus potentially alter the 
protein-GAG interaction. An alternative approach could be to use 3H labelled 
oligosaccharides and detect radioactivity, a technique that has been employed in 
similar experiments [66], [12]. 
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4.6 Gel filtration Studies of HGF-N and HGF-NK-G Complexed 
With Different GAGs 
It has been suggested that HGF dimerises/oligomerises upon addition of heparin/HS 
and possibly other GAGs that are long enough [2]. Most of the evidence comes from 
X-ray crystallography [14], crosslinking [265], [90] and gel filtration [14], [42], [16], 
[67] studies. In addition, it is a general mode of action of receptor tyrosine kinase 
ligands [18]. For example, the FGF-GAG complex is a well-characterised archetype 
of how a heparin binding growth factor oligomerises upon addition of the correct 
GAG motif [28], [270]. Although the stoichiometry of the HGF-GAG complex has 
been investigated before, it has not been as well studied as many other protein-GAG 
complexes, such as the FGF-GAG complex and the gel filtration studies of HGF-
GAG complexes have not taken the big hydrodynamic radius of the GAG into as 
careful consideration as some studies of the FGF-GAG complex [28], [29], [270], 
[271].  
 
It is likely that the HGF-GAG complex can oligomerise in several different ways and 
four possible different models (A-D) are shown in Figure 4.59. The most simple 
oligomerisation mode (A) is like beads on a string where one HGF molecule has one 
GAG binding site and if the GAG is long enough, many HGF molecules can bind. 
One can also imagine that HGF has one GAG binding site (B) and one HGF-HGF 
interface, this model is supported by the fact that HGF is reported as a 
dimer/oligomer in crystal structures and when it binds to GAGs [14]. Further, HGF 
could dimerise with the GAG between the two HGF molecules (C), the GAG being 
the spread that makes a double sandwich stick together. The most complex mode of 
dimerisation would be a combination of HGF-HGF interactions and a GAG 
sandwich model (D). Taking the Met receptor into consideration, these models are 





Figure 4.59 Four modes of oligomerisation of HGF-GAG complexes. 
 
To further study the oligomerisation and binding process, different oligosaccharide 
lengths of CS, DS and heparin GAGs were mixed with HGF-NK-G and HGF-N at 
different ratios and studied by gel filtration. The aim of the experiments was to 1) 
determine the shortest GAG fragment that makes the proteins oligomerise, 2) clarify 
the oligomerisation mode, 3) take the large hydrodynamic radius of GAGs into 
careful consideration. The results are likely to be important in that it is the first time 
that a range of oligosaccharide lengths of three different GAG types, in particular 
CS, has been used to study the oligomeric mode of HGF-N and HGF-NK-G. The 
shortest fragment that causes HGF-N and HGF-NK-G to oligomerise and the 
oligomerisation mode of the proteins is currently not known.  
 
Gel filtration is a common, simple and straightforward experiment to investigate the 
oligomeric state of proteins in solution that has been employed to clarify a wide 
range of biochemical problems. By using a gel filtration column that has been 
calibrated with protein standards in the investigated MW range it is possible to 
deduce the apparent molecular weight of the investigated species. In the current 
experimental setup, standards corresponding to monomeric and dimeric protein were 
used. The experiment design means that if the protein dimerises upon addition of 
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GAG, the apparent molecular weight as determined by gel filtration would double if 
the MW of the GAG can be ignored. The direct correlation between MW and elution 
volume on a gel filtration column depends on the hydrodynamic radius of the species 
and not the actual MW and thus the method is only reliable for globular proteins 
unless the column has been calibrated for other species. 
 
To clarify the individual contributions of the GAG and the protein to the retention 
time shifts, the different GAGs and proteins were injected separately. To be able to 
monitor the UV-trace of the GAGs, the BioCAD FPLC system was used and the UV 
detector was set to 232 nm. 
 
Results of the separate injections are summarised in the upper chromatogram in 
Figure 4.60. In these experiments CSC was used as a representative GAG. CSC 
DP12 migrates through the gel filtration column as a species with an apparent larger 
molecular weight than HGF-N and CSC DP22 migrates as a species with an apparent 
larger molecular weight than HGF-NK-G.  
 
The middle chromatogram in Figure 4.60 shows how heparin DP12 migrates as a 
smaller apparent MW than HGF-NK-G, but when bound to the protein, the complex 
migrates as a broad peak with a large apparent MW, the excess of free DP12 GAG is 
also be visible. The broadness of the peak can be explained by a monomer / oligomer 
equilibrium, or due to the protein sample being heterogeneous, containing species 
with different GAG affinity. 
 
The bottom chromatogram Figure 4.60 shows how heparin DP8 migrates at a larger 
apparent MW than HGF-N, the complex migrates as a narrow symmetrical peak and 
the free GAG can be seen. The MW of heparin DP8 is 2680 Da, the MW of HGF-N 
is 11370 Da, emphasising how quickly the elongated GAGs migrate through a gel 
filtration column compared to globular proteins. Although HGF-N is four times 
larger than heparin DP8, the latter still elutes earlier from the gel filtration column. 
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The tailing of the free protein peaks cannot be explained as no tailing is seen when 
running identical experiments on the Akta FPLC system. 
 
These experiments have shown that an increase of the apparent molecular weight of a 
protein-GAG complex is strongly affected by the large hydrodynamic radii of GAGs. 
It is difficult to determine the oligomeric state of a protein-GAG complex unless 
modelling of the hydrodynamic radii of the complexes is undertaken. Modelling of 
the complex requires knowledge of the geometry and strength of the complex. 
However, if the results are interpreted with care, keeping the hydrodynamic radius of 




Figure 4.60 Gel filtration of different HGF constructs and GAGs in PBS. a) All four 
species monitored in separate runs. b) Free HGF-NK-G, free heparin DP12, HGF-
NK-G + heparin DP12 in tenfold excess mixture. c) Free HGF-N, free heparin DP8 






To investigate the oligomerisation and binding differences between HGF-N, HGF-
NK-G and different GAG oligosaccharides, the proteins were mixed with GAGs of 
varied oligomer lengths at a 1:1 ratio (unless otherwise stated) and analysed by gel 
filtration monitored at 280 nm, which detects the protein but not the GAG. Similar 
experiments have been reported with Human Complement Factor H and dextran 
sulfate [272] and many other protein-GAG complexes, including HGF. 
 
Initially, HGF-N was mixed with DP4-DP16 heparin oligosaccharides and analysed 
by gel filtration (Figure 4.61). It can be seen that all oligosaccharides bind to HGF-N 
and induces elution volume shifts. The octasaccharide peak is broadened, the DP10 
and DP14 peaks have shoulders that disappear with DP16 at tenfold excess.  
 
There are several possible explanations for the appearance of shoulders for DP10 and 
DP14, the two most appealing are: 
1) A DP10 GAG is long enough to accommodate two protein molecules and 
equilibrium is reached where some DP10 molecules have two protein 
molecules bound (1:2) and some have one protein molecule bound (1:1).  
2) The factions are not clean and contaminated with longer oligosaccharides. 
 
These results support the beads on a string oligomerisation model in Figure 4.59 for 
HGF-N as no sharp shift in elution volume is seen and the elution volume shifts are 
likely due to the addition of more saccharide units. At tenfold excess DP16, some 
higher order complexes can be seen in the chromatogram: the UV absorbance 





Figure 4.61 Gel filtration of free HGF-N, free HGF-NK-G as a standard and HGF-N 
in the presence of heparin oligosaccharides. The UV-absorbance was monitored at 
280 nm.  
 
CSC with a lower sulfate and IdoA content is expected to bind HGF-N with much 
lower affinities than heparin. This is indeed the case as CSC mixture elutes mostly as 
free protein and the UV-traces are elongated (Figure 4.62). This suggests that at an 
equimolar ratio, the binding site is far from saturated. However, at tenfold excess of 
CSC DP20, only one symmetrical peak is visible. 
 
As discussed in section 4.5.1, there are few, if any reports at all on that HGF interacts 
with CS under physiological conditions. These gel filtration studies of HGF-CS 
complexes complements the results in section 4.5.1 and further shows that it is likely 
that HGF interact with CS under physiological conditions, although with much lower 






Figure 4.62 Gel filtration of free HGF-N, free HGF-NK-G as a standard and HGF-N 
in the presence of CSC oligosaccharides. The UV-absorbance was monitored at 280 
nm. 
 
The UV-traces for the HGF-N + DS mixtures are elongated and depending on the 
length of the DS oligosaccharide, a different proportion of the protein is in the free or 
bound form (Figure 4.63). For longer oligosaccharides, the elution UV profile consist 
of two peaks and for an increase in oligosaccharide length, a corresponding increase 
in apparent molecular weight is observed. One peak appears at the same elution 
volume as free protein and the other peak corresponds to the complex that gradually 
shifts towards higher apparent molecular weight with increasing oligosaccharide 
length. The splitting of peaks is interpreted as the lower apparent molecular weight 
corresponds to free protein and that the higher apparent molecular weight 
corresponds to the protein-GAG complex. This behaviour is similar to that of CSC. 
 
DS with a lower sulfate content than heparin, but with a higher IdoA content than 
CSC is expected to bind to HGF-N with affinities between CSC and heparin. This is 
also the case, as the bound form is more prevalent in the chromatogram, but the 
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results do not correlate with Figure 4.46, where it was found that HGF-N and HGF-
NK-G bind tighter to CS than to DS. This is probably due to that different sources of 
DS were used for the different experiments. The DS for this experiment was from 
Grampian Enzymes whereas the DS for the affinity chromatography was from 
Malcolm Lyon, University of Manchester. 
 
Interestingly, the elution profiles for heparin versus CSC/DS are different. The 
heparin peaks do not show free protein and only the complex peak can be seen. This 
is likely due to that HGF-N binds heparin with higher affinity. 
  
 
Figure 4.63 Gel filtration of free HGF-N, free HGF-NK-G as a standard and HGF-N 
in the presence of DS oligosaccharides. The UV-absorbance was monitored at 280 
nm. 
 
Comparison of HGF-N in the presence of DP10 and DP14 fractions of heparin, CSC 
and DS is particularly interesting. Heparin shows two peaks eluting at 73 and 78 
minutes which likely corresponds to 2:1 and 1:1 protein:GAG complexes. CSC also 
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shows two peaks eluting at 78 and 88 minutes, which corresponds to the 1:1 complex 
and free protein. The same applies to DS. These observations strongly support the A 
and B models in Figure 4.59. Only heparin binds tightly enough and has a high 
enough exothermic contribution to compensate for the loss in entropy associated with 
binding two protein molecules.  
 
To investigate the oligomerisation and binding properties of HGF-NK-G, the protein 
was mixed with different GAGs and analysed by gel filtration in a similar manner as 
for HGF-N. 
 
The gel filtration chromatograms of HGF-NK-G mixed with different heparin 
oligosaccharides exhibit similar behaviour as HGF-N. For shorter heparin 
oligosaccharides, an elution time shift can clearly be seen due to the larger 
hydrodynamic radius of the complex (Figure 4.64). A clear double peak can be seen 
for heparin DP16, comparable to the DP10 and DP14 results for HGF-N. This can be 
explained by that HGF-NK-G is a larger protein and a longer oligosaccharide is 
needed to host two protein molecules. 
 
Heparin DP16 was used in equimolar and tenfold excess ratios. The two 
chromatograms overlay well, but at tenfold excess, the 1:1 peak is larger than the 1:2 





Figure 4.64 Gel filtration of free HGF-NK-G, free ovalbumin as a standard and 
HGF-NK-G in the presence of heparin oligosaccharides. The UV-absorbance was 
monitored at 280 nm. 
 
HGF-NK-G binds very weakly to CSC as can be seen in Figure 4.65. Also, the 
apparent MW of the complexes seem smaller compared to those for the heparin 
oligosaccharides. This is likely due to that the protein spends more time 
uncomplexed than complexed. The effect can also be partly explained by that the 
heparin is more highly sulfated, which likely increases the hydrodynamic radius. 
HGF-NK-G complexed with CSC DP20 at tenfold excess migrates approximately at 





Figure 4.65 Gel filtration of free HGF-NK-G, free ovalbumin as a standard and 
HGF-NK-G in the presence of CSC oligosaccharides. HGF-NK-C was used for the 
10X DP20 chromatogram. The UV-absorbance was monitored at 280 nm. 
 
The results for HGF-NK-G complexed with DS are similar to those for CSC. 
Interestingly, the tenfold excess DS DP20 chromatogram in Figure 4.66 contains a 
third higher order shoulder that is not visible for CSC, this could possibly be two 
proteins on one GAG oligosaccharide or a DS impurity.  
 
Just like for HGF-N, no 2:1 complexes could be seen for HGF-NK-G in the presence 
of CSC or DS oligosaccharides, only heparin oligosaccharides showed 2:1 
complexes. As expected, HGF-NK-G due to its larger size needed a longer 
oligosaccharide than HGF-N to form a 2:1 complex. HGF-N formed 2:1 complexes 
with heparin DP10, whereas HGF-NK-G formed 2:1 complexes with heparin DP14 




Figure 4.66 Gel filtration of free HGF-NK-G, free ovalbumin as a standard and 
HGF-NK-G in the presence of DS oligosaccharides. The UV-absorbance was 
monitored at 280 nm. 
 
In conclusion the gel filtration experiments showed that: 
1) When interpreting gel filtration data of protein-GAG complexes, it is 
necessary to take the large hydrodynamic radius of the GAG into account. 
2) Evidence for binding of two protein molecules on one GAG oligosaccharide 
was obtained for heparin DP>10 for HGF-N and DP>14 for HGF-NK-G, but 
not for CSC or DS oligosaccharides. This suggests that HGF-N and HGF-
NK-G oligomerises like beads on a string in the presence of heparin (mode B 
in Figure 4.59) 
3) It is unlikely that that these complexes have a trans orientation (Figure 4.59) 
because: 
a. A trans orientation would also be possible for shorter GAGs, for 
which ternary complexes were not observed. 
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b. 2:1 complexes are only seen when the GAG oligosaccharide has 
sufficient length. 
c. HGF-NK-G requires a longer GAG than HGF-N 
4) It was not possible to determine if the interaction was cooperative and 
includes formation of protein-protein interfaces. 
 
In the current experiments, the column was not calibrated and the hydrodynamic 
radii of the complexes were not calculated and the results were interpreted using 
elution times only. With the structures for HGF-NK-G complexed with heparin 
available, PDB files for different complexes can be created and the hydrodynamic 
radii calculated with programs such as HYDROPRO [233] and CRYSOL [273]. This 
treatment could potentially lead to a more sophisticated analysis of the data. 
 
The gel filtration column used in the current experiments is a preparative column, 
leading to a big waste of material. A Superdex 75 10/300 GL or a Superdex 75 PC 
3.2/30 column would be better suited as it would use significantly less material and 
shorten run times. 
 
An alternative method to determine stoichiometry of protein-GAG complexes that 
overcomes the problem of the large hydrodynamic radius of carbohydrates is mass 
spectrometry and it has been successfully employed to characterise the FGF-heparin 
complex [28]. The most physiological way to carry out mass spectrometry for these 
complexes is to use an electrospray ionisation interface and a volatile buffer such as 
ammonium acetate or ammonium bicarbonate, but MALDI ionisation can also be 
used as shown in this project (Figure 4.86). However, mass spectrometry is clearly 
not a solution-based method and artefacts can easily arise and as often when studying 
protein-GAG interactions by mass spectrometry, the heterogeneity of the GAG 
oligosaccharides pose a problem. This is especially a problem in mass spectrometry 
experiments with relatively long heparin-derived oligosaccharides that can have a 
very high degree of heterogeneity, as the m/z spectrum will be crowded with broad 
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peaks stemming from different substitutions and adducts. Ideally, a GAG species 
purified to homogeneity should be used, but it is difficult to achieve with DP > 8 due 
to the resolution of SAX columns and loss of material. Although, the loss of material 
might not pose a big problem for mass spectrometry, as it is a very sensitive method. 
Sometimes alternative GAG purification methods can be employed to purify 
homogeneous species for mass spectrometry studies such as protein-GAG affinity 
chromatography, or mixing the GAG and protein and injecting the mixture on a gel 
filtration column and using the gel filtration fractions that correspond to the complex 
MW, as the low affinity GAGs will have diffused away from the protein during the 
gel filtration run. The heterogeneity also poses problems when using mixtures for 
other techniques such as NMR, SPR, ITC, affinity chromatography and AUC as 
some species in the mixture might not bind, some species bind with intermediate 
affinities and some species bind tightly.  
 
Alternative techniques to study stoichiometry of protein-GAG complexes are ITC 
that gives the stoichiometry of the complex and SPR where the response can be 
correlated to how many protein molecules bind to an immobilised ligand. AUC can 
also be used to study the stoichiometry of biomolecular complexes and is generally a 
more advanced and powerful technique compared to gel filtration, but the derived 
information is still similar and the large hydrodynamic radius of carbohydrates can 
again make it difficult to use for protein-GAG interactions.  
 
4.7 Analytical Ultracentrifugation 
Gel filtration results in section 4.6 suggested that HGF-N and HGF-NK-G 
oligomerise as beads on a string. It is always a good idea to use an alternative 
technique to confirm experimental results. Therefore, AUC was carried out for HGF-
N and HGF-NK-G complexed with Fondaparinux and heparin DP16 as a method to 
study oligomerisation in addition to gel filtration. The aim of the experiments was to 
determine the oligomeric state of the protein construct in their free and complexed 
states. The results are important in that they are the first of its kind for HGF-N and 
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HGF-NK-G and the support gel filtration results. AUC experiments were performed 
in collaboration with Alexandra Solovoya, University of Newcastle. 
 




Figure 4.67 Example of a moving boundary profile of HGF-N complexed with 
Fondaparinux at an equimolar ratio using interference optics. 
 
Distributions of sedimentation coefficients (c(s)) plotted vs sedimentation coefficient 
(Svedberg), show that both HGF-N and HGF-NK-G are monomeric in solution in the 
used concentration range (10-120 µM for HGF-N and 10-60 µM for HGF-NK-G) 
(Figure 4.68). When the proteins are complexed with Fondaparinux a sedimentation 
coefficient shift can be seen due to the larger hydrodynamic radius of the complex. A 
slight broadening of the peak can be noticed, probably due to the binding dynamics 
of the complex. The peak remains relatively sharp and symmetrical for HGF-N, 
indicative of a homogeneous ligand that does not cause oligomerisation while it is 
broader and asymmetric for HGF-NK-G. When the proteins are complexed with 
heparin DP16, a larger sedimentation coefficient shift can be seen and the peak 
becomes wider and more asymmetric, indicative of heterogeneity of the heparin 




The linear extrapolation of the sedimentation coefficients to zero concentration for 
free HGF-N and HGF-NK-G in solution does not indicate formation of higher order 
species in solution as can be seen in Figure 4.69. There is no noticeable 
concentration dependence for the HGF-N + Fondaparinux complex in the examined 
protein concentration range. On the other hand, concentration dependence was 
observed for the HGF-NK-G + Fondaparinux complex, indicating a presence of 
some higher molecular weight species. As expected, concentration dependence of the 
sedimentation coefficient can be seen for both proteins complexed with heparin 




Figure 4.68 Distributions of sedimentation coefficients (c(s)) plotted vs 
sedimentation coefficient (Svedberg) for HGF-N (a) and HGF-NK-G (b) at different 
protein concentrations using UV absorbance detection. Dotted lines represent protein 
alone, dashed lines represent protein complexed with Fondaparinux at a 1:1 radio and 
solid lines represent protein complexed with heparin DP16 at a 1:1 ratio. The black 
trace represents the lowest concentration, red the medium concentration, green the 
higher concentration and blue the highest concentration. Sample concentrations can 






Figure 4.69 Linear approximation of sedimentation coefficients to zero 
concentration using absorbance data. a) HGF-N, b) HGF-NK-G. Symbols: : free 
protein, : protein + Fondaparinux at 1:1 ratio, : protein + heparin DP16 at 1:1 
ratio. 
 
The sedimentation coefficients and molecular masses for free HGF-N and HGF-NK-
G correspond well with the calculated values for monomeric protein as can be seen 






Table 4.5 AUC parameters derived from absorbance data.  
One-dimensional c(s) 
model Two-dimensional c(s, f/f0) model 







 file (S) 
s20,w (S) M (kDa) 
s20,w (S) S20,w (S) s20,w (S) 
HGF-N 11.4 1.41 1.47±0.01 11.8±0.23    
HGF-N+Fx   1.78±0.02 13.4±0.24    
HGF-N +DP16     2.37±0.02 3.41±0.14 4.47±0.05 
HGF-NK-G 21.1 2.17 2.21±0.01 21.7±0.82    
HGF-NK-G + Fx     2.52±0.04 3.44±0.09  
HGF-NK-G + DP16     3.02±0.04 4.10±0.1 5.47±0.23 
 
HGF-N remains a homogeneous monomer when complexed with Fondaparinux, but 
the data is more complex for HGF-N + heparin DP16 and for HGF-NK-G + heparin 
DP16 and Fondaparinux. As can be seen in Figure 4.68 and Figure 4.69, these 
complexes show concentration dependence and their molecular weights cannot be 
determined. By employing an alternative data fitting method, it was possible to 
resolve several species for both the HGF-N and HGF-NK-G complexes. In this 
model, the frictional ratio (f/fo) was used, which corresponds to the ratio of the 
experimental frictional coefficient of a molecule relative to its theoretical spherical 
frictional coefficient [274]. The frictional ratio reports on particle shape, but it has 
been shown that the shape dependence is relatively weak and spherical proteins 
typically have a frictional ratio of 1.2-1.3 whereas asymmetrical proteins typically 
have a frictional ratio of 1.5-1.8 [275].  
 
The calculated c(s, f/fo) distribution is shown as a two-dimensional distribution with 
grid lines representing the sedimentation coefficient and frictional ratio of the 
analysis. In the c(s, f/fo) two-dimensional model of HGF-N complexed with heparin 
DP16, two to three species can be seen (Figure 4.70). These peaks could arise when 
several HGF-N molecules bind along the GAG chain, producing an elongated 
species as indicated by a high frictional ratio and a relatively small difference in 
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sedimentation coefficient. At an equimolar protein:GAG ratio, most of the protein 
binds in a 1:1 mode, while some 2:1 protein:GAG complex are also present. There 
are also two very small peaks indicating even higher order species. These could be 
artefacts from the data analysis or a due to 3:1 complex. Approximately 13.5% of the 
species seems to be present as a 2:1 protein:GAG complex. 
 
 
Figure 4.70 Two-dimensional distribution model c(s, f/fo) analysis of HGF-N + 
heparin DP16 complexes. 
 
Two peaks (one major and one minor) with higher sedimentation coefficients are 
also present in the two-dimensional c(s, f/fo) analysis the HGF-NK-G + 
Fondaparinux complex (Figure 4.71), indicating that a small fraction of HGF-NK-G 
binds two Fondaparinux molecules per protein molecule, although the sample was 
analysed at a 1:1 ratio. Reassuringly, this has also been noticed in MALDI-TOF 
spectra with HGF-NK-G + Fondaparinux (data not shown). The additional 
Fondaparinux molecule could bind to the weaker heparin binding site in the K 
domain [14].  It is therefore possible that the AUC data also shows formation of such 
a complex. The heparin DP16 results for HGF-NK-G are similar to those for HGF-N 
with two or three higher order complexes present, probably indicating binding of 
several protein molecules to one GAG. Approximately 16.4% of the species seems to 
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be present in a 2:1 protein:GAG form. Interestingly, a shoulder can be seen on the 
main peak of HGF-NK-G complexed with heparin DP16. It is possible that this peak 
represents a different binding mode, forming a more globular complex than the other 





Figure 4.71 Two-dimensional distribution model c(s, f/f0) analysis of HGF-NK-G 




The results obtained from the AUC experiments correspond well with the results 
from the gel filtration experiments. Higher-order complexes consisting of two 
proteins on one GAG chain could be seen for both HGF-N and HGF-NK-G in gel 
filtration experiments and AUC experiments. The special case of HGF-NK-G 
binding two Fondaparinux molecules was confirmed in MALDI-TOF experiments, 
but not by gel filtration as an equivalent gel filtration sample was not analysed. 
 
4.8 Isothermal Calorimetry 
Different experimental techniques for the determination of KD values often yield 
different results. NMR experiments carried out in this project and preliminary ITC 
data obtained by Bärbel Blaum, University of Edinburgh, suggest that the HGF-GAG 
interaction is relatively weak with a KD in the low micromolar range. FITC labelled 
heparin and fluorescence spectroscopy showed that the KD of the HGF-N - heparin 
interaction is 1-2 µM [21]. On the other hand, SPR/biosensor analysis of the HGF-
GAG interaction presented in several studies have reported KD values in a low 
nanomolar range.  
 
One of the first SPR studies of the HGF-GAG interaction used crude heparin that 
was biotinylated on the odd free amines of heparin in order to immobilise it on a 
BIAcore carboxymethyldextran - streptavidin surface. The study determined that the 
KD for the full-length HGF – heparin interaction is 4-30 nM and the KD for NK2 – 
heparin interaction is 2.3 nM [11]. A different study biotinylated the protein core of 
endocan, a CS/DS proteoglycan and immobilised it on an aminosilane-streptavidin 
surface determine the HGF - endocan interaction had a KD of 1.8 - 9.2 nM [40]. 
Using different types of HS, Rahmoune et al found three different types of HGF 
binding sites in HS with different kinetics and KDs in the range of 200 pM to 3 nM. 
Rahmoune et al studied the interactions by biotinylating the HS on free amines and 
using a carboxymethyldextran - streptavidin chip [276]. Using Decorin biotinylated 
on the core protein, it was established that full-length HGF binds to DS with 
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affinities in the range of 19.7 nM [12]. The KD of full-length HGF to Ascidia nigra 
DS that is 2O and 6O –sulfated is in the range of 29-37 nM [67].  
 
Delehedde et al biotinylated heparin oligosaccharides on the reducing end and 
established that full-length HGF binds to heparin-derived DP4-DP14 
oligosaccharides with similar KDs in a range of 9 - 16 nM [10]. Interestingly, no 
trend was observed indicating that longer oligosaccharides would bind tighter. 
Interpreting the study by Delehedde et al, heparin DP4 with a reducing end ring 
opened by attachment of a “XX” linker by reductive amination is enough to bind 
full-length HGF: the KD for heparin DP4 was 11 nM, DP6 9.1 nM and DP14 16 nM.  
 
A problem when studying protein-GAG interactions with SPR/biosensors is that 
GAGs are long and heterogeneous, making it hard to produce valid mathematical 
models. The mathematical model is complicated by the fact that there are different 
binding motifs with different KDs and dynamics and likely a number of protein 
molecules will bind to the same GAG chain, depending on its length. The higher the 
injected protein concentration, the more protein molecules will bind to the lower 
affinity GAG motifs, making it hard to saturate the surface, which is important for 
establishing a correct KD. By developing the right model for the right system and by 
using an extensive data analysis, the problem of multiple proteins on one GAG chain 
can be overcome for some well-characterised interactions [277]. 
 
Furthermore, the negatively charged dextran surface used in many biosensor systems 
such as the BIAcore CM5 chip is not suitable to study interactions of an electrostatic 
nature such as protein-GAG interactions (Tim Fagge, GE Healthcare, personal 
communication). Often, alternative surfaces with less dextran are available (such as 
BIAcore CM3 and CM4), or with a plain carboxylated surface (such as BIAcore C1), 





Some protein-GAG complexes have very low KDs in a low nM range, for example 
the ATIII-pentasaccharide complex, bFGF, annexin II and V, whereas other protein-
GAG and protein-carbohydrate interactions are in the µM range [69]. As pointed out 
above, different types of GAGs and immobilisation techniques have been used to 
study protein-GAG interactions by SPR. It has been shown that the protein-heparin 
binding kinetics depends on the heparin immobilisation technique [278]. Also, the 
determined kinetics varies with lab, type of instrument, experiment design and data 
analysis method [279]. The need of immobilisation of the ligand can affect the 
binding mode of the ligand and mass transfer can also affect the results. 
 
ITC, on the other hand, has been described as the golden standard for 
characterisation of the strength of biomolecular interactions [280]. ITC has been used 
to study several protein-GAG interactions, for example the FGF-GAG interaction 
[30]. In a single ITC experiment, the thermodynamics of the binding reaction are 
characterised by determining the stoichiometry of the interaction (n), the association 
constant (KA), the free energy (ΔG), enthalpy (ΔH) and entropy (ΔS). The main 
advantage of ITC over SPR is that it is a solution-based technique with no need for 
immobilisation and that it can obtain all thermodynamic parameters in one single 
experiment. A disadvantage of using ITC to study weak interactions is that a lot of 
material is required. This is because the heat change of the binding must be large 
enough to be measurable by the ITC experiment. The heat change depends on the 
enthalpy and strength of the interaction. 
  
The aim of these experiments was to use ITC as a robust solution state technique to 
study the affinity, thermodynamics and stoichiometry of the HGF-GAG interaction. 
To my knowledge, there are no published studies of this kind in the literature. The 
results are important, as very few solution-based alternative techniques to SPR have 




In order to get ITC c values that are high enough and yield reliable data for 
interactions with a KD ~ 10 µM, approximately 100 µM protein has to be used. This 
corresponds to approximately 2-5 mg of HGF-N and HGF-NK-G. The quality of ITC 
data, especially the stoichiometry of the interaction, is highly dependent upon 
accurate determination of the protein and ligand concentration. In this study, the 
concentrations were carefully determined by UV-absorbance.  
 
To compare the binding characteristics of different lengths of oligosaccharides to 
different protein constructs, HGF-N and HGF-NK-G was titrated with Fondaparinux, 
heparin DP6, DP10 and DP16. Control titrations were performed to establish the heat 
of dilution. Titration of CS and DS oligosaccharides into HGF-N was attempted, but 
sufficient responses were not achieved. Figure 4.72 shows examples of obtained ITC 
data and the results are summarised in Table 4.6. 
 
Figure 4.72 ITC data for HGF-N titrated with Fondaparinux (a) and with heparin 




It should be emphasised that the oligosaccharides used in these experiments were 
only size fractionated and therefore represent mixtures of many species with different 
sulfation patterns. The ITC data can therefore be analysed only in a qualitative 
manner, as different species have different thermodynamic binding properties.  
 
Table 4.6 ITC data for HGF-N and HGF-NK-G binding to different heparin 











16 0.56±0.003 1.76E-06±0.08E-06 -57.20±0.36 -78.24 
10 0.81±0.002 2.30E-06±0.08E-06 -48.70±0.20 -52.72 
6 0.82±0.004 1.41E-06±0.1E-06 -36.55±0.27 -8.58 











16 0.53±0.003 2.79E-06±0.13E-06 -55.48±0.44 -76.57 
10 0.95±0.004 5.43E-06±0.19E-06 -43.68±0.26 -43.51 
6 1.13±0.011 9.26E-06±0.60E-06 -28.62±0.38 1.98 
Fx 1.15±0.006 5.71E-06±0.26E-06 -18.02±0.12 40.88 
 
From the Gibbs free energy equation (ΔG = -RT lnK = ΔH – TΔS), it is clear that a 
negative ΔH (enthalpy) and a positive ΔS (entropy) are indicative of a tighter 
interaction. At the same time, when a decrease in enthalpy is compensated by an 
increase in entropy a similar KD is maintained. The data suggest that this indeed is 
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the case here and that the entropy contribution of the interaction becomes more 
favourable with decreased oligosaccharide length, while the enthalpy contribution 
becomes more favourable with increased oligosaccharide length (Figure 4.73).  
 
 
Figure 4.73 Enthalpy and entropy plotted against oligosaccharide length for HGF-N 
and HGF-NK-G. The error bars are too small to be visible. 
 
A possible explanation of this trend is that the longer oligosaccharides are more 
unstructured than the shorter oligosaccharides and thus loose more entropy when 
they bind to the protein. By other words, formation of more interactions afforded by 
longer oligosaccharides makes the GAG more rigid, leading to losses in entropy as 
illustrated in Figure 4.82. It is possible that the proteins make unspecific interactions 
to longer heparin oligosaccharides, further contributing to an entropy loss. Also, 
longer oligosaccharides can occupy more extended binding sites on the proteins, or 
even bind two protein molecules. These factors increase the number of protein-GAG 





Figure 4.74 Explanation of ITC results. The green lines symbolise unbound 
disordered GAG with DP6 having less entropy than DP16. The purple lines 
symbolises a structured bound GAG that has lost entropy. 
 
Similar results have been obtained for the interaction between extracellular 
superoxide dismutase and heparin [281]. In this study, it was noted that the short 
“oligosaccharides lose fewer degrees of freedom upon binding than the larger 
heparin molecules” and that this could be explained by “a large negative entropy 
contribution associated with more degrees of freedom being lost in heparin upon 
binding than for the smaller and relatively rigid oligosaccharides.”  
 
As a consequence of the enthalpy-entropy exchange observed for longer 
oligosaccharides, the KD does not vary much with oligomer length (Figure 4.83). 
This has also been reported for the HGF-heparin interaction by Delehedde et al [10].  
 
It is also evident that the stoichiometry decreases with increasing oligosaccharide 
length (Figure 4.73). This implies that longer heparin chains are more likely to be 
able to accommodate two protein molecules, suggesting that HGF-N and HGF-NK-G 
bind to GAGs like beads on a string. One GAG molecule binds one protein molecule 
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for short GAGs such as Fondaparinux and DP6, but for longer GAGs such as DP16, 
the ratio approaches two proteins per GAG chain. If the oligosaccharides were 
binding to protein molecules in a trans manner, two and four proteins would have 
been observed interacting with DP6 and DP16 oligosaccharides, respectively. This 
was not the case.  
 
 
Figure 4.75 Stoichiometry and KD data from ITC experiments plotted against 
heparin oligomer length. Most error bars are too small to be visible. 
  
Overall, the ITC data presented here is in a good agreement with results previously 
obtained for the interaction between HGF-N and FITC-labelled LMWH heparin 
(average DP12), which has been shown to have a KD of 1-2 µM and a stoichiometry 
of 1:0.82 [21]. 
 
The interaction of Fondaparinux with HGF-N and HGF-NK-G has a more favourable 
entropy than heparin hexasaccharide, which is just one monosaccharide longer. This 
observation can be explained by two factors: 1) The overall entropy change when a 
protein and a GAG form a complex depends on the loss of translational entropy and 
rigidifying of the GAG and protein. 2) In the opposite direction, the increased 
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translational entropy of the released sodium ions (the polyelectrolyte effect) and 
ordered water molecules covering the binding surface increases the entropy of the 
complex. Differences in any of these two factors could account for the more 
favourable entropy observed for Fondaparinux. It is possible that either the protein or 
Fondaparinux looses less entropy when interacting with the protein constructs than 
heparin hexasaccharide. This could be explained by the structural differences 
between Fondaparinux and heparin hexasaccharide, for example, the former contains 
an unsulfated iduronic acid sugar ring. By performing ITC titrations in buffers with 
different ionic strengths and heats of ionisation it is possible to estimate of the 
contribution of non-ionic interactions, deduce how many sodium ions that are 
released in the binding event and how many protons that are transferred [282]. It 
would be interesting to extend the studies presented here and to perform these 
experiments on Fondaparinux or other GAG mimetics and oligosaccharides. 
 
Fondaparinux also has a less favourable enthalpy than heparin DP6, which indicates 
that Fondaparinux forms fewer intermolecular bonds than heparin DP6. Again, it is 
likely that this is due to the structural differences between Fondaparinux and heparin 
hexasaccharide, in particular their different sulfation pattern.   
 
Deeper insights into GAG-protein interactions via ITC could potentially be obtained 
by using pure heparin species with a defined sulfation pattern. However, the 
formation of higher order complexes and the adaptability of the HGF – GAG 
interaction means that several different binding modes will likely make the atomic 
resolution interpretation of ITC data difficult. 
 
4.9 NMR Monitored Thermal Denaturation 
Thermal denaturation assays are common in drug discovery and ligand screening 
research to identify lead compounds [283].  A thermal denaturation assay is typically 
looking for shifts in melting temperature (Tm) upon ligand binding. Proteins are 
generally stabilised by ligand binding and the melting temperature increases, but the 
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opposite with a decreasing melting temperature can also be true [284]. Thermal 
denaturation monitored by NMR has an important advantage over many other 
thermal denaturation methods used for ligand screening: it is reporter-free. On the 
other hand, NMR requires relatively big amounts of material.  
 
To my knowledge, there are no thermal denaturation studies of the N-terminal 
domain of HGF. To address this shortage, the melting temperatures of HGF-N in the 
presence and absence of heparin were determined by NMR. The results are important 
in that they improve the understanding of HGF-N and how stable the protein is in its 
free and bound state. 
 
A series of 1H 1D spectra and 15N-1H HSQC NMR spectra were collected at 30 °C, 
50 °C, 60 °C, 70 °C, 75 °C, 80 °C, 85 °C and 90 °C in the presence and absence of 
ten times excess heparin decasaccharide (DP10). 
 
The disappearance of amide signals from 15N-1H HSQC spectra and a clear change in 
1D spectra including disappearance of methyl signals (resonating at < 1 ppm) at 60-
70 °C indicated denaturation of free HGF-N as can be seen in Figure 4.76.  
 
The NMR data suggests that HGF-N is stabilised by the presence of tenfold excess 
heparin DP10 and denatures at approximately 75-80 °C (Figure 4.77).  
 
In conclusion, the Tm of HGF-N is approximately 65 °C and the value increases 







Figure 4.76 Partial 1H spectra of HGF-N at the following temperatures: blue 50 °C; 
red 60 °C; green 70 °C.  
 
Figure 4.77 Partial 1H spectra of HGF-N in the presence of ten times excess heparin 
at the following temperatures: blue 70 °C; red 75 °C; green 80 °C. 
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4.10 NMR Titrations of Crude Heparin, GAG mimetics and 
Enzymatically Derived DP4 and DP10 GAGs 
The HGF-N – GAG interaction has previously been studied by NMR [21], [68], 
however, no comprehensive study comparing different GAGs and different lengths 
of oligosaccharides is available. In this section, the binding modes of different types 
of GAGs and GAG mimetics such as Fondaparinux and chemically sulfated maltose 
were compared and studied on a molecular level by NMR. The results show how 
different GAGs bind to HGF in different modes and are important in increasing the 
basic understanding of the HGF-GAG interaction. 
 
By titrating different GAGs into 15N-labelled HGF-N and monitoring 1H-15N HSQC 
spectra, the GAG binding site was mapped onto the protein structure and KDs of 
complexes were estimated. An example of overlaid 1H-15N HSQC spectra of a 
protein – GAG titration is shown in Figure 4.78.  The movement of NH crosspeaks 
was quantified by combined chemical shift differences calculated using equation 
2.12 as described in section 3.11, the data was then visualised in histograms as a 
function of residue number (Figure 4.81). The histograms were produced by 
comparing the titration starting point and the saturation point, which is defined as the 
excess of GAG where the NH crosspeaks are not moving if more GAG is added to 





Figure 4.78 Overlaid 1H-15N HSQC spectra HGF-N-Δ-6 in the presence of fully 
sulfated heparin-derived tetrasaccharide (DP4C). The protein:ligand ratio was varied 
between 1:0.1 to 1:6.  
 
Some NH cross peaks are not visible in 1H-15N HSQC spectra of HGF-N due to 
protein dynamics on an unfavourable timescale. The crosspeaks that cannot be seen 
in uncomplexed 1H-15N HSQC spectra are: Gly31-Asn37, Asn77, Lys78 (weak), 
Gly79, Ser106 (very weak), Tyr107 (very weak). 
 
The majority of the visible HGF-N 1H-15N HSQC crosspeaks were found to exhibit 
fast-exchange attributes when titrated with ligand: the crosspeaks were moving 
stepwise as ligand was titrated. Some crosspeaks showed signs of intermediate 
exchange: they initially weakened but sharpened as more of the ligand was titrated 
in. A peak in intermediate exchange might have distorted shape and will appear 






Figure 4.79 Peak shapes of slow, intermediate and fast exchange NMR peaks of a 
protein – ligand complex.  
 
The higher affinity interaction, the more time the ligand will be part of the complex 
and the off-rate (koff) will be slower. High affinity interactions are therefore more 
likely to give rise to slow exchange spectra when a ligand is titrated. As a rule of 
thumb, interactions with a KD of less than 10 µM fall into a slow or intermediate 
exchange. However there are many exceptions to this general rule: slow exchange 
has been shown for the interaction between Hsp70 and a peptide with a KD of 500 
µM (because of slow kon) and fast exchange was encountered for the binding of a 
phosphate compound to haemoglobin with a KD of approximately 1 nM (because of a 
multisite binding mechanism) [285].  
Complex Free •  Slow exchange: high affinity ligand, slow koff. 
The on/off rate of the ligand is so slow on an NMR time-scale 
that two distinct peaks are observed in the spectrum. 
 
•  Fast exchange: weak affinity ligand, fast koff. 
Peak shape is getting narrower as the free state and 
complexed states interchange so quickly that they are not 
observable on an NMR-timescale. 
•  Intermediate exchange: medium affinity ligand, medium koff. 
Peak shape is getting broader as both the free and complex peak 
contribute to the peak shape. The protein spends significant time 
in both complexed state and free state on an NMR time-scale. 
 
Averaged peak from free 
and complexed state 
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Several protein-GAG interactions with KDs in the µM range have been characterised 
by NMR and shown to exhibit fast exchange attributes when the protein is titrated 
with ligand. The 13-14F3 fragment of fibronectin and its interaction with heparin has 
been shown to have a KD of 2.9 µM and exhibit fast exchange NMR attributes [286]. 
The N and C -terminal domains of Pleiotrophin bind heparin DP14 with KD values of 
53 µM and 20 µM, respectively, and show fast exchange properties [287]. The SOS - 
FGF-1 interaction has been shown to have a KD of 59 µM and the interaction 
between the ligand binding D2 domain of FGFR binds SOS with a KD of 27 µM and 
both interactions show fast exchange attributes [288]. 
 
The interactions between HGF-N, heparin and SOS have previously been shown to 
exhibit typical fast exchange properties [21]. The interaction between HGF-N and 
FITC-labelled LMWH heparin (average DP12) has been shown to have a KD of 1-2 
µM and a stoichiometry of 1:0.82 [21]. These findings are in excellent agreement 
with the results from the NMR and ITC experiments in this thesis. 
 
The peaks that exhibited signs of an intermediate exchange when titrated with 
heparin oligosaccharides and Fondaparinux were typically the peaks that displayed 
large CCSDs, in particular Arg73 and Arg76. This is easily explained, as the 
classification of signals into different exchange regimes depends on the relationship 
between koff and the NH chemical shift difference of the free and bound protein. 
Peaks with larger chemical shift separation therefore are more likely to be in an 
intermediate exchange regime. Because of this, the KD of the Fondaparinux - HGF-N 
interaction is not reported in section 4.10.4.  
 
4.10.1 Crude Heparin 
It has been reported that HGF-N precipitates upon addition of crude heparin [17]. 
However, as results often differ between heparin batches, conditions and 
laboratories, it was attempted to titrate crude bovine lung heparin into 15N-labelled 
HGF-N, monitoring 15N-1H HSQC spectra. When heparin was added to the sample, it 
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instantaneously went cloudy, but as the protein did not precipitate and sink to the 
bottom, it is believed that large complexes are formed that stay in solution but are too 
big to be observed by NMR (Figure 4.80). Some crosspeaks come back when a very 
large excess of heparin is added, these crosspeaks mostly belong to side chains and 
termini. 
 
When a large excess of crude heparin is added to an NMR sample, the salt 
concentration soon becomes problematic. For example, if heparin is added to 
fiftyfold excess, every heparin chain contains fifty Na+ atoms and the protein 
concentration is 100 µM, the increased Na+ concentration is 250 mM, which severely 
decreases the sensitivity of the experiment, especially when using instruments 
equipped with a cryoprobe. To compensate for this effect, the number of scans was 





Figure 4.80 Titration of crude heparin into 15N-labelled HGF-N monitored by 15N-







4.10.1 Fully Sulfated Heparin DP4 and Fondaparinux 
Two protein constructs were used for Fondaparinux and heparin NMR titration 
experiments: HGF-N and HGF-N-Δ6. The later construct does not contain the first 
six N-terminal residues (GQRKRR). At physiological pH, the arginines and lysine in 
this sequence are positively charged and could therefore be involved in GAG 
binding. This suggestion is supported by the fact that HGF-N-Δ6 was found to bind 
weaker to a heparin column than the HGF-N (section 4.5.2) and by previous studies 
[63]. Fortuitous cleavage of HGF-N by a protease during secretion of P. pastoris 
(section 4.2.1) allowed the contribution of these N-terminal residues to heparin 
binding to be studied by NMR. These N-terminal residues are flexible and neither X-
ray nor NMR can determine their positions, consequently their role in GAG binding 
must be studied indirectly.  
 
It is worth pointing out that a high density of positive charge does not automatically 
translate into heparin affinity. For example, module 13 of factor H has the highest pI 
value among the twenty modules of factor H, yet it does not bind heparin [289]. 
HGF-N is a 127-residue protein that contains 16 lysines and 7 arginines; out of these 
four lysine and two arginine backbone NH resonances show significant combined 
chemical shift differences (CCSDs) during GAG titrations (Figure 4.81).  The non-
moving basic residues are lysines 43, 44, 47, 52 of the β1 strand and lysines 109, 110 

































Figure 4.81 Histogram comparing different oligosaccharides titrated into HGF-N 
monitored by 1H-15N HSQC spectra. Combined chemical shift perturbation is 
displayed on the y-axis and residue number on the x-axis. Δ6: HGF-N-Δ6 was used 




Figure 4.82 A protomer from the 1GMO PDB file was rendered in UCSF Chimera 
with transparent columbic surface colouring, showing residues 43, 44, 47, 52, 109, 
110, and 122 on the ribbon structure in purple. 
 
Titrating fully sulfated heparin tetrasaccharide (DP4C) into HGF-N caused large 
combined chemical shift differences for residues 70-84, which are part of the α2-
helix and the L2 loop. The second most affected region of the protein is comprised of 
residues 38-42, where T38 is the first residue that is visible in 1H-15N HSQC spectra 
of HGF-N. None of the NH resonances of the first six residues are observable by 
NMR due to the movement of these residues on an unfavourable timescale [21], [17]. 
Residues 38-42 (TIHEF) are not positively charged, and although they can play a 
supportive role in the GAG binding through hydrogen bonding, it is likely that the 
basic four N-terminal amino acids (RKRR) are more important. Secondary effects 
from the more N-terminal residues therefore likely cause the CCSDs of residues 38-
42. The first indirect evidence for this hypothesis comes from the appearance of new 
NH crosspeaks in 1H-15N HSQC spectra of HGF-N during the course of titration 
(Figure 4.83). These new signals which move during the titration likely belong to the 
‘invisible’ N-terminal residues, which become rigidified upon GAG binding [21]. As 
expected, most of these new crosspeaks cannot be seen when titrating heparin DP10 





Figure 4.83 The appearance of new peaks as Fondaparinux is titrated into HGF-N. 
The purple spectrum is the starting point, blue: 0.5X excess Fondaparinux over the 
protein, brown: 2X excess, pink: 6X excess, orange: 20X excess. 
 
The appearance of new NH crosspeaks is more evident when titrating Fondaparinux 
compared to when titrating heparin DP4C. This is likely due to the extra saccharide 
unit and 3-O-sulfate of Fondaparinux. 
 
The second line of evidence for the involvement of the N-terminus in GAG binding 
comes from comparing the CCSDs caused by titrating DP4C into HGF-N and HGF-
N-Δ6 (Figure 4.81): 
a) For HGF-N, residues 38-42 are affected, but for HGF-N-Δ6, these residues 
are not affected. This implies that by loosing the positively charged N-
terminus, the binding to this part of the protein is abolished. 
b) For the more native HGF-N protein construct, residues 70-73 of the α2-helix 
are affected more than the rest of the helix and the following loop. For HGF-
N-Δ6, residues 74-80 (L2) are affected more than 70-73 (α2). This implies 




c) Only HGF-N-Δ6 shows large CCSDs for the β2 strand residues 59-64+66 and 
β4 strand residues 95-96. This again implies that the binding mode of DP4C 
is different for HGF-N-Δ6 compared to HGF-N. The differences are 
summarised in Figure 4.84. 
 
 
Figure 4.84 The 2HGF PDB file was rendered in UCSF Chimera and overlaid with a 
heparin oligosaccharide from the 1GMO PDB file. Green: residues 31-37. Blue: 38-
42. Purple: 70-73. Red: 74-84. Orange: 59-64, 66, 95 and 96. 
 
The results imply that when titrating shorter heparin oligosaccharides into HGF-N, 
the oligosaccharides bind preferably to residues 70-84 of the α2-helix and residues 
38-42 of the N-terminal region that is disrupted in HGF-NK-G and HGF-N-Δ6. This 
native HGF-N binding mode is different from the binding mode of HGF-N-Δ6 and 
HGF-NK-G in the heparin co-crystal structure where residues 59-64, 66, 95 and 96 
of the β2/4-strands are more important because the oligosaccharide has moved away 
from the disrupted N-terminus. Therefore, it would be interesting to dock the heparin 
to HGF-N with HADDOCK (http://www.nmr.chem.uu.nl/haddock/), AutoDock 
(http://autodock.scripps.edu/) or similar docking software to further clarify the 
differences. 
Affected more in: 
HGF-N   HGF-N-Δ6 
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To summarise, the HGF-N heparin binding site consists of three binding regions: the 
main α2-helix binding region (residues 70-84), the N-terminal region (residues 32-
42) and the β2/4-strands region (residues 59-64, 66, 95 and 96). For HGF-N, the 
main α2-helix binding region and the N-terminal region are the most important 
binding regions. For HGF-N-Δ6, the main α2-helix binding region and the β2/4-
strands region are the most important binding regions. Only one tetrasaccharide is 
bound at a given time to the protein. The results are illustrated in Figure 4.85.  
 
a)      b) 
 
Figure 4.85 a) The N domain of a protomer from the 1GMO PDB files was rendered 
in UCSF Chimera with only four sugar units displayed and residues 38-42 (N-
terminal binding region) coloured in red, residues 70-73 coloured in purple, residues 
74-84 coloured in green (α2-helix main binding region) and residues 59-64, 66, 95 
and 96 (β2/4 binding region) coloured in blue. a) This binding mode is seen for 
HGF-NK-G and HGF-N-Δ6. b) The protein has been manually rotated in relation to 
the heparin oligosaccharide to put the N-terminus closer to the GAG, visualising the 




To further confirm that only one DP4C molecule binds to native HGF-N, the 
stoichiometry of DP4C binding to HGF-N was studied by MALDI-TOF. DP4C was 
titrated from 0.1 to 20–fold molar excess. The MALDI-TOF spectra are 
characteristic of a 1:1 protein:ligand interaction as only one higher MW species can 




Figure 4.86 MALDI-TOF titration of DP4C into HGF-N. a) 0.5:1 DP4C:HGF-N 
ratio. b) 20:1 DP4C:HGF-N ratio. 
 
The pentasaccharide Fondaparinux was titrated into HGF-N. Compared to DP4C, it 
is one monosaccharide unit longer, it does not contain a modified uronic ring with a 
double bond from enzymatic cleavage, it has one 3-O-sulfate and it is a Me-
M+ 
M+ + DP4C 
M+ 









glycoside (Figure 1.22). The CCSDs upon titration of HGF-N with Fondaparinux are 
very similar to those observed for HGF-N titrated with DP4C (Figure 4.81). The only 
major difference is that Fondaparinux causes larger changes for the N-terminal and 
main α2-helix binding regions. This could be due to the increased length, extra 
sulfate and that it is a Me-glycoside. 
 
When plotting the residues with a combined chemical shift perturbation >0.12 and 
>0.17 ppm for Fondaparinux, i.e. the residues that are most affected by binding on 
the structure of HGF-N, a single well defined binding site that matches well with 




Figure 4.87 The 2HGF PDB file was rendered in UCSF with a heparin 
oligosaccharide from the 1GMO PDB file overlaid. Residues 31-37 are coloured in 
blue, residues with a CCSD > 0.17 ppm are coloured in red, residues with a 0.12< 
CCSD < 0.17 ppm are coloured in green. 
 
4.10.2 Chemically Sulfated Maltose Oligosaccharides  
Chemically O-sulfated maltose is a glucose-based disaccharide with a D-
Glucopyranosyl-D-glucose structure that is similar to sucrose octasulfate, a widely 
used GAG mimetic (Figure 4.88). Chemically O-sulfated maltohexaose is a GAG 
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mimetic similar to Muparfostat (section 1.2.6). In an attempt to determine the degree 
of chemical O-sulfation of the species used in these experiments, MALDI-TOF 
spectra of chemically sulfated maltohexaose were collected. The spectra showed 
extensive loss of NaSO3, as often seen for similar species [290], which made it 
difficult to clarify if the sample was homogeneously sulfated or not. The spectra 
showed a range of peaks, corresponding to loss of all sulfates except one or two, up 
to fully sulfated maltohexaose (data not shown). It is therefore unknown what the 
sulfation degree was as it cannot be said if the sulfates were lost during MALDI-





Figure 4.88 a) Structure of chemically sulfated maltohexaose. b) Structure of 
chemically sulfated maltose. 
 
Initially, titration of maltohexaose into HGF-N at 0.1 to 0.4 molar excess caused 
CCSDs similar to other GAGs, but as the maltohexaose was added, the protein 
precipitated. In the 1H spectra, protein peaks decrease in intensity and the sugar 
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peaks increase in intensity (Figure 4.89), indicative of that the protein precipitates 
and that the oligosaccharide remains in solution and no longer binds to the protein. It 
is likely that a combination of the length and very high degree of sulfation of the 
carbohydrate are the main reasons for causing protein precipitation. 
 
 
Figure 4.89 1H NMR spectra of chemically sulfated maltohexaose titrated into HGF-
N at the following maltohexaose : protein ratios; purple: 0.4:1, green: 0.8:1, red: 
1.6:1, blue: 5:1. 
 
Chemically sulfated maltose did not precipitate the protein and was used instead. 
This compound is similar to sucrose octasulfate (SOS), a GAG mimetic that is often 
used in experiments when crude or digested heparin is not suitable. There are 
examples in the literature where heparin and SOS have been binding to the same 
binding site and in similar modes to a protein despite the different structures [21], 
[291].  
 
The sulfated maltose bound to the main α2-helix and N-terminal regions, but 
induced small CCSDs for the β2/4 region, producing a CCSD profile similar to that 
for Fondaparinux and DP4C (Figure 4.81).  
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4.10.3 Heparin, CSC, CSA and DS Decasaccharides 
After titrating relatively short oligosaccharides, longer GAGs were titrated to better 
mimic the native in vivo GAG polysaccharides. When comparing these results with 
those obtained for shorter oligosaccharides, it is clear that the overall trends are 
similar, but some interesting differences are apparent.  
 
Interestingly, for the Fondaparinux, sulfated maltose and DP4C titrations, differences 
between HGF-N and HGF-N-Δ6 can be seen in the N-terminal binding region, the 
main α2-helix binding region and the β2/4-strands binding region (Figure 4.81). 
However, when titrating heparin decasaccharide, differences between the two 
proteins can only be seen in the N-terminal region where the CCSDs for HGF-N-Δ6 
were much smaller (Figure 4.90). This is however expected, as a decasaccharide is 
long enough to span the N-terminal, α2-helix and β2/4-strands binding regions, 
differences should only be seen in the N-terminal binding region that is lacking in the 
HGF-N-Δ6 protein.  
 
For a long GAG to be able to bind across the whole binding surface, utilising all 
binding regions, it has to be able to adopt an optimal conformation to maximise 
intermolecular bonds. This explains HGF’s preference for flexible IdoA sugar units 
[67] and the interaction could possibly be aided by a kink in the GAG, just like for 
FGF [194]. HGF-N is also itself likely to undergo conformational change and 
possibly, the flexible N-terminus rearranges, reaches towards the GAG and rigidifies 
as discussed above and evidenced by the appearance of new crosspeaks in 1H-15N 
HSQC spectra of HGF-N titrated with Fondaparinux (Figure 4.83). Similarly, five 
new 1H-15N HSQC crosspeaks can be seen when titrating heparin decasaccharide into 
HGF-N. On the other hand, only one new crosspeak can be seen for HGF-N-Δ6 


























Figure 4.90 Histogram comparing different decasaccharides titrated into HGF-N 
monitored by 1H-15N HSQC spectra. Combined chemical shift perturbation is 
displayed on the y-axis and residue number on the x-axis. 
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Interestingly, it seems like heparin binds in a different mode compared to CSC, CSA 
and DS. Despite the decasaccharides being relatively long and able to span the whole 
binding site, the CS and DS oligosaccharides only induce very small CCSDs in the 
N-terminal and β2/4-strands region, but relatively large CCSDs in the main α2-helix 
region. Heparin induces shift changes in all three regions and also induces larger 
CCSDs than the other GAGs (Figure 4.90). CSA, CSC and DS have lower sulfate 
densities than heparin: CS/DS typically have one sulfate per disaccharide whereas 
heparin typically has three sulfates per disaccharide. This probably explains the 
smaller shift differences for CS and DS and different binding modes of the different 
GAGs. CSA, CSC and DS exhibit similar CCSD profiles and thus bind in similar 
modes despite the different types of sugar unit backbones and sulfation patterns. 
Overall, the relative order of the CCSDs is heparin > DS > CSC > CSA, however, 
the differences in CCSDs do not translate into differences in KD as discussed in 
section 4.10.4. The inability of CSA, CSC and DS to utilise the whole binding site 
and their lower CCSDs explain their lower affinity for HGF-N compared to heparin. 
The results from all protein – oligosaccharide titrations are summarised in Figure 
4.91. 
 
In a previous study, Deakin et al conducted NMR titrations of heparin 
tetrasaccharide and DS hexasaccharide into 15N labelled HGF-NK-G [68]. Although 
clear differences between the two oligosaccharides were seen in this study, the 
overall binding site and binding mode was thought to be the same and it was 
hypothesised that the differences were possibly due to differences in lengths and 
structures. Even if two different GAGs induce somewhat different CCSD profiles, it 








 N-terminal Main α2-helix β2/4-strands 
Hep DP4C + + - 
Hep DP4C HGF-N-Δ6 - + + 
Fondaparinux + + - 
Sulfated Maltose + + - 
Hep DP10 HGF-N-Δ6 - + + 
Hep DP10 + + + 
CSA DP10 - + - 
CSC DP10 - + - 
DS DP10 - + - 
 
 
Figure 4.91 The rendered picture of HGF-N shows the three most important GAG 
binding regions within the protein binding site. The table summarises the results 





(59-64, 66, 95, 96) 
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4.10.4 KD Determination 
NMR titration data can be used to quantify the strength of the studied interaction. 
There are several NMR approaches for determining dissociation constants for 
protein-ligand interactions. A common approach that was employed in this project in 
conjunction with binding site mapping is to analyse a series of 1H-15N HSQC spectra 
as a ligand is titrated into the protein [292-297].  
 
For the KD determination to be straightforward and reliable it is important that the 
interaction falls into a fast exchange regime and the chemical shifts and relaxation 
rates are completely averaged between the bound and free states. If this is true, the 
gradual chemical shift change corresponds to the fraction of bound ligand and it is 
possible to use the CCSDs of NH crosspeaks as they move from the free to the bound 
state to determine the KD. As a general rule, only the residues that exhibit the largest 
chemical shift changes and are in the fast exchange regime should be used. These 
usually coincide with the main residues of the binding site. In the case of protein-
GAG interactions, many residues can be involved as GAGs usually bind over a large 
surface rather than in a small pocket. The precision of the method is limited and 
typically a spread of KD values will be obtained for different residues. 
 
Furthermore, monitoring the backbone NH chemical shift change might not be a 
good reporter for binding as it is often the side chains of the amino acids that are 
involved in binding. NMR and MS techniques to overcome this problem have 
recently been developed [298]. 
 
To obtain the KD values, either a global fit in a scientific plotting program such as 
GraphPad Prism (http://www.graphpad.com/prism/) or Erithacus Grafit 
(http://www.erithacus.com/grafit/) can be employed. An alternative approach that 
was employed in this study is to take the average of KD determined for all the main 
binding residues. Recently, a program called Auto-Face has been developed that can 
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automatically produce a CCSD histogram and calculate the KDs for many different 
types of interactions [293]. 
 
A 1:1 interaction was assumed for all interactions in these experiments and the KD 
values were determined as described in section 3.11. A typical titration curve is 
shown in Figure 4.92. 
 
 
Figure 4.92 Typical 1H-15N HSQC titration fitting curve from the CcpNmr Analysis 
software. Red: fitted curve, blue: experimental curve. 
 
Table 4.7 summarises the determined KDs for the interactions between different 
GAGs, sulfated maltose, HGF-N and HGF-N-Δ6. The KDs vary between 11.6 and 
84.6 µM. 
 
It was expected that the HGF-N-Δ6 protein would display lower affinity for heparin 
DP4C than native HGF-N as suggested by heparin affinity chromatography. 
However, practically identical values were obtained. It is noticeable that the error for 
the titration using HGF-N-Δ6 protein is lower and a general observation is that the 
1H-15N HSQC crosspeaks move in a more symmetrical and coherent way for this 
protein. Possibly, this can be explained by the different binding modes of the two 
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proteins and that it is difficult to directly compare the KDs between the two proteins 
and binding modes. 
 
Table 4.7 KDs determined by NMR for the interaction between HGF-N and different 
GAGs. Titration curves for each protein residue were fitted in CcpNmr Analysis after 
titrating the GAGs into 15N-labelled HGF-N, monitoring 1H-15N HSQC crosspeaks. 
The titration curve data was then converted into a KD in Open Office Calc and the 
average KD was calculated for the residues displaying the largest CCSDs and fitting 
well to the equation in CcpNmr Analysis. The “number of residues” column 








Sulfated maltose 84.6 22 20 
Heparin DP4C 11.8 11 19 
Heparin DP4C HGF-N-Δ6 11.6 2 20 
CSA DP10 41.4 15 23 
CSC DP10 38.9 11 22 
DS DP10 36.5 11 22 
 
The data corresponds well to the values determined by ITC in section 4.8 and by 
fluorescence [21]. However, the values are several orders of magnitude different to 
those determined by SPR [10-13]. This is possibly due that SPR utilises immobilised 
ligands and suffers from inherent difficulties of characterising protein – GAG 
interactions due to the multivalency of GAG chains. The KDs of CSA, CSC and DS 
DP10 are very similar. This is in agreement with the affinity chromatography carried 
out in section 4.5.1, where it was found that HGF-N elutes approximately at the same 
time from CSA, CSC and DS affinity columns. It should be however emphasised that 
the decasaccharides used in the experiments were only size fractionated and are 
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therefore a potentially are mixtures of species with different level and position of 
sulfates. The obtained KD values must therefore be treated conservatively. 
  
The KDs for heparin DP10 and Fondaparinux could not be determined because 
several crosspeaks do not move on a symmetrical straight line. This is possibly due 
to a secondary process, such as the protein dimerising. As the binding and 
dimerisation is a two-phase process, it is difficult to come up with a valid model that 
the titration can be fitted to. Using a model for bivalent ligands [299] to fit titration 
data in the GraphPad software was unsuccessful.  
 
In general, NMR is not the method of choice for KD determination as only relatively 
weak interactions can be studied and that it is a relatively labour and cost intensive 
method [300]. On the other hand, coupled to mapping the binding interface and 
studying the dynamics of the interaction, it is a powerful technique that yields a lot of 
data in one major experiment. Compared to other techniques, NMR has the 
advantage of being a solution based technique and it typically requires less material 
than ITC, making it a competitive method for the right kind of interaction. 
 
4.10.5 Possible Dimerisation With Heparin DP10 
When 1H-15N HSQC spectra of heparin DP10 titrated into 15N labelled HGF-N were 
studied, it soon became apparent that several crosspeaks do not move on a straight 
line between titration points, some move in an U-shape, some in a L-shape and some 
move on a straight line and then turn around and move back in the opposite direction. 
This behaviour can also be seen for Fondaparinux, but to a much smaller extent. The 
fact that the crosspeaks do not move on a straight line implies that the chemical 
environment of the backbone amides does not change in the same manner throughout 
the titration. This implies that two or more different processes are taking place during 
the titration. This behaviour cannot be seen for heparin DP4C or any other titrated 




Generally, the crosspeaks for heparin DP10 move on a relatively straight line up to 
approximately 0.5:1 GAG:protein ratio and change direction above this ratio. This 
behaviour could be due to that the protein is dimerising in the beginning of the 
titration when there is excess protein over GAG. After this point, the probability of 
dimerisation decreases and monomeric species become more prevalent. Residue 
number 72 is a good example of a turning residue. Its crosspeak also becomes 
stronger during the titration, suggesting that the protein dynamics change upon GAG 
binding (Figure 4.93).  
 
 
Figure 4.93 Overlaid 1H-15N HSQC spectra showing how the 72N crosspeak does 
not move on a straight line during the course of a heparin DP10 titration and how the 
crosspeak becomes stronger. 
 
The less frequent occurrence of turning peaks for HGF-N-Δ6 suggests that the N-
terminal residues play a role in the potential dimerisation process. Figure 4.94 shows 
an expansion of a 1H-15N HSQC spectrum showing the different behaviours of 








a)      b) 
     
Figure 4.94 1H-15N HSQC spectra illustrating how residues 40, 41, 63 and 72 move 
on a curved line for native HGF-N (a), but not for HGF-N-Δ6 (b) as the proteins are 
titrated with heparin DP10. GAG:protein ratios: a) purple: Starting point, blue: 0.3:1, 
light blue: 1:1, green: 10:1. b) purple: Starting point, blue: 0.2:1, light blue: 0.8:1, 
green: 6.4:1.  
 
The crosspeaks that do not move on straight lines belong to residues 37-42 and 68-76 
(70 and 74 moving straight for heparin DP10, but not for Fondaparinux). These 
crosspeaks correspond relatively well to the main α2-helix and N-terminal binding 
regions (Figure 4.95). It is notable that the L2 loop residues (77-84), neighbouring 
the turning peaks of the main α2-helix binding region, are moving on a straight line, 
























Figure 4.95 Histogram showing Fondaparinux and heparin decasaccharide titrated 
into HGF-N monitored by 1H-15N HSQC spectra. The crosspeaks that do not move 
on a straight line are indicated with a green line. Combined chemical shift 
perturbation is displayed on the y-axis and residue number on the x-axis. 
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The turning crosspeaks belong to residues that form a consistent surface-exposed 
patch, spanning the main α2-helix and N-terminal binding regions (Figure 4.96). 
This implies that this patch is most affected by the potential dimerisation and could 
be in the dimerisation interface. 
 
a)      b) 
 
Figure 4.96 Comparison of the binding site regions and the turning peaks for heparin 
DP10 mapped onto the 2HGF PDB file using UCSF Chimera. a) The same as Figure 
4.91; the N-terminal binding region (32-42) is coloured red, the main α2-helix 
binding region (70-84) is coloured green and the β2/4-strands binding region (59-64, 
66, 95, and 96) is in coloured in blue. b) The N-terminal residues that cannot be seen 
by NMR (32-37) are coloured red and the crosspeaks that change direction during the 
titration (residues 38-42 and 68-76) are coloured purple. 
 
It is likely that heparin DP10 is able to host two HGF-N molecules and makes the 
protein dimerise in a cis or trans mode, binding along the GAG chain (Figure 4.97). 
Judging from what residues that are affected by binding and the possible 
dimerisation, it is likely that there is an overlap between the protein-protein interface 





Figure 4.97 Explanation of turning 1H-15N HSQC crosspeaks during NMR titrations 
of heparin DP10. 
 
The only evidence for that oligomerisation takes place at the beginning of titrations 
of HGF-N with Fondaparinux comes from NMR experiments. No clear evidence for 
dimerisation with Fondaparinux as ligand was seen by AUC or ITC. This could be 
due to the fact that NMR is the only technique able to monitor binding on an amino 
acid level. Although the same crosspeaks did not move on a straight line for both 
Fondaparinux and heparin DP10 (with the exception of residues 70 and 74), this 
behaviour was less obvious for Fondaparinux than for heparin DP10 suggesting that 
if a dimer is formed, it is less abundant in the case of Fondaparinux. 
 
It is possible that the turning crosspeaks are not due to dimerisation, but a different 
process. This could for example be the existence of two or more binding modes with 
different affinities and the observed changes could be due to the existence of more 
complex equilibria than would correspond to a simple binary process. Although the 
results are difficult to interpret, they are reported on and discussed. Further studies 




4.11 Titration of TEMPO Conjugated Heparin Hexasaccharide into 
15N Labelled HGF-N Monitored by NMR 
GAGs display reducing end/nonreducing end directionality, just like other biological 
polymers such as DNA and proteins display 5’/3’ and N-terminus/C-terminus 
directionality, respectively. The interacting points (for example sulfate groups and 
arginines) of a protein-GAG interaction will have different positions depending on in 
what direction the GAG is presented to the protein. It is therefore likely that many 
protein-GAG interactions display directional specificity. This directional specificity 
is difficult to study with many biophysical methods, including normal NMR 
techniques such as 1H-15N HSQC monitored titrations. One way of addressing this 
question is by attaching a spin-label to the reducing end of the GAG. In these 
experiments, a heparin oligosaccharide was spin-labelled and titrated into HGF-N to 
study the directionality of the binding event. The aim of the experiments was to 
produce a spin-labelled heparin oligosaccharide purified to homogeneity and titrate it 
into 15N-labelled HGF-N, monitoring NMR relaxation times to study the 
directionality of the complex. The results are important in that they are the first of its 
kind for HGF, confirming the directionality of the HGF-NK-G – heparin co-crystal 
structure. 
  
A TEMPO spin label was attached to the reducing end of a fully sulfated heparin-
derived hexasaccharide by reductive amination. The spin labelled hexasaccharide 
was titrated into 15N labelled HGF-N and chemical shift perturbation and NH proton 
spin-lattice relaxation rates (R1 = 1/T1) values were monitored. A reduction in the 
relaxation times of NH protons indicates spatial proximity of the free electron radical 
of specific residues. This information was used to determine the orientation in which 
the oligosaccharide binds to HGF-N. After the residues with enhanced relaxation 
were mapped onto the structure of HGF-N it became clear that the heparin-derived 




Similar approaches have been employed to label saccharides with TEMPO and study 
their interaction with proteins. TEMPO-labelled N-acetyllactosamine was used to 
study its binding to galectin-3 and it was found that the carbohydrate binds in a 
specific direction and manner [301]. Another study probed the interaction between β-
1,4-glucanase CenC and oligosaccharides and found that the oligosaccharide can 
bind in both directions due to structural symmetry of the oligosaccharide [302].  
 
Although GAGs and carbohydrates have a direction, just like DNA, it is difficult to 
know whether the GAG binds in a specific direction to a protein. For example, 
molecular docking of protein - heparin interactions using AutoDock “cannot 
distinguish between 180° pairs of heparin orientations” [303]. This is likely due to 
the crude nature of the AutoDock method and the relative structural symmetry of the 
sulfate pattern along fully sulfated heparin regardless the direction.  
 
4.11.1 Reductive Amination 
There are many ways to conjugate different functionalities and reporter groups to 
carbohydrates [268], [304]. Reductive amination is one way of attaching an amine or 
hydrazide-containing molecule to the reducing end of a carbohydrate. It has the 
advantage of being relatively straightforward and the disadvantages of opening the 
reducing end monosaccharide and producing a relatively flexible linker. 
 
In reductive amination, a free amine reacts with a carbonyl group to form an imine 
[268] (Figure 4.98). The imine can then be reduced with a suitable reducing agent 
such as sodium cyanoborohydride to form an amine. In the case of glycans, the 
reducing end contains a masked carbonyl in the form of a ketal or acetal group, 
depending on if the sugar is a ketose or aldose. The carbonyl only exists in the open 





Figure 4.98 Reductive amination of a glycan. The amine attacks the carbonyl and an 
imine intermediate is reduced with sodium cyanoborohydride to form a conjugate. 
Taken from [268]. 
 
Hydrazides are more reactive and can be employed in the same reaction instead of an 
amine to speed it up (Figure 4.99). If the product is not reduced, an unstable 
hydrazide compound is formed that can hydrolyse in the presence of water [305]. 
 
Reductive amination has been widely employed to conjugate glycans to affinity 
labels [251], chromophores [168], etc. 
 
 




A different reaction that also can be used for similar purposes is the Kochetkov 
amination [304], which replaces the C1 hydroxyl with an amine group that then can 
be used for conjugation. The reaction has the advantage of not opening the reducing 
end ring, preserving the ring conformation and rigidity, but the disadvantage of being 
very inefficient and taking several days to complete. Kochetkov amination has been 
employed to conjugate TEMPO to N-acetyllactosamine to characterise its interaction 
with galectin-3 by NMR [301]. 
 
4.11.2 Production, Purification and Analysis of the TEMPO 
Conjugate 
To produce large quantities of heparin-derived fully sulfated hexasaccharide, an 
automated semi-preparative SAX chromatography method was set up on the 
BioCAD FPLC system. The SAX purified fully sulfated heparin DP6 was desalted, 
freeze-dried and conjugated to TEMPO as described in section 3.12. 
 
After the conjugation reaction, the reaction mixture was desalted and purified by 
SAX chromatography, see Figure 4.100. 
 
 
Figure 4.100 SAX chromatogram after the reductive amination of fully sulfated 
heparin-derived hexasaccharide by 4-Amino TEMPO. The labelled peaks contain the 






Fractions from SAX chromatography were desalted and analysed by MALDI-TOF 
mass spectrometry (Figure 4.101 and Figure 4.102). Chromatography peaks eluting 
between 30-50 minutes did not contain any GAGs. The peak eluting at 55 minutes 
contained fully sulfated heparin DP6 with a conjugated TEMPO. The peak eluting at 
60 minutes contained a mixture of unconjugated and conjugated DP6. The peak 
eluting at 63 minutes contained unconjugated DP6. Peaks eluting after 63 minutes 
did not contain any GAGs. The mass shift between the two species in Figure 4.102 is 
155.7 Da. The mass of 4-Amino TEMPO is 171.3 Da, a water molecule is lost in 
imine formation and two hydrogens are donated by the reducing agent, which means 
that the final mass error is 0.4 Da, which is acceptable as no internal standards were 
used and the spectrum was not deisotoped. The peak eluting at 55 minutes was 
desalted, freeze-dried and used for the protein titration. 
 
 
Figure 4.101 MALDI-TOF spectrum of the pure TEMPO-DP6 species eluting from 





Figure 4.102 MALDI-TOF spectrum of the SAX peak eluting at 60 minutes (peak 
B) containing both conjugated and unconjugated DP6 with typical sodium adducts. 
 
To further assess purity and structural integrity of the conjugate, its 1H NMR 
spectrum was collected and compared with the starting material (Figure 4.103). 
 
 
Figure 4.103 Overlaid 1H NMR spectra showing fully sulfated heparin DP6 in blue 




New signals can be seen in the spectrum of the conjugate at around 1.5 ppm. This is 
the region where TEMPO signals resonate. However, the radical broadens the signals 
and they should not be visible at all if they were from the TEMPO spin label. 
Possibly, the new signals are from a contaminant. Nevertheless, carbohydrate signals 
dominate the spectrum, indicating sufficient purity of the sample and its stability for 
further experiments. 
 
To further confirm that the spin label was attached to DP6, 1H T1 inversion recovery 
spectra were collected (see Table 4.8 for relaxation delay times). Spectra were 
collected for both the starting material and the conjugate (Figure 4.104 and Figure 
4.105, respectively).  
 






Estimated T1  
based on zero signal 
1 0.15 0.21 
2 0.2 0.28 
3 0.25 0.35 
4 0.3 0.42 
5 0.4 0.56 
6 0.5 0.7 
7 0.6 0.84 
8 0.8 1.12 
9 1 1.4 
 
It can be seen that most of the signals in the DP6 have close to zero intensity in 
spectra 4, 5, and 6. Based on this approximation, the proton relaxation times of 
heparin DP6 can be estimated to be in the range of 0.4 to 0.7 s. This estimate is based 
on the relationship between relaxation delay and T1, where T1= √2RD, where RD is 




Figure 4.104 1H T1 relaxation spectra for starting material, fully sulfated heparin 
DP6, see Table 4.8 for delay times. 
 
 
Figure 4.105 1H T1 relaxation spectra for TEMPO-DP6, see Table 4.8 for delay 
times.  
 
As expected, the protons of the conjugate relaxed much faster than those of the 
starting material.  Note that all GAG signals are positive already in the first spectrum 
of the TEMPO-DP6 conjugate shown in Figure 4.105. This is due to the spin label 
enhancing the relaxation of the protons. Because all the signals are positive, the 
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relaxation times cannot be determined, but it can be said that the T1 is below 0.21 s. 
The signal at 6 ppm in Figure 4.105 and Figure 4.106 belongs to the double bond 
proton of the non-reducing end monosaccharide of the hexasaccharide. Comparing 
this signal in both sets of spectra, it is clear that this proton is less affected by the 
spin-label than the other protons. Its T1 relaxation time changed only from 0.28 s to 
0.21 s. This is because the paramagnetic relaxation enhancement decreases quickly 
with the increasing distance from the spin label according to equation 4.1 [301] and 
that this proton is furthest away from the spin label.  
 
  (4.1) 
where τc is the correlation time for the molecule, ωH is the Larmor frequency for the 
proton in question, T is the longitudinal relaxation time, r is the distance of the 
nucleus from the unpaired electron, and K is a collection of fundamental constants 
related to spin properties of the system.  
 
The doublet signal at 1.3 ppm seen in both DP6 and TEMPO-DP6 spectra is likely a 
contaminant and it is reassuring to see that it is not as affected by the TEMPO spin 
label as the GAG signals. For this signal, its estimated T1 relaxation time actually 
increased from 0.42 s to 0.56 s. We can therefore argue that the TEMPO-DP6 did not 
cause non-specific relaxation at the concentration used. 
 
In addition to the faster T1 relaxation, T2 values of the protons of TEMPO-DP6 are 
also smaller than those of the pure DP6. This is manifested in the broader lines of the 
1H spectrum of the conjugate. 
 
It was concluded that the TEMPO was conjugated to DP6 and that it was possible to 
purify the conjugate by SAX chromatography. NMR and MS analysis showed the 





Figure 4.106 Fully sulfated heparin hexasaccharide, conjugated with 4-amino 
TEMPO by reductive amination. The molecule is fully protonated as in acidic mass 
spectrometry conditions. 
 
4.11.3 NMR Titration of HGF-N and TEMPO Conjugated Fully 
Sulfated Heparin-Derived Hexasaccharide 
As the TEMPO-DP6 was titrated into HGF-N, both chemical shift changes and 
intensity changes of the crosspeaks could be observed in 1H-15N HSQC spectra 
(Figure 4.107). The chemical shift differences are due to the binding of the TEMPO-
DP6 and reflect changes in the chemical environment of the backbone NH protons. 
The intensity changes are caused by the enhanced relaxation of the backbone NH 
protons due to the presence of TEMPO or due to chemical exchange. Intensity 







Figure 4.107 1H-15N HSQC spectra of HGF-N monitored as TEMPO-DP6 is titrated. 
The purple spectrum is the starting point, the green is at 0.5 times excess of TEMPO-
DP6 and the brown spectrum is at equimolar ratio. Note how for example 61T, 65N, 
69Q and 77N quench in the presence of spin labelled GAG, while the chemical shifts 
of other crosspeaks such as 38T, 40H, 41E, 70C, 72N, 73R, and 80L change. 
 
Specific binding of the TEMPO-DP6 and relaxation enhancement by the spin label 
rather than by chemical exchange is illustrated by comparing a residue that is not 
affected by the binding of the TEMPO-DP6 spin label with another that is strongly 





   
   
   
   
Figure 4.108 Partial 1H-15N HSQC spectra that show how Asn127 (on the left) is not 
affected by the spin label, whereas Thr83 (on the right) is affected by the spin label. 




Combined chemical shift differences of 1H and 15N atoms and paramagnetic 
contributions to the relaxation rates (ΔR1) of NH protons were calculated in the 
presence of an equimolar amount of TEMPO-DP6. T1 values of NH protons were 
determined from a series of relaxation experiments as described in section 3.13 for 
the free protein and three TEMPO-DP6 titration points. The contribution of the spin 
label towards the spin-lattice relaxation rates was calculated as 
 
where ,  = R1 of the HGF-N – TEMPO-DP6 complex and 
= R1 of free HGF-N protein. 
The combined chemical shift perturbation was expressed as as 
described in section 3.11.  
 
Chemical shift perturbations and R1 values were determined in CcpNmr Analysis 
2.1.2 and the data for was plotted in Open Office Calc 3.1.1 (Figure 4.109). Studying 
Figure 4.109, it can be noted that the ΔR1 values are elevated above zero. There are 
three potential reasons for this:  
A) The relaxation rates increase upon binding of the hexasaccharide. This is a 
diamagnetic contribution not caused by the spin label. 
B) The relaxation rates increase due to non-specific relaxation caused by 
TEMPO-DP6. 
C) Free contaminating TEMPO, although this is less likely after two gel 

























Figure 4.109 Chemical shift perturbation and ΔR1 data. The secondary structure of 




There are also some ΔR1 outliers that have a negative value and some residues could 
not be fitted to the equation at all because of unknown reasons. The negative ΔR1 
values imply that the relaxation rates are slower in the presence of TEMPO-DP6, 
meaning that the residues become more flexible upon TEMPO-DP6 binding. The 
general school of thought is that proteins become stabilised upon ligand binding. It is 
likely that most parts of HGF-N are rigidified upon GAG binding, but at the same 
time it has been shown that the protein undergoes conformational exchange upon 
heparin binding and that the protein contains several flexible loops [21]. 
Interestingly, residues 53 to 58 all have negative ΔR1 values and belong to a flexible 
loop not far away from the heparin binding site. These residues belong to the L1 
loop, which is one of the most flexible parts of the protein together with the L2 loop 
[21]. It is therefore possible that this loop becomes even more flexible upon heparin 
binding to accommodate the conformational changes in the other parts of the protein. 
This question could be answered by determining ΔR1 values for free HGF-N and 
HGF-N complexed with heparin DP6 without a spin label, but this experiment was 
not carried out due to time constraints. 
 
A conservative ΔR1 cut off value of 0.35 was chosen to select residues that had 
elevated relaxation rates in the presence of TEMPO-DP6. These were mapped onto 
protomer C of the 1GMO pdb file with UCSF Chimera 1.4 (Figure 4.111) it is clear 
that L1, L2 and β2/4 are more affected by the spin label than the rest of HGF-N and 
that the N-terminal residues and α2 helix are more affected by TEMPO-DP6 binding 
as evidenced by the CCSDs. This implies that TEMPO-DP6 is binding preferentially 
in one direction, with the reducing end monosaccharide towards the protein β2/4 
sheet and L1 loop. Using the glycosidic bonds as a handle, one could also say that 





Figure 4.111 Ribbon presentation of the N domain of protomer C of the 1GMN pdb 
file. Residues coloured red have a shift perturbation ≥0.09 ppm, i.e. they are strongly 
affected by GAG binding, residues coloured green have a ΔR1 ≥0.35 s, i.e. they are 
strongly affected by the TEMPO spin label. The orange residue is affected by both 
binding and the spin label. The TEMPO spin label is represented as a purple circle. 
Some areas of the green and red surfaces do not form consistent patches as ΔR1 
could not be determined for some of the residues.   
 
To compare the results with the literature, the HGF-NK-G - heparin crystal structure 
was analysed [14]. This crystal structure contains several protein-heparin interfaces. 
It was found that in all protomers except one, the heparin oligosaccharide bound in 
the same direction as determined in this project. Therefore, it can be said that there is 
a preference for the heparin oligosaccharide to bind in a C1 to C4 direction rather 
than in a C4 to C1 direction (Table 4.9). This shows that although the HGF-GAG 
interaction is promiscuous, there is some specificity and preference for the GAG to 
bind in a certain direction. One can imagine that although the cell surface GAGs 
form a complex network in vivo, HGF needs to bind GAGs in a specific direction to 








Table 4.9 GAG binding directions from the HGF-N N-terminus. The “H – B” 
annotation refers to that the protein-heparin interaction is taking place between the 
two different protomers.  
Source Direction 
1GMO Protomer A  C4 to C1 
1GMO Protomer B  C1 to C4 
1GMO Protomer C  C1 to C4 
1GMO Protomer F  C1 to C4 
1GMO Protomer G  C1 to C4 
1GMO Protomer H - B  C1 to C4 
1GMN  C1 to C4 
NMR experiment:  C1 to C4 
 
One potential drawback of using spin labelled oligosaccharides to study binding 
events as in this experiment is that the oligosaccharide is modified on the reducing 
end and that this could alter the binding mode of the oligosaccharide due to steric 
hindrance or other effects. The spin labelled GAG will situate itself on the binding 
site in the most favourable way. For example, it was found in section 4.10 that the 
main α2-helix and N-terminal binding regions of HGF-N were of high importance 
for the interaction with heparin and that the β2/4-strands region was of less 
importance. The TEMPO-DP6 used in this study is therefore more likely to situate 
itself with the TEMPO group pointing towards the β2/4-strands region to maximise 
normal interactions between heparin and the more important main α2-helix and N-
terminal binding regions. 
 
This approach used in this experiment is applicable to many other protein-
carbohydrate interactions and can help elucidating questions about binding directions 
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and specificities. Using a reductive amination reaction to link the spin label to a 
carbohydrate opens the reducing end sugar unit and produces a flexible linker to the 
spin label. This is not optimal for paramagnetic relaxation enhancement experiments 
as structural information about the reducing end sugar unit is lost and the flexible 
linker makes it difficult to use the spin label to measure distances. Nevertheless this 
experiment proves that it is possible to derive structural information using reductive 
amination to conjugate a spin label. Kochetkov amination and other alternative 
reactions can be employed to produce more rigid linkers. 
 
It would be interesting to determine T1 relaxation times as a normal heparin 
oligosaccharide is being titrated. This could potentially help to clarify the elevated 
relaxation times across the protein and why some residues, particularly in the L1 
loop deviate from the overall ΔR1 increase. It could also potentially clarify the 
conformational change that HGF-N undergoes when binding a GAG as indicated by 
the appearance of new 1H-15N HSQC peaks [21]. 
 
4.12 Future Studies 
4.12.1 The role of GAGs in the Activation of HGFA and HGF 
HGF and HGFA are potential therapeutic targets and the signalling cascade is 
currently being targeted for drug development [306-310]. Activation of HGFA by 
thrombin and kallikrein 4 are dependent upon the presence of a negatively charged 
molecule such as dextran sulfate [56], [57]. Further, it has been shown that HGFA 
acquires heparin affinity after it is activated by thrombin [62]. These two facts 
indicate that HGFA interacts with GAGs. As described in the introduction, HGFA is 
activated by cleavage, creating a short chain consisting of the first 25 N-terminal 
amino acids and has a theoretical pI of 11.71. The long chain consists of 248 amino 
acids with a theoretical pI of 7.22. The high pI of the short chain implies that the 
GAG binding site is located there. It is possible that the GAG binding site is covered 
in the unactivated state and exposed in the activated state after thrombin cleavage. In 
vivo, the unactivated HGFA is likely to be present and diffusing in many tissues, but 
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after tissue injury and HGFA activation it acquires heparin affinity, becomes less 
mobile at the injury site as it binds to GAGs, which ensures localised HGF 
activation. HGF’s inherent GAG affinity brings it closer to the cell surface where it 
can be activated by HGFA and then bind the Met receptor. These examples point to 
the central role of GAGs in the HGF signalling cascade as shown in Figure 1.8. It 
would therefore interesting to investigate the activation and GAG binding of HGFA 
in more detail to understand the central role these central processes in Met activation 
and how it could be involved in different physiological functions and disease states. 
 
There are several relevant experiments to characterise the interactions between 
HGFA, HGF and GAGs, for example: 
A) Crystal trials with complexes of different versions and mutations of HGF and 
HGFA.  
B) Kinetics (Km and Kcat) for HGF activation by HGFA. This could for example 
be done by ITC and SPR. 
C) NMR studies on activated and unactivated HGFA. There is no NMR 
assignment or dynamics studies of HGFA, which would supplement the 
crystal structure data and clarify the structural differences between the two 
different forms. Further, HGFA has been shown to undergo an extreme 
conformational change upon binding of its substrate and HGFA inhibitors. 
NMR would be an ideal technique to characterise the conformational 
dynamics. 
D) Activation of 15N-labelled HGFA by unlabelled thrombin monitored by 
NMR. This would clarify the structural differences between the two different 
forms and how heparin affinity is acquired. 
E) HGFA binding to GAGs. 
a. Comparison of different GAGs. 
b. Minimal GAG oligosaccharide length. 
c. ITC, NMR and SPR binding parameters. 
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d. NMR structural differences in the presence and absence of GAGs. 
F) The role of GAGs in HGFA activation by thrombin and kallikrein 4. 
 
4.12.2 The Hepatocyte Growth Factor – Glycosaminoglycan 
Interaction 
The two most well characterised protein - GAG interactions are probably the AT-III-
heparin and FGF-heparin interactions. AT-III exhibits a relatively high degree of 
specificity, whereas FGF exhibits less specificity and oligomerises upon heparin and 
receptor binding. The HGF-GAG interaction is also relatively well characterised, but 
it seems to differ from FGF and AT-III in that it is more promiscuous and has a 
different oligomerisation mode, although the latter is not completely clarified yet. As 
the HGFA-HGF-Met signalling cascade has been implicated in many important 
diseases, it is relevant to investigate the HGF-GAG interaction further, not only for 
its involvement in disease, but also as a model for protein-GAG interactions. 
 
As the heparin-HGF-N/NK interaction was successfully characterised by ITC, it 
would be interesting to extend the studies to estimate the contribution of non-ionic 
interactions, deduce how many sodium ions that are released and how many protons 
that are transferred in the binding event [282]. This would help clarifying how many 
and what kind of intermolecular bonds that are formed in the binding event. It would 
also be interesting to further compare the difference between different 
oligosaccharide lengths. With the GAG oligosaccharide preparation method that was 
setup in this project and the good expression levels of HGF-N, sufficient material for 
ITC studies can easily be achieved. The MicroCal Auto VP-ITC instrument is well 
suited for these kinds of experiments as it is equipped with an auto-sampler. 
 
It was shown in this project that the N-terminal residues of the HGF N domain are 
important for GAG binding. Further, it was shown that it is likely that the HGF-NK-
G protein construct used in the HGF-NK-G-heparin co-crystal is binding in a 
different mode to heparin due to an N-terminal cloning artefact. To clarify the 
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differences between the native HGF N domain and the HGF-NK-G protein construct, 
it would be interesting to solve the crystal or NMR structure of a protein construct 
with a native N-terminus in the presence of a heparin oligosaccharide. Solving the 
NMR structure in the presence of heparin/Fondaparinux could also help clarifying 
the occurrence of new 1H-15N HSQC in titrations of these ligands. 
 
Although HGF-N has been relatively well characterised by NMR, T1/T2/NOE data in 
the absence of a GAG oligosaccharide, these parameter have still not been 
established in the presence of a GAG oligosaccharide ligand. The investigation of 
these relaxation parameters would help clarifying the conformational change that the 
protein undergoes upon binding of a GAG as has been shown previously [21] and in 
this project. For example, data in section 4.11.3 suggested that the L2 loop becomes 
more flexible upon ligand binding. 
 
The results from the gel filtration studies of HGF-N and HGF-NK-G complexed with 
CS, DS and heparin oligosaccharides of varying lengths showed that all GAG 
oligosaccharides bound and it was pointed out that the large hydrodynamic radius of 
GAGs has to be taken into consideration when interpreting the data. A more 
quantitative approach that involves calculating hydrodynamic properties of the 
different oligomerisation modes seen in Figure 4.59, using for example the 
HYDROPRO software [233], and comparing them with the experimental values 
would give deeper insight into the interaction. 
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5 Conclusions 1 
Protein – GAG interactions are involved in the regulation of a wide range of 2 
physiological processes such as blood coagulation, tissue regeneration and 3 
embryogenesis. Hepatocyte growth factor regulates physiological processes as 4 
diverse as cell growth, survival, proliferation, chemotaxis, cell morphology, tissue 5 
regeneration and angiogenesis. In this project, the interactions between different 6 
GAGs and several protein constructs of the GAG binding domains of HGF have been 7 
characterised using a range of biophysical techniques.  8 
 9 
The three different protein constructs (HGF-N, HGF-K and HGF-NK-C) were cloned 10 
into an expression vector for P. pastoris from human cDNA, expressed in a bench- 11 
top fermenter and purified to homogeneity.  The protein construct HGF-NK-G was 12 
obtained from a collaborator. Expression levels of HGF-N and HGF-K were 13 
relatively good with a 5-litre fermentation yielding more than 100 mg of one-step 14 
purified protein. Some of the expressed HGF-N protein was shown by mass 15 
spectrometry to have N-terminal truncations due to faulty signal-peptide cleavage 16 
during secretion. Expression of HGF-NK-C proved difficult due to N-terminal 17 
truncations and two protease sites, which were mapped by mass spectrometry. 18 
Inclusion of peptone or tryptone in the expression medium allowed unlabelled HGF- 19 
NK-C to be expressed in useable amounts. It can be concluded that protein 20 
production was successful and most hurdles were overcome. P. pastoris was an 21 
effective protein expression system for the investigated protein constructs, but N- 22 
terminal truncations and proteolysis decreased the yields.  23 
 24 
To compare the binding affinity between the different protein constructs and GAGs, 25 
CSA, CSC, DS and heparin hexadecasaccharides were biotinylated and immobilised 26 
on Sepharose-streptavidin columns, effectively producing GAG affinity columns 27 
(section 4.5.1). The results showed that all investigated protein constructs bind with 28 
the highest affinity to a standard GE Healthcare HiTrap heparin column, followed by 29 
the in-house produced heparin column and with the lowest but similar affinities to 30 
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CSA, CSC and DS -columns. The affinity of HGF-N for hyaluronan was judged to 31 
be non-significant under physiological conditions. To my knowledge, it has 32 
previously not been shown that HGF binds to CS. In these experiments, HGF-N, 33 
HGF-NK-C and HGF-NK-G bound with similar affinity to CS and DS and the 34 
interaction is thought to be physiologically relevant as the proteins elute from the 35 
GAG affinity column at approximately 200-400 mM NaCl. The results align well 36 
with the gel filtration results in section 4.6, where it was found that the investigated 37 
protein constructs bind to both CS and DS under gel filtration conditions in PBS. 38 
Different preparations of DS was used in section 4.6 and 4.5.1, which likely explains 39 
why the general observation was that the affinity was higher for DS in the gel 40 
filtration experiments and higher for CS in the affinity chromatography experiments. 41 
 42 
ITC was employed to study the thermodynamics of the interactions between HGF-N 43 
and HGF-NK-G protein constructs and Fondaparinux and different heparin 44 
oligosaccharide lengths. The ITC results show that the entropy contribution was 45 
favourable for short oligosaccharides and disfavourable for long oligosaccharides 46 
and that the enthalpy contribution was smaller for short oligosaccharides than for 47 
long oligosaccharides. The opposite trends in enthalpy and entropy as a function of 48 
oligosaccharide length explain why the dissociation constants do not change much 49 
with varied oligosaccharide length. It has previously been shown by SPR that the 50 
affinity of HGF for heparin-derived oligosaccharides does not change with length 51 
[10]. To my knowledge, this is the first time ITC has been used to study the HGF- 52 
GAG interaction and the entropy and enthalpy contribution to the binding has been 53 
determined. The results help explain the affinity of the HGF-GAG interaction and 54 
why long oligosaccharides do not necessarily bind tighter than short 55 
oligosaccharides. This knowledge can aid in drug design of GAG mimetics. The 56 
experiments can be extended by performing ITC titrations in buffers with different 57 
ionic strengths and heats of ionisation. By using different buffers, the contribution of 58 
non-ionic interactions can be determined as well as how many sodium ions that are 59 




The ITC data showed that the dissociation constant between HGF-N, HGF-NK-G, 62 
different heparin oligosaccharide lengths and Fondaparinux varied between 0.35 µM 63 
and 9.26 µM. Dissociation constants determined by NMR and ITC for the interaction 64 
in this project were in the same range as previously reported for the HGF-N - heparin 65 
interaction by solution-based fluorescence methods [21]. However, the dissociation 66 
constants between different HGF constructs and GAGs determined by SPR are in a 67 
low nM range in many previous studies [10-13]. Thus the dissociation constants 68 
determined by NMR and ITC in this project deviate several orders of magnitude 69 
from those determined by SPR in other studies. The main reason for the large 70 
difference in dissociation constants is likely that NMR and ITC are solution based 71 
techniques, whereas SPR requires ligand immobilisation on a surface, which can give 72 
rise to artefacts. In addition, it is often difficult to correct for the multivalency of 73 
protein-GAG interactions in SPR experiments. SPR has been the most common 74 
method to study the HGF-GAG interaction and surprisingly few alternative solution- 75 
based methods have been used. The results presented in this thesis, in particular those 76 
obtained by the ITC and NMR experiments, are therefore important. They indicate 77 
that solution-based methods could be more appropriate for studies of the HGF-GAG 78 
interaction. More solution-based techniques need to be employed in studying the 79 
HGF-GAG interaction in order to clarify the wide range of KDs determined by 80 
different methods. 81 
 82 
NMR titrations of CSA, CSC, DS, heparin -decasaccharides, heparin tetrasaccharide, 83 
Fondaparinux and chemically sulfated maltose into 15N labelled HGF-N allowed the 84 
GAG binding site to be mapped and studied in detail. It is shown that all ligands bind 85 
to the same general HGF-N binding site, but different binding modes exists between 86 
the different ligands. Three binding regions were identified within the binding site, 87 
with the α2-helix and L2 loops playing key roles (residues 70-84). All GAGs also 88 
utilise a N-terminal binding region (residues 32-42), whereas long heparin 89 
oligosaccharides can also utilise a binding region formed mainly by the β2 and β4 - 90 
strands (residues 59-64, 66, 95, 96). The latter binding region is more important 91 
when the first six N-terminal residues are removed (HGF-N-Δ6) compared to the 92 
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native HGF-N protein. It is likely that this binding mode is also present in HGF-NK- 93 
G, which has a non-native N-terminus. The importance of these residues was also 94 
confirmed by heparin affinity chromatography: both HGF-N-Δ6 and HGF-NK-G 95 
eluted from heparin affinity columns earlier than HGF-N and HGF-NK-C. The 96 
results are in line with previously published data [63] and are important as they 97 
provide detailed insight into the importance of the N-terminal binding region of 98 
HGF, which can’t be studied by NMR or X-ray methods due to its flexibility. To my 99 
knowledge, this is also the first time a repertoire of GAGs has been used to compare 100 
different binding modes to HGF on a molecular level. The detailed mapping of 101 
HGF’s GAG binding site in conjunction with the ITC results in this thesis improves 102 
the understanding of this important interaction and can aid in the development of 103 
GAG mimetics. 104 
 105 
Thermal denaturation of HGF-N monitored by NMR showed that heparin binding 106 
stabilises HGF-N; the melting temperature of HGF-N increases in the presence of 107 
heparin decasaccharide. These novel results improve the basic understanding of the 108 
HGF-N construct as its melting temperature is determined and it is shown that HGF- 109 
N is stabilised by heparin decasaccharide.  110 
 111 
A number of protein–carbohydrate interactions exhibit directional specificity [301], 112 
whereas others proteins can bind its ligand in any direction [302]. To investigate 113 
whether HGF-N exhibits directional specificity, a spin-label was attached to the 114 
reducing end of fully sulfated heparin hexasaccharide. The effect of the spin label on 115 
HGF-N was examined by determining the CCSDs and relaxation times of the protein 116 
backbone NH protons by NMR. After the data was mapped onto the structure of 117 
HGF-N it became clear that the heparin-derived hexasaccharide bound preferably in 118 
one direction. Although the HGF-GAG interaction appears to be relatively 119 
promiscuous as the protein can bind several different types of GAGs and 120 
accommodate a variety of sulfation patterns, the results suggest that the protein 121 
preferably binds heparin and HS in one direction. This is not surprising because even 122 
though HGF-N has the ability to bind different GAGs and sulfation patterns, the 123 
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protein is likely to exhibit some specificity and preference for sugar backbone 124 
sequences and sulfation patterns. In the same manner, the protein is likely to exhibit 125 
directional preference as the positions of sulfates and other interaction points will 126 
clearly change depending on what direction the GAG binds. The results are novel in 127 
that it is the first time that binding directionality is studied for the HGF-GAG 128 
interaction by NMR. The results show the same orientation of the GAG as seen in 129 
the X-ray structure of the HGF-NK-G - heparin complex. The X-ray structure is 130 
based on the protein with a cloning artefact, which affects the binding as 131 
demonstrated in our work. It was therefore important to investigate whether the 132 
direction of the binding is the same for the HGF-N protein construct and in solution. 133 
The directionality of GAG binding is important for the design of GAG mimetics, 134 
when targeting the HGF-GAG interaction for drug development. The results are also 135 
important in that it is shown that reductive amination can be used to attach spin- 136 
labels to GAGs, derive structural information and determine the directionality of 137 
their binding to proteins. Reductive amination gives rise to an opened sugar unit and 138 
a flexible linker on the reducing end where the spin-label is attached. This is not 139 
optimal for paramagnetic relaxation enhancement experiments as structural 140 
information is lost in the ring opening and the flexible linker makes it more difficult 141 
to determine the position of the spin label accurately.  142 
 143 
It has previously been suggested that HGF binds preferably highly sulfated GAG 144 
species containing iduronic acid. To investigate what heparin sequence in a 145 
hexasaccharide mixture that binds tightest to HGF-N, an affinity column was 146 
prepared by biotinylating the protein construct and immobilising it on a GE 147 
Healthcare Streptavidin HiTrap column. A mixture of enzymatically derived heparin 148 
hexasaccharides was loaded onto the column and eluted with a salt gradient. The 149 
affinity-purified hexasaccharides were characterised by SAX chromatography and 150 
MALDI-TOF mass spectrometry. The results were in line with previously published 151 
studies [67]: HGF-N bound tightest to fully sulfated heparin hexasaccharide that was 152 
likely built up by IdoA sugar units. Somewhat unexpectedly, no 3-O sulfated 153 
hexasaccharide was detected, likely due to the low abundance of 3-O sulfate in 154 
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heparin and relative insensitivity of the method. Hexasaccharides lacking more than 155 
three sulfates did not bind under the experimental conditions. It appears that HGF, 156 
just like many other heparin binding proteins, is able to accommodate a wide range 157 
of sulfation patterns and degrees of sulfation, although a preference for highly 158 
sulfated species exists. These results are important as they show that fluorescent tag 159 
labelling of GAGs is not required for their direct detection after affinity 160 
chromatography. 161 
 162 
A self-associating dimer of HGF-N that bound with extraordinary high affinity to 163 
heparin was characterised by heparin affinity chromatography, gel filtration and 164 
NMR. Heparin affinity chromatography showed that dimeric HGF-N binds tighter to 165 
heparin than monomeric HGF-N. Gel filtration proved that the tight binding species 166 
was indeed a dimer that is relatively stable at 4 °C, but dissociates into a monomer if 167 
incubated at 37 °C. The dissociation of the dimeric species was studied by NMR at 168 
30 °C and as it took several hours for the dimer to dissociate, it can be concluded that 169 
the off-rate of the complex must be very slow. What induces dimerisation is 170 
unknown. The dissociation of the complex is slow on an NMR timescale, which 171 
makes it difficult to follow the NH crosspeaks in H-15N HSQC spectra. Some 172 
crosspeaks that could be assigned with satisfactory confidence were mapped on the 173 
protein structure. The mapped surface does not correspond to any protein-protein 174 
interfaces seen in the crystal structures of HGF. Further studies have to be conducted 175 
to clarify the nature of this complex, for example, the binding interface can be 176 
mapped by mass spectrometry methods. HGF-NK-G crystallises as a head-to-tail 177 
dimer, but the protein is likely monomeric in solution. These results are novel as a 178 
HGF-N dimer has not been reported before. Further studies could clarify if the higher 179 
affinity is solely due to the dimer having two GAG binding sites or if a more 180 
complex mechanism is involved. 181 
 182 
Gel filtration is a common technique used to study the oligomeric state of protein- 183 
GAG complexes. However, due to the very large hydrodynamic radii of GAGs, it is 184 
difficult to interpret experiments when a mixture of a protein and GAG is analysed 185 
 
 238 
by gel filtration. Based on previous gel filtration experiments and crystal structures, 186 
it has been suggested that HGF-NK oligomerises upon the addition of GAGs. To 187 
clarify the contribution of the GAG to the elution time in gel filtration studies, free 188 
GAGs and free proteins were analysed separately by gel filtration before analysing 189 
the mixtures. The results showed that free CSC DP12 migrated as an apparent larger 190 
molecular weight than free HGF-N and that free CSC DP22 migrated as an apparent 191 
larger molecular weight than free HGF-NK-G. This emphasises the importance of 192 
taking the hydrodynamic radius of the GAG into consideration when performing gel 193 
filtration experiments of protein-GAG complexes. It also stresses how difficult it is 194 
to interpret the results as a change in protein oligomeric state will partly be hidden by 195 
the large hydrodynamic radius of the GAG. Nevertheless, when taking the GAG 196 
radius into consideration, evidence for a 2:1 protein:GAG complex could be 197 
observed for heparin chains that were long enough to accommodate two protein 198 
molecules (≥DP10 for HGF-N and ≥DP14 for HGF-NK-G), implying that HGF-N 199 
and HGF-NK-G have a simple oligomerisation mode like beads on a string. AUC 200 
analysis was employed to confirm the gel filtration results and it was found that free 201 
HGF-N and HGF-NK-G are monomeric in solution and in the presence of equimolar 202 
Fondaparinux. In the presence of equimolar heparin decahexasaccharide, higher- 203 
order species could be detected, likely representing two proteins bound to one 204 
decahexasaccharide. The AUC results also suggested a simple beads on a string 205 
oligomerisation mode. ITC analysis further confirmed the beads on a string model, 206 
showing 1:1 interactions for Fondaparinux and heparin hexasaccharide, but a 2:1 207 
protein:GAG interaction for heparin decahexasaccharide. The results are important in 208 
that they provide good evidence for that the HGF-N and HGF-NK protein construct 209 
have a simple beads on a string oligomerisation mode, which is a novel finding that 210 
increases our basic understanding of how these protein constructs interact with 211 
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